Latest DPCO 2024

You might also like

Download as pdf or txt
Download as pdf or txt
You are on page 1of 121

रजिस्ट्री सं. डी.एल.- 33004/99 REGD. No. D. L.

-33004/99

सी.जी.-डी.एल.-अ.-30032024-253444
xxxGIDHxxx
CG-DL-E-30032024-253444
xxxGIDExxx

असाधारण
EXTRAORDINARY
भाग II—खण्ड 3—उप-खण्ड (ii)
PART II—Section 3—Sub-section (ii)
प्राजधकार से प्रकाजित
PUBLISHED BY AUTHORITY

सं. 1478] नई दिल्ली, मंगलवार, मार्च 26, 2024/र्ैत्र 6, 1946


No. 1478] NEW DELHI, TUESDAY, MARCH 26, 2024/CHAITRA 6, 1946

( )
( )

नई दिल्ली, 26 मार्च, 2024


का. आ. 1547(अ).—
, नवम्बर
4, 6, 10, 11, 14, 16, 17 18

a b

2263 GI/2024 (1)


2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

@ 0.00551% बढाकर

(0.00551%

(1) (2) (3) (4) (5) (6a) (6b)


1 मर्कैपटॉप्यरू िन गोली 50 मिलीग्राि 1 गोली 5.26 4663(अ) 25-10-23
2 अबार्कवीि गोली 300 मिलीग्राि 1 गोली 48.59 1574(अ) 31-03-23
अबार्कवीि (ए) + गोली 600 मिलीग्राि (ए) 4663(अ)
3 1 गोली 72.32 25-10-23
लाममवड
ु ाइन (बी) +300 मिलीग्राि (बी)
4 एमिटाजोलामाइड गोली 250 मिलीग्राि 1 गोली 4.06 4663(अ) 25-10-23
5 dSIlwy 250 fexzk- 1 dSIlwy 5.05 4663(अ) 25-10-23
,afVªd dksfVM xksyh 75 4663(अ)
6
fexzk-
1 xksyh 0.35 25-10-23
dkWuosu'kuy@bQsjoslVsa 4663(अ)
7 @fMLijflcy@,afVªd 1 xksyh 0.71 25-10-23
dksfVM xksyh 150 fexzk-
एक्टटनोमाइमिन डी
पाउडर फोर इजं ेक्शन 0.5 4663(अ)
8 1 वाइल 331.03 25-10-23
मिलीग्राि
9 ऐिीटलोववि गोली 400 मिलीग्राि 1 गोली 13.66 4663(अ) 25-10-23
10 ऐिीटलोववि गोली 200 मिलीग्राि 1 गोली 7.61 1574(अ) 31-03-23

ऐिीटलोववि
पाउडर फोर इजं ेक्शन 250 4663(अ)
11 1 वाईल 426.40 25-10-23
मिलीग्राि
ऐिीटलोववि
पाउडर फोर इजं ेक्शन 500 4663(अ)
12 1 वाईल 528.45 25-10-23
मिलीग्राि
13 ऐिीटलोववि गोली 800 मिलीग्राि 1 गोली 37.66 1574(अ) 31-03-23
14 ऐिीटलोववि ओइटं िेंट 3% 1 ग्राि 11.67 1574(अ) 31-03-23
vksjy fyD;wbZM 400 4663(अ)
15
fexzk-@5 fefy-
1 fefy- 1.36 25-10-23
16 एडेनोिाइन इजं ेक्शन 3 मिलीग्राि/मि.ली. 1 मि.ली. 92.86 4663(अ) 25-10-23
17 एड्रेनालाईन इजं ेक्शन1मिलीग्राि/मि.ली. 1 मि.ली. 12.23 1574(अ) 31-03-23
vksjy fyD;wbZM 200 1577(अ)
18
fexzk-@5 fefy-
1 fefy- 1.79 31-03-23
19 xksyh 400 fexzk- 1 xksyh 7.04 1577(अ) 31-03-23
च्बेवेबल xksyh 400 4663(अ)
20 1 xksyh 8.13 25-10-23
fexzk-
21 एलोप्यूररनॉल गोली 300 मिलीग्राि 1 गोली 5.63 4663(अ) 25-10-23
22 एलोप्यूररनॉल गोली 100 मिलीग्राि 1 गोली 1.89 1574(अ) 31-03-23
इजं ेक्शन 0.5 1574(अ)
23 अलप्रोस्ट्टैजडल 1 मि.ली. 6106.75 31-03-23
मिलीग्राि/मि.ली.
इंजेटशन 250 4663(अ)
24 एजमकाजसन 1 मम.ली. 54.17 25-10-23
ममलीग्राम /मम.ली.
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 3

25 ऐजमयोडैरोन गोली 200 मिलीग्राि 1 गोली 11.51 1574(अ) 31-03-23


26 ऐजमयोडैरोन गोली 100 मिलीग्राि 1 गोली 6.14 1574(अ) 31-03-23
इजं ेक्शन 50 1574(अ)
27 ऐजमयोडैरोन 1 मि.ली. 21.13 31-03-23
मिलीग्राि/मि.ली.
28 ऐजमररजप्टलाइन गोली 50 मिलीग्राि 1 गोली 5.99 4663(अ) 25-10-23
29 ऐजमररजप्टलाइन गोली 75 मिलीग्राि 1 गोली 5.45 4663(अ) 25-10-23
30 ऐजमररजप्टलाइन गोली 25 मिलीग्राि 1 गोली 2.49 4663(अ) 25-10-23
31 ऐजमररजप्टलाइन गोली 10 मिलीग्राि 1 गोली 2.39 4663(अ) 25-10-23
32 अम्लोजडजपन गोली 2.5 मिलीग्राि 1 गोली 1.79 1574(अ) 31-03-23
33 अम्लोजडजपन गोली 5 मिलीग्राि 1 गोली 2.50 1574(अ) 31-03-23
34 अम्लोजडजपन गोली 10 मिलीग्राि 1 गोली 5.45 4663(अ) 25-10-23
35 एमोजससजसजलन कै प्सूल 250 मिलीग्राि 1 कै प्सूल 2.44 1574(अ) 31-03-23
36 एमोजससजसजलन कै प्सूल 500 मिलीग्राि 1 कै प्सूल 7.36 4663(अ) 25-10-23
vksjy fyD;wbZM 250 4663(अ)
37
fexzk-@5 fefy- (पी)
1 fefy- 1.56 25-10-23

इंजेटशन र्के मलए


38 एमोजससजसजलन पाउडि 250 1 वाईल 24.79 1578(अ) 31-03-23
ममलीग्राम
इंजेटशन र्के मलए
39 एमोजससजसजलन पाउडि 500 1 वाईल 54.65 4663(अ) 25-10-23
ममलीग्राम
ओिल मलक्टवड
40 एमोजसससीजलन 125 ममलीग्राम 1 मम.ली. 1.02 1579(अ) 31-03-23
/5 मम.ली. (पी)
एमोजससजसजलन (ए) पाउडर फोर इजं ेक्शन 1 ग्राि
41 +सलैवुलाजनक एजसड (ए) +200 मिलीग्राि 1 वाईल 140.66 4663(अ) 25-10-23
(बी) (बी)
पाउडर फोर इजं ेक्शन 500
एमोजससजसजलन (ए) +
42 मिलीग्राि (ए) + 100 1 वाईल 101.35 4663(अ) 25-10-23
सलैवुलाजनक एजसड (बी)
मिलीग्राि (बी)
ड्राई मसरप 125 मिलीग्राि
एमोजससजसजलन (ए) +
43 (ए) + 31.25 1 मि.ली. 2.05 1574(अ) 31-03-23
सलैवुलाजनक एजसड (बी)
(बी)/5मिली..(पी)
एमोजससजसजलन (ए)
गोली 500 मिलीग्राि (ए)
44 +सलैवुलाजनक एजसड 1 गोली 18.30 4663(अ) 25-10-23
+ 125 मिलीग्राि (बी)
(बी)
ओरल मलमक्वड 200
एमोजससजसजलन (ए) + मिलीग्राि (ए) + 28.5
45 1 मि.ली. 2.02 4663(अ) 25-10-23
सलैवुलाजनक एजसड (बी) मिलीग्राि (बी)/5
मि.ली.(पी)
,EQksVsfjflu
ch&dkWuosu'kuy
46 batSD'ku 50 fexzk-/ 1 वाईल 227.40 1577(अ) 31-03-23
वाईल
4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

पाउडर फोर इजं ेक्शन 500 1574(अ)


47 एम्पीजसलीन 1 वाईल 14.25 31-03-23
मिलीग्राि
आटेमेडर (ए) + गोली 40 मिलीग्राि (ए) + 1574(अ)
48 1 गोली 18.04 31-03-23
ल्यूमेफैंररन (बी) 240 मिलीग्राि (बी)
आटेमेडर (ए) + गोली 80 मिलीग्राि (ए) + 4663(अ)
49 1 गोली 25.51 25-10-23
ल्यूमफैं ररन (बी) 480 मिलीग्राि (बी)
आटेमेडर (ए) + गोली 20 मिलीग्राि (ए) + 4663(अ)
50 1 गोली 12.65 25-10-23
ल्यूमफैं ररन (बी) 120 मिलीग्राि (बी)
पाउडर फोर इजं ेक्शन 60 4663(अ)
51 आर्टचसुनेट 1 वाईल 244.73 25-10-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 120 4663(अ)
52 आर्टचसुनेट 1 वाईल 454.44 25-10-23
मिलीग्राि
कोम्बी पैक (ए + बी) 1
आटेसुनेट (ए) +
53 सल्फै डॉजससन -
गोली 50 मिलीग्राि (ए) + 1 1 कोम्बी पैक 22.55 4663(अ) 25-10-23
गोली (500 मिलीग्राि + 25
पाइररमेथामाइन (बी)
मिलीग्राि) (बी)
54 xksyh 100 fexzk- 1 xksyh 0.24 4663(अ) 25-10-23

55 xksyh 500 fexzk- 1 xksyh 1.48 1577(अ) 31-03-23


गोली 300 मिलीग्राि (ए)
एटाजानवीर (ए) +
56 + गोली 100 मिलीग्राि 1 गोली 99.83 1574(अ) 31-03-23
ररटोनवीर (बी)
(बी)
57 एटोरवास्ट्टेरटन गोली 40 मिलीग्राि 1 गोली 19.30 4663(अ) 25-10-23
58 एटोरवास्ट्टेरटन गोली 20 मिलीग्राि 1 गोली 12.56 4663(अ) 25-10-23
59 एटोरवास्ट्टेरटन गोली 10 मिलीग्राि 1 गोली 4.94 1574(अ) 31-03-23
60 एटोरवास्ट्टेरटन गोली 80 मिलीग्राि 1 गोली 40.58 4663(अ) 25-10-23
batSD'ku 10 fexzk- 4663(अ)
61
@fefy-
1 fefy- 16.98 25-10-23
62 एरोजपन ड्रोप 1% 1 मि.ली. 3.94 4663(अ) 25-10-23
63 एरोजपन ओइटं ् िटें 1% 1 ग्राि 4.71 4663(अ) 25-10-23
इजं ेक्शन 0.6 1574(अ)
64 एरोजपन 1 मि.ली. 4.57 31-03-23
मिलीग्राि/मि.ली.
65 अजैजथयोप्राइन गोली 50 मिलीग्राि 1 गोली 11.26 4663(अ) 25-10-23
गोली 25 ममलीग्राम 1578(अ)
66 अजैजथयोप्राइन 1 गोली 7.24 31-03-23
(पी)
पाउडर फोर इजं ेक्शन 500 1574(अ)
67 एजजथ्रोमाइजसन 1 वाईल 204.72 31-03-23
मिलीग्राि
68 एजजथ्रोमाइजसन गोली 250 मिलीग्राि 1 गोली 11.65 4663(अ) 25-10-23
69 एजजथ्रोमाइजसन गोली 500 मिलीग्राि 1 गोली 23.57 4663(अ) 25-10-23
ओरल मलमक्वड 200 4663(अ)
70 एजजथ्रोमाइजसन 1 मि.ली. 3.41 25-10-23
मिलीग्राि/5 मि(पी) .ली.
71 dSIlwy 250 fexzk- 1 dSIlwy 10.62 4663(अ) 25-10-23
गोली 1000 4663(अ)
72 एजजथ्रोमाइजसन 1 गोली 57.78 25-10-23
ममलीग्राम
73 एजजथ्रोमाइजसन र्कैप्िल
ू 500 1 कै प्सूल 19.03 2124(अ) 04-05-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 5

ममलीग्राम
74 बैसलोफे न गोली 20 मिलीग्राि 1 गोली 16.28 1574(अ) 31-03-23
75 बैसलोफे न गोली 10 मिलीग्राि 1 गोली 11.90 4663(अ) 25-10-23
76 बैसलोफे न गोली 5 मिलीग्राि 1 गोली 6.37 4663(अ) 25-10-23
बेंडामुस्ट्टाइन इजं ेक्शन 100 मिलीग्राि / 1574(अ)
77 1 वाईल 4946.80 31-03-23
हाइड्रोसलोराइड वाईल
78 बेंजोइल पेरोससाइड जेल 2.5 1 ग्राि 3.62 1574(अ) 31-03-23
79 बेंजोइल पेरोससाइड जेल 5 % 1 ग्राि 7.97 1574(अ) 31-03-23
80 बेंजोइल पेरोससाइड जेल 3.5% 1 ग्राम 10.11 1578(अ) 31-03-23
batSD'ku 4 fexzk- 1577(अ)
81
@fefy-
1 fefy- 4.74 31-03-23
82 बेटामेथासोन वैलेरेट क्रीि 0.05% 1 ग्राि 0.67 1574(अ) 31-03-23
83 बेटामेथासोन वैलेरेट क्रीि 0.1% 1 ग्राि 1.04 1574(अ) 31-03-23
84 बाइकलुटामाइड गोली 50 मिलीग्राि 1 गोली 43.30 1574(अ) 31-03-23
85 जबसकॉडल गोली 5 मिलीग्राि 1 गोली 1.17 4663(अ) 25-10-23
86 जबसकॉडल सपोमसटरी 5 मिलीग्राि 1 सपोमसटरी 9.98 4663(अ) 25-10-23
पाउडर फोर इजं ेक्शन 15 1574(अ)
87 ब्लोमाइजसन 1 वाईल 677.41 31-03-23
यमू नट् स
पाउडर फोर इजं ेक्शन 2 4663(अ)
88 बोटेजोजमब 1 वाईल 5260.50 25-10-23
मिलीग्राि
jslfijsVkWjh lksyq'ku 4663(अ)
89 QkWj ;wt bu uscy q kbtj 1 fefy- 11.90 25-10-23
0-5 fexzk-@fefy-
jslfijsVkWjh lksyq'ku 1577(अ)
90 QkWj ;wt bu uscy q kbtj 1 fefy- 13.14 31-03-23
1 fexzk-@fefy-
batSD'ku 0-5% ds lkFk 4663(अ)
91 1 fefy- 7.39 25-10-23
7-5% Xywdkst
92 batSD'ku 0-50% 1 fefy- 4.42 4663(अ) 25-10-23
93 batSD'ku 0-25% 1 fefy- 2.83 4663(अ) 25-10-23
गोली (सब(मलंगिं ल- 0.4 4663(अ)
94 बुप्रेनॉर्फच न 1 गोली 9.43 25-10-23
मिलीग्राि
गोली (मलंगिं ल-सब) 2 4663(अ)
बुप्रेनॉर्फच न (ए)
95 मिलीग्राि + (ए) 0.5 1 गोली 36.98 25-10-23
+नालॉससोन (बी)
मिलीग्राि (बी)
गोली 0.4 )मलंगिं ल-सब) 4663(अ)
बुप्रेनॉर्फच न (ए)
96 मिलीग्राि (ए) + 0.1 1 गोली 11.82 25-10-23
+नालॉससोन (बी)
मिलीग्राि (बी)
ओरल मलमक्वड 20 1574(अ)
97 कै फीन 1 मि.ली. 245.68 31-03-23
मिलीग्राि/मि.ली.
batSD'ku 20 fexzk- 1577(अ)
98
@fefy-
1 fefy- 250.50 31-03-23
yks'ku ¼vkbZih ds 1577(अ)
99
vuqlkj½
1 fefy- 0.95 31-03-23
100 कै जल्ियम फोजलनेट गोली 15 मिलीग्राि 1 गोली 47.54 4663(अ) 25-10-23
101 कै पेजसटाबाइन गोली 500 मिलीग्राि 1 गोली 112.73 4663(अ) 25-10-23
िोडीफाइड ररलीज – गोली 4663(अ)
102 काबाचमेिापाइन 1 गोली 2.40 25-10-23
200 मिलीग्राि
6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

िोडीफाइड ररलीज– गोली 1574(अ)


103 काबाचमेिापाइन 1 गोली 4.66 31-03-23
400 मिलीग्राि
104 काबाचमेिापाइन गोली 400 मिलीग्राि 1 गोली 3.55 1574(अ) 31-03-23
105 काबचमेजपाइन गोली 200 मिलीग्राि 1 गोली 1.57 4663(अ) 25-10-23
ओरल मलमक्वड 100 1574(अ)
106 काबचमेजपाइन 1 मि.ली. 0.31 31-03-23
मिलीग्राि/5मि.ली. (पी)
107 काबचमेजपाइन गोली 100 मिलीग्राि 1 गोली 1.07 4663(अ) 25-10-23
108 कार्बचमाजोल गोली 10 मिलीग्राि 1 गोली 4.26 1574(अ) 31-03-23
109 कार्बचमाजोल गोली 5 मिलीग्राि 1 गोली 2.19 4663(अ) 25-10-23
110 कार्बचमाजोल गोली 20 मिलीग्राि 1 गोली 13.87 4663(अ) 25-10-23
इजं ेक्शन 10 4663(अ)
111 काबोप्लैरटन 1 मि.ली. 59.07 25-10-23
मिलीग्राि/मि.ली.
काबोजससजमथाइल 4663(अ)
112 ड्रोप 0.5% 1 मि.ली. 12.30 25-10-23
सेलुलोि
काबोजससजमथाइल 1574(अ)
113 ड्रोप 1% 1 मि.ली. 16.58 31-03-23
सेलुलोि
114 सेफैड्रोजसल गोली 500 मिलीग्राि 1 गोली 4.47 1574(अ) 31-03-23
ओरल मलमक्वड 125 1574(अ)
115 सेफैड्रोजसल 1 मि.ली. 0.68 31-03-23
मिलीग्राि/5मि.ली. (पी)
116 सेदफजससम गोली 400 मिलीग्राि 1 गोली 22.10 4663(अ) 25-10-23
117 सेदफजससम गोली 200 मिलीग्राि 1 गोली 9.78 4663(अ) 25-10-23
ओरल मलमक्वड 50 4663(अ)
118 सेदफजससम 1 मि.ली. 1.63 25-10-23
मिलीग्राि/5 मि.ली. (पी)
ओरल मलमक्वड 100 4663(अ)
119 सेदफजससम 1 मि.ली. 2.39 25-10-23
मिलीग्राि/5मि.ली.(पी)
120 dSIlwy 200 fexzk- 1 dSIlwy 14.68 4663(अ) 25-10-23
पाउडर फोर इं िेसिन 4663(अ)
121 सेफोटाजससम 1 वाईल 17.72 25-10-23
250 जमलीग्राम
पाउडर फोर इजं ेक्शन 500 4663(अ)
122 सेफोटाजससम 1 वाईल 24.38 25-10-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 1000 1574(अ)
123 सेफोटाजससम 1 वाईल 39.96 31-03-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 1000 1574(अ)
124 सेफ्टाजजडाइम 1 वाईल 227.02 31-03-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 250 4663(अ)
125 सेफ्टाजजडाइम 1 वाईल 79.07 25-10-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 500 4663(अ)
126 सेजफ्रयाससोन 1 वाईल 50.28 25-10-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 250 1574(अ)
127 सेजफ्रयाससोन 1 वाईल 28.34 31-03-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 1000 1574(अ)
128 सेजफ्रयाससोन 1 वाईल 62.38 31-03-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 2000 1574(अ)
129 सेजफ्रयाससोन 1 वाईल 138.12 31-03-23
मिलीग्राि
गोली 500 1578(अ)
130 सेफ्यूरोजससम 1 गोली 51.43 31-03-23
ममलीग्राम
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 7

इंजेटशन 1500 1579(अ)


131 सेफ्रॉजससम 1 वाईल 338.76 31-03-23
ममलीग्राम
132 सेटीररजजन गोली 10 मिलीग्राि 1 गोली 1.88 1574(अ) 31-03-23
ओरल मलमक्वड 5 1574(अ)
133 सेटीररजजन 1 मि.ली. 0.66 31-03-23
मिलीग्राि/5 मि(पी).ली.
134 सलोरोदिन गोली 150 मिलीग्राि 1 गोली 1.17 4663(अ) 25-10-23
ओरल मलमक्वड 50 4663(अ)
135 सलोरोदिन 1 मि.ली. 0.34 25-10-23
मिलीग्राि/5मि.ली.
136 कॉलेकैजल्सफे रॉल गोली 1000 आईयू 1 गोली 4.31 4663(अ) 25-10-23
ओरल मलमक्वड 400 1574(अ)
137 कॉलेकैजल्सफे रॉल 1 मि.ली. 2.61 31-03-23
आईयू /मि.ली.
सॉमलड ओरल डोज़ फॉिम 1574(अ)
138 कॉलेकैजल्सफे रॉल 1 गोली 22.50 31-03-23
60000 आईयू गोली
139 dSIlwy 60000 vkbZ;w 1 dSIlwy 30.78 4663(अ) 25-10-23
140 dSIlwy 1000 vkbZ;w 1 dSIlwy 4.89 4663(अ) 25-10-23
िैिे ग्रेनअ
ु ेि/
141 कॉलेकैजल्सफे रॉल पाउडि/60000 1 ग्राम 33.98 1578(अ) 31-03-23
आईयू

142 जसप्रोफ्लोससाजसन गोली 250 मिलीग्राि 1 गोली 2.20 4663(अ) 25-10-23


143 जसप्रोफ्लोससाजसन गोली 500 मिलीग्राि 1 गोली 4.25 4663(अ) 25-10-23
144 जसप्रोफ्लोससाजसन ड्रॉप 0.3 % 1 मि.ली. 1.54 4663(अ) 25-10-23
इजं ेक्शन 200 1574(अ)
145 जसप्रोफ्लोससाजसन 1 मि.ली. 0.20 31-03-23
मिलीग्राि/100मि.ली.
vksjy fyD;wbZM 250 1577(अ)
146 1 fefy- 0.74 31-03-23
fexzk-@5 fefy- (पी)
147 जसप्रोफ्लोससाजसन ओइटं िेंट 0.3% 1 ग्राि 1.29 4663(अ) 25-10-23
148 जसस्ट्प्लैरटन इजं ेक्शन 1 मिलीग्राि/मि.ली. 1 मि.ली. 7.09 4663(अ) 25-10-23
149 सलैररथ्रोमाइजसन गोली 250 मिलीग्राि 1 गोली 23.89 1574(अ) 31-03-23
150 सलैररथ्रोमाइजसन गोली 500 मिलीग्राि 1 गोली 39.84 4663(अ) 25-10-23
ओरल मलमक्वड 125 4663(अ)
151 सलैररथ्रोमाइजसन 1 मि.ली. 4.61 25-10-23
मिलीग्राि/5 मि.ली. (पी)
152 कसलंडामाइजसन कै प्सूल 150 मिलीग्राि 1 कै प्सूल 16.36 4663(अ) 25-10-23
153 कसलंडामाइजसन कै प्सूल 300 मिलीग्राि 1 कै प्सूल 28.37 4663(अ) 25-10-23
154 कसलंडामाइजसन गोली 300 मिलीग्राि 1 गोली 18.97 1574(अ) 31-03-23
इंजेटशन 150
155 जसलन्डामाईजसन 1 मम.ली. 60.60 1579(अ) 31-03-23
ममलीग्राम / मम.ली.
156 सलोबाजम गोली 5 मिलीग्राि 1 गोली 5.73 4663(अ) 25-10-23
157 सलोबाजम गोली 10 मिलीग्राि 1 गोली 9.84 1574(अ) 31-03-23
158 सलोफाजजमाइन कै प्सूल 100 मिलीग्राि 1 कै प्सूल 3.98 2540(अ) 08-06-23
8 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

159 सलोफाजजमाइन कै प्सूल 50 मिलीग्राि 1 कै प्सूल 2.11 2540(अ) 08-06-23


160 सलोमीफीन साइरेट कै प्सूल 50 मिलीग्राि 1 कै प्सूल 27.37 2124(अ) 04-05-23
161 सलोमीफीन साइरेट कै प्सूल 100 मिलीग्राि 1 कै प्सूल 51.14 2124(अ) 04-05-23
162 सलोमीफे नेजसरेट गोली 100 मिलीग्राि 1 गोली 13.95 4663(अ) 25-10-23
163 सलोमीफे नेजसरेट गोली 50 मिलीग्राि 1 गोली 8.84 4663(अ) 25-10-23
164 xksyh 10 fexzk- 1 xksyh 2.85 4663(अ) 25-10-23
165 xksyh 25 fexzk- 1 xksyh 6.22 1577(अ) 31-03-23
166 xksyh 75 fexzk- 1 xksyh 16.46 4663(अ) 25-10-23
167 सलोनाजेपम गोली 0.25 मिलीग्राि 1 गोली 2.02 4663(अ) 25-10-23
168 सलोनाजेपम गोली 0.5 मिलीग्राि 1 गोली 3.45 1574(अ) 31-03-23
169 सलोनाजेपम गोली 1 मिलीग्राि 1 गोली 4.77 4663(अ) 25-10-23
170 सलोजपडोग्रेल गोली 75 मिलीग्राि 1 गोली 6.66 1574(अ) 31-03-23
171 सलोजपडोग्रेल गोली 150 मिलीग्राि 1 गोली 20.48 1574(अ) 31-03-23
172 yks'ku 1% 1 fefy- 3.89 1577(अ) 31-03-23
173 isljh 100 fexzk- 1 isljh 10.01 1577(अ) 31-03-23
174 MªksIl 1% 1 fefy- 3.37 1577(अ) 31-03-23
175 Øhe 1% 1 xzke 3.00 1577(अ) 31-03-23
176 सलोजापाइन गोली 25 मिलीग्राि 1 गोली 2.78 1574(अ) 31-03-23
177 सलोजापाइन गोली 50 मिलीग्राि 1 गोली 5.19 1574(अ) 31-03-23
178 सलोजापाइन गोली 100 मिलीग्राि 1 गोली 8.45 1574(अ) 31-03-23
179 कोल्सीजसन गोली 0.5 मिलीग्राि 1 गोली 3.26 1574(अ) 31-03-23
xksyh 400 fexzk- ¼,½ $ 4663(अ)
180
80 fexzk- ¼ch½
1 xksyh 0.90 25-10-23

को-ररमोससाजोल गोली 800 मिलीग्राि (ए)


181 [सल्फामेथोससाजोल 1 गोली 2.30 4886(अ) 10-11-23
(ए)+राइमेथोजप्रम (बी)] + 160 मिलीग्राि (बी)
vksjy fyD;wbZM 200 4663(अ)
182 fexzzk-¼,½ $ 40 fexzk- 1 fefy- 0.35 25-10-23
¼ch½@5 fefy-
पाउडर फोर इजं ेक्शन 500 1574(अ)
183 साईसलोफॉस्ट्फोमाईड 1 वाईल 73.48 31-03-23
मिलीग्राि
184 xksyh 50 fexzk- 1 xksyh 3.73 1577(अ) 31-03-23
185 साइसलोसेरीन कै प्सूल 250 मिलीग्राि 1 कै प्सूल 59.19 4663(अ) 25-10-23
186 xksyh 250 fexzk- 1 xksyh 46.01 1577(अ) 31-03-23
187 साइसलोस्ट्पोररन कै प्सूल 25 मिलीग्राि 1 कै प्सूल 28.04 1574(अ) 31-03-23
ओरल मलमक्वड 100 1574(अ)
188 साइसलोस्ट्पोररन 1 मि.ली. 80.58 31-03-23
मिलीग्राि/मि.ली. (पी)
189 साइसलोस्ट्पोररन कै प्सूल 50 मिलीग्राि 1 कै प्सूल 55.11 4663(अ) 25-10-23
190 साइसलोस्ट्पोररन कै प्सूल 100मिलीग्राि 1 कै प्सूल 103.12 4663(अ) 25-10-23
इजं ेक्शन 1000 4663(अ)
191 साइटोजसनएराजबनोसाइड 1 वाईल 1130.33 25-10-23
मिलीग्राि/वाईल
192 साइटोजसनएराजबनोसाइड इजं ेक्शन 100 मिलीग्राि / 1 वाईल 139.59 1574(अ) 31-03-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 9
वाईल
इजं ेक्शन 500 मिलीग्राि/ 1574(अ)
193 साइटोजसनएराजबनोसाइड 1 वाईल 536.33 31-03-23
वाईल
194 डबीगारान कै प्सूल 110 मिग्रा. 1 कै प्सल
ू 31.81 2822(अ) 28-06-23
195 डबीगारान कै प्सूल 150 मिग्रा. 1 कै प्सूल 35.59 2822(अ) 28-06-23
पाउडर फोर इजं ेक्शन 200 4663(अ)
196 डकारबाजीन 1 वाईल 381.75 25-10-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 500 4663(अ)
197 डकारबाजीन 1 वाईल 518.83 25-10-23
मिलीग्राि
198 डेकलाटसवीर गोली 60 मिलीग्राि 1 गोली 199.97 4663(अ) 25-10-23
199 डापसोन गोली 100 मिलीग्राि 1 गोली 0.41 2540(अ) 08-06-23
200 िारुनवीर गोली 600 मिलीग्राि 1 गोली 154.44 4663(अ) 25-10-23
201 डेससामेथासोन गोली 0.5 मिलीग्राि 1 गोली 0.22 1574(अ) 31-03-23
202 डेससामेथासोन गोली 4 मिलीग्राि 1 गोली 4.62 4663(अ) 25-10-23
इजं ेक्शन 4 मिलीग्राि / मि.ली. 2124(अ)
203 डेससामेथासोन 1 मि.ली. 5.09 04-05-23
(2 मि.ली.)
इजं ेक्शन 4 मिलीग्राि / मि.ली. 2125(अ)
204 डेससामेथासोन (5 मि.ली.) 1 मि.ली. 2.57 04-05-23

batSD'ku 4 fexzk- 4663(अ)


205 @fefy- ¼izfr iSd 10 1 fefy- 1.57 25-10-23
fefy-½
batSD'ku 4 fexzk- 4663(अ)
206 @fefy- ¼izfr iSd 20 1 fefy- 1.35 25-10-23
fefy-½
batSD'ku 4 fexzk- 4663(अ)
207 @fefy- ¼izfr iSd 30 1 fefy- 0.90 25-10-23
fefy-½
208 डायिेपाम गोली 5 मिलीग्राि 1 गोली 1.63 4663(अ) 25-10-23
209 डायिेपाम इजं ेक्शन 5 मिलीग्राि/मि.ली. 1 मि.ली. 5.54 4663(अ) 25-10-23
210 xksyh 2 fexzk- 1 xksyh 1.44 4663(अ) 25-10-23
211 lqIiksftVªh 5 fexzk- 1 lqIiksftVªh 6.19 4663(अ) 25-10-23
212 डाईसलोफे नाक गोली 50 मिलीग्राि 1 गोली 2.05 1574(अ) 31-03-23
इजं ेक्शन 25 1574(अ)
213 डाईसलोफे नाक 1 मि.ली. 1.69 31-03-23
मिलीग्राि/मि.ली.
batSD'ku 10 fexzk- 4663(अ)
214 @fefy-¼10 fefy- iSd 1 fefy- 3.32 25-10-23
िे र्कम½
batSD'ku 10 fexzk- 4663(अ)
215 @fefy-¼10 fefy- औि 1 fefy- 2.10 25-10-23
अधिर्क iSd½
डायथाइलकाबाचमाजीन 1574(अ)
216 गोली 100 मिलीग्राि 1 गोली 1.67 31-03-23
(डी ई सी)
डायथाइलकाबाचमाजजन 1574(अ)
217 गोली 50 मिलीग्राि 1 गोली 0.56 31-03-23
(डीईसी)
डायथाइलकाबाचमाजजन ओरल मलमक्वड 120 1574(अ)
218 1 मि.ली. 0.48 31-03-23
(डीईसी) मिलीग्राि/ 5 मि.ली.(पी)
10 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

219 जडिोजससन गोली 0.25मिलीग्राि 1 गोली 1.33 1574(अ) 31-03-23


vksjy fyD;wbZM 0-05 4663(अ)
220 जडिोजससन fexzk-@ fefy-
1 fefy- 1.47 25-10-23
batSD'ku 0-25 fexzk- 4663(अ)
221 जडिोजससन @fefy-
1 fefy- 3.87 25-10-23
222 जडजल्टयाजेम गोली 60 मिलीग्राि 1 गोली 5.46 1574(अ) 31-03-23
223 xksyh 30 fexzk- 1 xksyh 2.68 4663(अ) 25-10-23
batSD'ku 5 fexzk- 4663(अ)
224
@fefy-
1 fefy- 3.50 25-10-23
225 डाइनोप्रोस्ट्टोन जेल 0.5 मिलीग्राि 1 ग्राि 84.72 4663(अ) 25-10-23
batSD'ku 50 fexzk- 4663(अ)
226
@fefy-
1 fefy- 9.03 25-10-23
पाउडर फोर इजं ेक्शन 20 1574(अ)
227 डॉसीटेससेल 1 वाईल 2868.39 31-03-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 80 1574(अ)
228 डॉसीटेससेल 1 वाईल 10333.69 31-03-23
मिलीग्राि
229 डॉlलूटेग्रेजवर गोली 50 मिलीग्राि 1 गोली 112.79 1574(अ) 31-03-23
230 डोमपररडोन गोली 10 मिलीग्राि 1 गोली 2.31 4663(अ) 25-10-23
ओरल मलमक्वड 1 1574(अ)
231 डोमपररडोन 1 मि.ली. 1.24 31-03-23
मिलीग्राि/मि.ली.
232 डोनेपेजजल गोली 10 मिलीग्राि 1 गोली 17.46 4663(अ) 25-10-23
233 डोनेपेजजल गोली 5 मिलीग्राि 1 गोली 12.11 4663(अ) 25-10-23
इजं ेक्शन 40 4663(अ)
234 डोपामाइन 1 मि.ली. 4.77 25-10-23
मिलीग्राि/मि.ली.
batSD'ku 2 fexzk- 1577(अ)
235
@fefy-
1 fefy- 31.75 31-03-23
236 डॉससीसाइजसलन कै प्सूल 100 मिलीग्राि 1 कै प्सूल 3.08 1574(अ) 31-03-23
237 डॉससीसाइजसलन xksyh 100 fexzk- 1 xksyh 1.22 1577(अ) 31-03-23
इजं ेक्शन के मलए पाउडर 100 4663(अ)
238 डॉससीसाइजसलन
मिलीग्राि 1 वाईल 502.64 25-10-23
239 डी- पेजनजसलमाइन कै प्सूल 250 मिलीग्राि 1 कै प्सूल 15.65 1574(अ) 31-03-23
izfr 0-1 4663(अ)
240 लाइसेंस के नसिं ार
fefy- 75.65 25-10-23

241 इफावरे न्ि गोली 600 मिलीग्राि 1 गोली 70.59 1574(अ) 31-03-23
242 xksyh 200 fexzk- (पी) 1 xksyh 22.54 4663(अ) 25-10-23
र्कैप्िल
ू 200
243 1 कै प्सूल 21.98 2124(अ) 04-05-23
ममलीग्राम
244 एनालाजप्रल गोली 5 मिलीग्राि 1 गोली 3.70 1574(अ) 31-03-23
245 एनालाजप्रल गोली 2.5 मिलीग्राि 1 गोली 2.19 4663(अ) 25-10-23
batSD'ku 40 fexzk-@0-4
fefy-
246
batSD'ku 60 fexzk-@0-6
0-1 fefy- 111.99 4663(अ) 25-10-23
fefy-
247 एंटेकावीर गोली 1 मिलीग्राि 1 गोली 130.24 4663(अ) 25-10-23
248 एंटेकावीर गोली 0.5 मिलीग्राि 1 गोली 84.44 4663(अ) 25-10-23
249 एररथ्रोपोइटीन इजं ेक्शन 2000 1 मि.ली. 549.58 1574(अ) 31-03-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 11

आईय/ू मि.ली.
इजं ेक्शन 10000 आईयू 1574(अ)
250 एररथ्रोपोइटीन 1 मि.ली. 1969.11 31-03-23
/मि.ली.
251 एजस्ट्सटालोप्राम गोली 5 मिलीग्राि 1 गोली 5.02 1574(अ) 31-03-23
252 एजस्ट्सटालोप्राम गोली 10 मिलीग्राि 1 गोली 9.00 1574(अ) 31-03-23
253 एजस्ट्सटालोप्राम गोली 20 मिलीग्राि 1 गोली 14.36 1574(अ) 31-03-23
batSD'ku 10 fexzk- 1577(अ)
254
@fefy-
1 fefy- 26.38 31-03-23
255 एथेमब्युटोल गोली 600मिलीग्राि 1 गोली 4.08 1574(अ) 31-03-23
256 एथेमब्युटोल गोली 800 मिलीग्राि 1 गोली 4.96 4663(अ) 25-10-23
257 एथेमब्युटोल गोली 400 मिलीग्राि 1 गोली 2.61 1574(अ) 31-03-23
258 xksyh 200 fexzk- 1 xksyh 1.14 1577(अ) 31-03-23
गोली 0.03 मिलीग्राि (ए)
एजथजनलएस्ट्राजडयोल (ए)
259 + गोली 0.15 मिलीग्राि 1 गोली 3.17 1574(अ) 31-03-23
+ लेवोनोगेस्ट्रेल (बी)
(बी)
260 एजथओनामाइड गोली 250 मिलीग्राि 1 गोली 14.81 1574(अ) 31-03-23
261 एटोपोसाइड कै प्सूल 50 मिलीग्राि 1 कै प्सूल 56.63 1574(अ) 31-03-23
इजं ेक्शन 20 1574(अ)
262 एटोपोसाइड 1 मि.ली. 34.51 31-03-23
मिलीग्राि/मि.ली.
263 दफल्ग्राजस्ट्टम इजं ेक्शन 300 एिसीजी 1 वाइल 1159.97 1574(अ) 31-03-23
264 फ्लुकोनाजोल गोली 400 मिलीग्राि 1 गोली 29.75 4663(अ) 25-10-23
265 फ्लूकोनाजोल गोली 200 मिलीग्राि 1 गोली 17.46 4663(अ) 25-10-23
266 फ्लूकोनाजोल गोली 100 मिलीग्राि 1 गोली 7.62 1574(अ) 31-03-23
267 फ्लुकोनाजोल गोली 150 मिलीग्राि 1 गोली 12.06 1574(अ) 31-03-23
268 फ्लुकोनाजोल गोली 50 मिलीग्राि 1 गोली 9.68 4663(अ) 25-10-23
269 dSIlwy 200 fexzk- 1 dSIlwy 40.11 4663(अ) 25-10-23
270 dSIlwy 150 fexzk- 1 dSIlwy 19.22 4663(अ) 25-10-23
batSD'ku 200 fexzk-@ izfr 100 1577(अ)
271
100 fefy- fefy- वाईल 92.33 31-03-23

272 dSIlwy 100 मिलीग्राि 1 कै प्सूल 21.40 2124(अ) 04-05-23

273 फ्लड्रोकोर्टचसोन गोली 0.1 मिलीग्राि 1 गोली 13.20 2541(अ) 08-06-23


274 फ्लुनाररजजन गोली 5 मिलीग्राि 1 गोली 2.48 4663(अ) 25-10-23
275 फ्लुनाररजजन गोली 10 मिलीग्राि 1 गोली 4.82 1574(अ) 31-03-23
276 फ्लुससोटाइन कै प्सूल 20 मिलीग्राि 1 कै प्सूल 3.99 1574(अ) 31-03-23
277 फ्लुससोटाइन कै प्सूल 60 मिलीग्राि 1 कै प्सूल 11.10 1574(अ) 31-03-23
278 फ्लुससोटाइन कै प्सूल 40 मिलीग्राि 1 कै प्सूल 6.49 1574(अ) 31-03-23
279 फ्लुससोटाइन कै प्सूल 10 मिलीग्राि 1 कै प्सल
ू 3.32 4663(अ) 25-10-23
280 फ्लुससोटाइन गोली 10 मिलीग्राि 1 गोली 2.78 2124(अ) 04-05-23
281 फ्लुससोटाइन गोली 40 मिलीग्राि 1 गोली 5.56 2124(अ) 04-05-23
282 फ्लुससोटाइन गोली 60 मिलीग्राि 1 गोली 8.25 2124(अ) 04-05-23
12 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

283 फ्लुससोटाइन गोली 20 मिलीग्राि 1 गोली 4.15 2124(अ) 04-05-23


इजं ेक्शन 25 1574(अ)
284 फ्लूफेनजीन 1 मि.ली. 55.26 31-03-23
मिलीग्राि/मि.ली.
285 फोजलक एजसड गोली 5 मिलीग्राि 1 गोली 1.51 1574(अ) 31-03-23
286 फ्रैमाइसेरटन क्रीि 1 % 1 ग्राि 1.66 2541(अ) 08-06-23
287 फ़्यूरोसेमाइड गोली 40 मिलीग्राि 1 गोली 0.91 4663(अ) 25-10-23
इजं ेक्शन 10 1574(अ)
288 फ़्यूरोसेमाइड 1 मि.ली. 2.99 31-03-23
मिलीग्राि/मि.ली.
vksjy fyD;wbZM 10 4663(अ)
289
fexzk-@fefy-
1 fefy- 3.32 25-10-23
290 फ्यूजसजडक एजसड क्रीि 2 % 1 ग्राि 9.83 1574(अ) 31-03-23
291 जिदफरटजनब गोली 250 मिलीग्राि 1 गोली 237.14 4663(अ) 25-10-23
पाउडर फोर इजं ेक्शन 1000 1574(अ)
292 िेमजसटाबाइन 1 वाईल 5592.55 31-03-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 200 4663(अ)
293 िेमजसटाबाइन 1 वाईल 1299.80 25-10-23
मिलीग्राि
इजं ेक्शन 40 मिलीग्राि / 2125(अ)
294 िेंटामाइजसन मि.ली. (1.5 मि.ली.) 1 मि.ली. 2.90 04-05-23
इजं ेक्शन 10 1574(अ)
295 िेंटामाइजसन 1 मि.ली. 2.41 31-03-23
मिलीग्राि/मि.ली.
batSD'ku 40 fexzk- 1577(अ)
296 @fefy- ¼izfr iSd 10 1 fefy- 1.51 31-03-23
fefy-½
batSD'ku 40 fexzk- 4663(अ)
297 @fefy- ¼izfr iSd 20 1 fefy- 1.55 25-10-23
fefy-½
batSD'ku 40 fexzk- 1577(अ)
298 @fefy- ¼izfr iSd 30 1 fefy- 1.23 31-03-23
fefy-½
batSD'ku 40 fexzk- 2124(अ)
299
@fefy- 2 1 मि.ली. 4.85 04-05-23
300 जललमेपाइराइड गोली 2 मिलीग्राि 1 गोली 5.80 4663(अ) 25-10-23
301 जललमेपाइराइड गोली 1 मिलीग्राि 1 गोली 3.70 1574(अ) 31-03-23
1574(अ) 31-03-23
302 ललूकोि इजं ेक्शन 25% 1 मि.ली. 0.20
जललसेररन/ललीसेरॉल 1579(अ)
303 (आईपी में उल्लेख दकए टॉमपकल-लोशन 1 मि.ली. 1.23 31-03-23
गए अनुसार)
जललसेररन/ललीसेरॉल 4663(अ)
304 (आईपी में उल्लेख दकए टॉमपकल - क्रीि 1 ग्राि 2.37 25-10-23
गए अनुसार)
305 जललसरील ररजनरेट इजं ेक्शन 5 मिलीग्राि/मि.ली. 1 मि.ली. 6.19 4663(अ) 25-10-23
lcfyaxq,y xksyh 0-5 4663(अ)
306
fexzk-
1 xksyh 1.27 25-10-23
इजं ेक्शन 0.2 1574(अ)
307 ललाइकोपीरोलेट 1 मि.ली. 14.53 31-03-23
मिलीग्राि/मि.ली.
308 जग्रसोफु जल्वन गोली 250 मिलीग्राि 1 गोली 1.77 1574(अ) 31-03-23
309 हैलोपेरीडोल गोली 5 मिलीग्राि 1 गोली 3.57 4663(अ) 25-10-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 13

310 हैलोपेरीडोल गोली 10 मिलीग्राि 1 गोली 4.78 4663(अ) 25-10-23


ओरल मलमक्वड 2 1574(अ)
311 हैलोपेरीडोल 1 मि.ली. 2.24 31-03-23
मिलीग्राि/5मि.ली.
batSD'ku 5 fexzk- 1577(अ)
312
@fefy-
1 fefy- 6.51 31-03-23
313 xksyh 20 fexzk- 1 xksyh 5.36 4663(अ) 25-10-23
314 हैलोपेरीडोल गोली 1.5 मिलीग्राि 1 गोली 1.58 1697(अ) 12-04-23
315 हालोथाने मलक़िंड फोर इनहेलेशन 1 मि.ली. 6.10 4663(अ) 25-10-23
इजं ेक्शन 1000 आईय/ू 1574(अ)
316 हेपाररन 1 मि.ली. 21.21 31-03-23
मि.ली.
इजं ेक्शन 5000 आईयू / 1574(अ)
317 हेपाररन 1 मि.ली. 59.96 31-03-23
मि.ली.
318 लाइसेंस के नसिं ार 1 वाईल 5498.70 4663(अ) 25-10-23

319 लाइसेंस के नसिं ार 1 fefy- 78.82 1577(अ) 31-03-23


320 होमेरोजपन ड्रोप 2% 1 मि.ली. 6.40 1574(अ) 31-03-23
blesa 52 fexzk- 4663(अ)
321
ysoksuksxZLs Vsªy 'kkfey gS
1 vkbZ;wMh 4103.53 25-10-23
ह्यूमन कोररओजनक 1574(अ)
322 इजं ेक्शन 5000 आईयू 1 वाइल 417.47 31-03-23
गोनाडोरोजपन
जललसेररन/ललीसेरॉल
323 (आईपी में उल्लेख दकए इजं ेक्शन 10000 आईयू 1 वाईल 928.30 4663(अ) 25-10-23
गए अनुसार)
जललसेररन/ललीसेरॉल
324 (आईपी में उल्लेख दकए इजं ेक्शन 2000 आईयू 1 वाईल 343.66 1579(अ) 31-03-23
गए अनुसार)
325 हाइड्रोसलोरोजथयाजिड गोली 25 मिलीग्राि 1 गोली 1.75 4663(अ) 25-10-23
326 हाइड्रोसलोरोजथयाजिड गोली 12.5 मिलीग्राि 1 गोली 1.04 1574(अ) 31-03-23
पाउडर फोर इजं ेक्शन 100 1574(अ)
327 हाइड्रोकार्टचसोन 1 वाईल 44.79 31-03-23
मिलीग्राि
328 हाइड्रोकार्टचसोन गोली 10 मिलीग्राि 1 गोली 6.70 1574(अ) 31-03-23
पाउडर फोर इजं ेक्शन 20 1574(अ)
329 हाइड्रोकार्टचसोन 1 वाइल 65.60 31-03-23
0मिलीग्राि
330 हाइड्रोकार्टचसोन गोली 5 मिलीग्राि 1 गोली 3.12 4663(अ) 25-10-23
331 हाइड्रोकार्टचसोन गोली 20 मिलीग्राि 1 गोली 14.89 4663(अ) 25-10-23
हायड्रोससीप्रोपायल 4663(अ)
332 इजं ेक्शन 2% 1 मि.ली. 29.21 25-10-23
जमथायलसेलुलॉि
333 हाइड्रोससीसलोरोिीन गोली 400 मिलीग्राि 1 गोली 13.80 1574(अ) 31-03-23
334 हाइड्रोससीसलोरोिीन गोली 200 मिलीग्राि 1 गोली 6.36 4663(अ) 25-10-23
335 हाइड्रोससीयूररया कै प्सूल 500 मिलीग्राि 1 कै प्सूल 12.12 1574(अ) 31-03-23
336 आइबुप्रोफे न गोली 200 मिलीग्राि 1 गोली 0.71 4663(अ) 25-10-23
337 आइबुप्रोफे न गोली 400 मिलीग्राि 1 गोली 1.20 4663(अ) 25-10-23
ओरल मलमक्वड 100 1574(अ)
338 आइबुप्रोफे न 1 मि.ली. 0.22 31-03-23
मिलीग्राि / 5 मि.ली.(पी)
batSD'ku ds fy, ikmMj
339
2000 fexzk- 1 वाईल 643.16 4663(अ) 25-10-23
340 batSD'ku ds fy, ikmMj 1 वाईल 318.96 1577(अ) 31-03-23
14 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

1000 fexzk-
341 इमैरटजनब गोली 100 मिलीग्राि 1 गोली 69.75 1574(अ) 31-03-23
342 इमैरटजनब गोली 400 मिलीग्राि 1 गोली 199.62 1574(अ) 31-03-23
343 dSIlwy 100 fexzk- 1 dSIlwy 73.48 1577(अ) 31-03-23
batSD'ku 40 4663(अ)
344
vkbZ;w@fefy-
1 fefy- 16.99 25-10-23
इंजेटशन 100 4663(अ)
345 इं सुजलन ललार्िचन 1 fefy- 203.46 25-10-23
आईयू / मम.ली.
इं सुजलन इं टरमीजडएट 4663(अ)
346 इजं ेक्शन 40 आई/मि.ली. 1 मि.ली. 16.99 25-10-23
एकसटंग (एनपीएर्)
batSD'ku 300 fexzk- 4663(अ)
347
vk;ksfMu@fefy-
1 fefy- 16.90 25-10-23
इंजेटशन 140 to
350 ममलीग्राम
348 आयोहेससोल 1 मम.ली. 14.24 4663(अ) 25-10-23
आयोडडन.ली.मम/
(350ममलीग्राम)
इंजेटशन हे तु
इररनोटेकन
349 िॉेयश
ू न 20 1 मम.ली. 964.89 1579(अ) 31-03-23
एर्सीएलररहाइड्रेट
ममलीग्राम/मम.ली.
इजं ेक्शन 20 4663(अ)
350 आयरन सुक्रोि 1 मि.ली. 57.41 25-10-23
मिलीग्राि/मि.ली.
351 आइसोफ्लुरेन मलक़िंड फोर इनहेलेशन 1 मि.ली. 9.65 1574(अ) 31-03-23
352 आइसोजनयाजजड गोली 300 मिलीग्राि 1 गोली 1.29 2540(अ) 08-06-23
353 आइसोजनयाजजड गोली 100 मिलीग्राि 1 गोली 0.65 2540(अ) 08-06-23
354 आइसोसॉरबाइड जडजनरेट गोली 5 मिलीग्राि 1 गोली 0.82 4663(अ) 25-10-23
355 आइसोसॉरबाइड जडजनरेट गोली 10मिलीग्राि 1 गोली 0.81 4663(अ) 25-10-23
356 इस्ट्पघुला ग्रेनल
िं ेस/ हस्कपाउडर / 1 ग्राि 0.94 1574(अ) 31-03-23
ओरल मलमक्वड 10
357 इराकोनािोल मिलीग्राि / मि.ली. 1 मि.ली. 4.94 1574(अ) 31-03-23

र्कैप्िल
ू 100
358 इराकोनािोल 1 र्कैप्िल
ू 16.67 1579(अ) 31-03-23
ममलीग्राम
र्कैप्िल
ू 200
359 इराकोनािोल 1 र्कैप्िल
ू 22.12 1579(अ) 31-03-23
ममलीग्राम
360 ykblsal ds :i esa 1 vkbZ;wMh 281.02 4663(अ) 25-10-23
361 आइवरमेजसटन गोली 6 ममलीग्राम 1 गोली 21.58 1578(अ) 31-03-23
362 आइवरमेजसटन गोली 12 ममलीग्राम 1 गोली 37.37 1578(अ) 31-03-23
लाइिेंि र्के अनि
ु ाि
िापनीि इं सेफेलाइरटस
363 (4 एमिीजी िे 6 1 वाइल 677.17 2124(अ) 04-05-23
वैससीन
एमिीजी)
िापनीि इं सेफेलाइरटस लाइिेंि र्के अनि
ु ाि
364 1 वाइल 518.66 2124(अ) 04-05-23
वैससीन (3 एमिीजी तर्क)
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 15

इजं ेक्शन 50
365 के टामाइन 1 मि.ली. 12.12 1574(अ) 31-03-23
मिलीग्राि/मि.ली.
366 लेबेटालोल इजं ेक्शन 5 मिलीग्राि/मि.ली. 1 मि.ली. 49.98 1574(अ) 31-03-23
गोली 100
367 लेबेटालोल 1 गोली 15.16 4663(अ) 25-10-23
ममलीग्राम
ओरल मलमक्वड 10 ग्राि
368 लैसटु लोि 1 मि.ली. 1.23 1574(अ) 31-03-23
/15मि.ली.
369 लैमीवुडीन गोली 100 मिलीग्राि 1 गोली 10.40 1574(अ) 31-03-23
370 लैमीवुडीन गोली 150 मिलीग्राि 1 गोली 10.86 1574(अ) 31-03-23
पाउडर फोर इजं ेक्शन 5000
371 एल- ऐस्ट्पैरिाइनेस 1 वाईल 1034.88 4663(अ) 25-10-23
के यू
पाउडर फोर इजं ेक्शन
372 एल- ऐस्ट्पैरिाइनेस 1 वाईल 1707.74 4663(अ) 25-10-23
10000 के यू
373 लैटानोप्रोस्ट्ट ड्रोप 0.005% 1 मि.ली. 232.58 2542(अ) 08-06-23
374 लेजनलेडोमाइड कै प्सूल 5 मिलीग्राि 1 कै प्सूल 67.25 1574(अ) 31-03-23
375 लेजनलेडोमाइड कै प्सूल 25 मिलीग्राि 1 कै प्सूल 292.28 4663(अ) 25-10-23
376 लेरोजोल गोली 2.5 मिलीग्राि 1 गोली 29.32 4663(अ) 25-10-23
पाउडर फोर इजं ेक्शन 22.5
377 ल्यूप्रोलाइड एसीटेट 1 वाईल 17081.50 4663(अ) 25-10-23
मिलीग्राि
पाउडर फोर इजं ेक्शन
378 ल्यूप्रोलाइड एसीटेट 1 वाईल 9294.48 4663(अ) 25-10-23
11.25 मिलीग्राि
पाउडर फोर इजं ेक्शन 3.75
379 ल्यूप्रोलाइड एसीटे ट 1 वाईल 3112.67 1574(अ) 31-03-23
मिलीग्राि
380 लेवेरटरासेटम गोली 250 मिलीग्राि 1 गोली 6.30 1574(अ) 31-03-23
381 लेवेरटरासेटम गोली 500 मिलीग्राि 1 गोली 12.98 1574(अ) 31-03-23
िोडीफाइड ररलीज गोली
382 लेवेरटरासेटम 1 गोली 18.30 4663(अ) 25-10-23
750 मिलीग्राि
383 लेवेरटरासेटम गोली 750 मिलीग्राि 1 गोली 19.34 1574(अ) 31-03-23
ओरल मलमक्वड 100
384 लेवेरटरासेटम 1 मि.ली. 3.97 4663(अ) 25-10-23
मिलीग्राि/मि.ली. (पी)
इजं ेक्शन 100 मिलीग्राि/
385 लेवेरटरासेटम 1 मि.ली. 23.02 4663(अ) 25-10-23
मि.ली.
िोडीफाईड ररलीज –गोली
लेवोडोपा (ए) +
386 200 मिलीग्राि (ए) + 1 गोली 4.73 1574(अ) 31-03-23
कार्बचडोपा (बी)
50 मिलीग्राि (बी)
गोली 100 ममलीग्राम
लेवोडोपा (ए) +
387 (ए) + 25 ममलीग्राम 1 गोली 2.58 4663(अ) 25-10-23
कार्बचडोपा (बी)
(बी)
गोली 100 ममलीग्राम
लेवोडोपा (ए) +
388 (ए) + 10 ममलीग्राम 1 गोली 1.76 1574(अ) 31-03-23
कार्बचडोपा (बी)
(बी)
लेवोडोपा (ए) + गोली 250 मिलीग्राि (ए)
389 1 गोली 4.42 4663(अ) 25-10-23
कार्बचडोपा (बी) +25 मिलीग्राि (बी)
िोडीफाइड ररलीज –गोली
लेवोडोपा (ए) +
390 100 मिलीग्राि (ए) + 25 1 गोली 2.79 1574(अ) 31-03-23
कार्बचडोपा (बी)
मिलीग्राि (बी)
16 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

391 जलवोफ़्लॉससाजसन गोली 750 मिलीग्राि 1 गोली 12.45 4663(अ) 25-10-23


392 जलवोफ़्लॉससाजसन गोली 250 मिलीग्राि 1 गोली 4.82 1697(अ) 12-04-23
393 जलवोफ़्लॉससाजसन गोली 500 मिलीग्राि 1 गोली 8.99 1697(अ) 12-04-23
394 लेवोथायरोजससन गोली 50 एिसीजी 1 गोली 1.03 1574(अ) 31-03-23
395 लेवोथायरोजससन गोली 75 एिसीजी 1 गोली 1.44 4663(अ) 25-10-23
396 लेवोथायरोजससन गोली 88 एिसीजी 1 गोली 1.65 4663(अ) 25-10-23
397 लेवोथायरोजससन गोली 112 एिसीजी 1 गोली 1.66 4663(अ) 25-10-23
398 लेवोथायरोजससन गोली 25 एिसीजी 1 गोली 1.45 4663(अ) 25-10-23
399 लेवोथायरोजससन गोली 62.5 एिसीजी 1 गोली 1.61 1574(अ) 31-03-23
400 लेवोथायरोजससन गोली 12.5 एिसीजी 1 गोली 1.48 1574(अ) 31-03-23
401 लेवोथायरोजससन गोली 100 एिसीजी 1 गोली 1.32 1574(अ) 31-03-23
402 लेवोथायरोजससन गोली 125 एिसीजी 1 गोली 1.69 1574(अ) 31-03-23
403 लेवोथायरोजससन गोली 150 एिसीजी 1 गोली 1.70 1577(अ) 31-03-23
404 जलग्नोके न टोमपकल फोिम 2-5 % 1 ग्राि/मि.ली. 1.13 1574(अ) 31-03-23
405 जलग्नोके न इजं ेक्शन 2% 1 मि.ली. 1.04 1574(अ) 31-03-23
406 batSD'ku 1% 1 fefy- 8.87 4663(अ) 25-10-23
batSD'ku 5% Xywdkst
407 1 fefy- 3.50 4663(अ) 25-10-23
7-5% ds lkFk
batSD'ku 2% ¼,½ $
408 1%200000 ¼5 1 fefy- 1.05 1577(अ) 31-03-23
,elhth@fefy-½ ¼ch½
409 जलनेजोजलड गोली 600 मिलीग्राि 1 गोली 35.67 4663(अ) 25-10-23
गोली 300
410 जलनेिोजलड 1 गोली 22.65 4663(अ) 25-10-23
ममलीग्राम
411 जलजथयम गोली 300 मिलीग्राि 1 गोली 1.63 4663(अ) 25-10-23
412 लोपेरामाइड गोली 2 मिलीग्राि 1 गोली 2.28 4663(अ) 25-10-23

413 dSIlwy 2 fexzk- 1 dSIlwy 3.79 4663(अ) 25-10-23

लोजपनवीर (ए) + गोली 200 मिलीग्राि (ए)


414 1 गोली 47.97 4663(अ) 25-10-23
ररटोनवीर (बी) + 50 मिलीग्राि (बी)
415 लोरािेपेम गोली 1 मिलीग्राि 1 गोली 2.31 4663(अ) 25-10-23
416 लोरािेपेम गोली 2 मिलीग्राि 1 गोली 2.81 1574(अ) 31-03-23
batSD'ku 2 fexzk-
417
@fefy-
1 fefy- 8.10 4663(अ) 25-10-23
इजं ेक्शन 500
418 मैगनीजियम सल्फे ट 1 मि.ली. 4.87 4663(अ) 25-10-23
मिलीग्राि/मि.ली.
419 मैजनटोल इजं ेक्शन 20 % 1 मि.ली. 0.35 4663(अ) 25-10-23
420 batSD'ku 10% 1 fefy- 0.19 1577(अ) 31-03-23
421 मेबेंडािोल गोली 100 मिलीग्राि 1 गोली 2.90 1574(अ) 31-03-23
ओरल मलमक्वड 100
422 मेबेंडािोल 1 मि.ली. 0.84 1574(अ) 31-03-23
मिलीग्राि/5 मि.ली. (पी)
मेड्रोससीप्रोिेस्ट्टेरोन
423 गोली 10 मिलीग्राि 1 गोली 6.25 4663(अ) 25-10-23
एसीटेट
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 17

मेड्रोससीप्रोिेस्ट्टेरोन इजं ेक्शन 150 मिलीग्राि


424 1 मि.ली. 289.77 4663(अ) 25-10-23
एसीटेट /मि.ली.
ओरल मलमक्वड 100
425 मेफानाजमक एजसड 1 मि.ली. 0.56 1574(अ) 31-03-23
मिलीग्राि / 5 मि.ली. (पी)
426 xksyh 250 fexzk- 1 xksyh 2.11 4663(अ) 25-10-23
427 मेफ्लोिाइन गोली 250 मिलीग्राि 1 गोली 52.16 4663(अ) 25-10-23
428 मेललुमाइन डायरीजोएट इजं ेक्शन 60% डब्ल्यू वी / 1 मि.ली. 9.47 1574(अ) 31-03-23
429 मेललुमाइन डायरीजोएट इजं ेक्शन 76% डब्ल्यू वी / 1 मि.ली. 10.20 1574(अ) 31-03-23
इंजेटशन हे तु
पाउडि 500
430 मेरोपेनम ममलीग्राम 1 वाईल 723.02 1579(अ) 31-03-23
(ट्राइहाइड्रेट र्के रूप
में )
इंजेटशन र्के मलये
पाउडि 1000
431 मेरोपेनम ममलीग्राम 1 वाईल 952.74 4663(अ) 25-10-23
(ट्राइहाइड्रेट र्के रूप
में )
इजं ेक्शन 100
432 मेस्ना 1 मि.ली. 15.51 4663(अ) 25-10-23
मिलीग्राि/मि.ली.
433 मेटफोर्मचन गोली 1000 मिलीग्राि 1 गोली 3.49 4663(अ) 25-10-23
434 मेटफोर्मचन गोली 500 मिलीग्राि 1 गोली 2.02 4663(अ) 25-10-23
िोडीफाइड ररलीज गोली
435 मेटफोर्मचन 1 गोली 4.05 4663(अ) 25-10-23
1000 मिलीग्राि
436 मेथोरेससेट गोली 10 मिलीग्राि 1 गोली 13.29 4663(अ) 25-10-23
437 मेथोरेससेट गोली 2.5 मिलीग्राि 1 गोली 5.31 1574(अ) 31-03-23
438 xksyh 5 fexzk- 1 xksyh 9.43 4663(अ) 25-10-23
439 जमथाइलिोमेररन गोली 0.125 मिलीग्राि 1 गोली 8.94 4663(अ) 25-10-23
इजं ेक्शन 0.2
440 जमथाइलिोमेररन 1 मि.ली. 14.95 4663(अ) 25-10-23
मिलीग्राि/मि.ली.
batSD'ku 40 fexzk-@
441
fefy-
1 fefy- 45.67 4663(अ) 25-10-23
442 मेटोसलोप्रमाइड गोली 10 मिलीग्राि 1 गोली 1.35 4663(अ) 25-10-23
इजं ेक्शन 5 मिलीग्राि/मि.ली.
443 मेटोसलोप्रमाइड 1 मि.ली. 2.67 4663(अ) 25-10-23
(लेस देन 10 मि.ली. पैक)
batSD'ku 5 fexzk-
444 @fefy- ¼10 fefy- 1 fefy- 1.63 4663(अ) 25-10-23
औि अधिर्क iSd½
ओरल मलमक्वड 5
445 मेटोसलोप्रमाइड 1 मि.ली. 0.50 1577(अ) 31-03-23
मिलीग्राि/5मि.ली. (पी)
446 मेटोप्रोलोल गोली 25 मिलीग्राि 1 गोली 4.20 1574(अ) 31-03-23
447 मेटोप्रोलोल गोली 50 मिलीग्राि 1 गोली 5.84 1574(अ) 31-03-23
िोडीफाईड ररलीज गोली
448 मेटोप्रोलोल 1 गोली 14.99 1574(अ) 31-03-23
100 मिलीग्राि
449 मेटोप्रोलोल गोली 100 मिलीग्राि 1 गोली 11.13 1574(अ) 31-03-23
18 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

450 dSIlwy 25 fexzk- 1 dSIlwy 4.14 4663(अ) 25-10-23


451 dSIlwy 50 fexzk- 1 dSIlwy 5.82 4663(अ) 25-10-23
इंजेटशन 1
452 मेटोप्रोलोल 1 मम.ली. 3.40 4663(अ) 25-10-23
ममलीग्राम .ली.मम /
453 मेरोजनडािोल गोली 200 मिलीग्राि 1 गोली 0.82 4663(अ) 25-10-23
454 मेरोजनडािोल गोली 400 मिलीग्राि 1 गोली 1.52 1574(अ) 31-03-23
इजं ेक्शन 500
455 मेरोजनडािोल 1 मि.ली. 0.21 1574(अ) 31-03-23
मिलीग्राि/100मि.ली.
ओरल मलमक्वड 200
456 मेरोजनडािोल 1 मि.ली. 0.52 4663(अ) 25-10-23
मिलीग्राि/5मि.ली. (पी)
नैजल स्रै 1.25 मिलीग्राि
457 जमडाजोलम 1 मि.ली. 216.82 4663(अ) 25-10-23
/ क़िंएसन
नैजल स्रै 0.5 मिलीग्राि /
458 जमडाजोलम 1 मि.ली. 79.93 1574(अ) 31-03-23
क़िंएसन
इजं ेक्शन 1 मिलीग्राि/
459 जमडाजोलम 1 मि.ली. 5.92 1574(अ) 31-03-23
मि.ली.
इजं ेक्शन 5 मिलीग्राि/
460 जमडाजोलम 1 मि.ली. 10.88 4663(अ) 25-10-23
मि.ली.
461 जमफे जप्रस्ट्टोन गोली 200 मिलीग्राि 1 गोली 350.92 4663(अ) 25-10-23
462 जमसोप्रोस्ट्टोल गोली 200 एिसीजी 1 गोली 18.97 1574(अ) 31-03-23
463 जमसोप्रोस्ट्टोल गोली 100 एिसीजी 1 गोली 9.92 1574(अ) 31-03-23
464 मोंटेलुकास्ट्ट गोली 4 मिलीग्राि 1 गोली 10.03 1574(अ) 31-03-23
465 मोंटेलुकास्ट्ट गोली 10 मिलीग्राि 1 गोली 16.44 4663(अ) 25-10-23
इजं ेक्शन
466 मॉर्फच न 1 मि.ली. 19.60 4663(अ) 25-10-23
10मिलीग्राि/मि.ली.
इजं ेक्शन 15
467 मॉर्फच न 1 मि.ली. 14.93 1574(अ) 31-03-23
मिलीग्राि/मि.ली.
468 मोससीफ्लोससाजसन गोली 400 मिलीग्राि 1 गोली 25.82 1574(अ) 31-03-23
469 मुजपरोजसन ओइंटमें ट 2% 1 ग्राम 20.29 1579(अ) 31-03-23
470 मायकोफे नोलेट मोफे रटल गोली 250 मिलीग्राि 1 गोली 49.60 1574(अ) 31-03-23
इजं ेक्शन 200
471 एन-एजसटाइलजसस्ट्टीन 1 मि.ली. 23.64 4663(अ) 25-10-23
मिलीग्राि/मि.ली.
इजं ेक्शन 0.4
472 नालोससोन 1 मि.ली. 92.73 1574(अ) 31-03-23
मिलीग्राि/मि.ली.
473 नैटामाइजसन ड्रोप 5% 1 मि.ली. 23.38 4663(अ) 25-10-23
इजं ेक्शन 0.5
474 जनओजस्ट्टलमाइन 1 मि.ली. 5.01 1574(अ) 31-03-23
मिलीग्राि/मि.ली.
475 जनओजस्ट्टलमाइन गोली 15 मिलीग्राि 1 गोली 4.59 4663(अ) 25-10-23
476 नेजवरे पीन गोली 200 मिलीग्राि 1 गोली 15.80 4663(अ) 25-10-23
जनकोटीन (जनकोटीन
477 लॉजेंग 2 ममलीग्राम 1 लॉजेंग 7.92 4663(अ) 25-10-23
ररप्लेसमेंट थेरेपी के जलए)
जनकोटीन (जनकोटीन
478 गम 2 ममलीग्राम 1 गम 8.59 4663(अ) 25-10-23
ररप्लेसमेंट थेरेपी के जलए)
जनकोटीन (जनकोटीन
479 गम 4 ममलीग्राम 1 गम 10.64 1579(अ) 31-03-23
ररप्लेसमेंट थेरेपी के जलए)
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 19

जनकोटीन (जनकोटीन
480 लॉजेंग 4 ममलीग्राम 1 लॉजेंग 9.75 1579(अ) 31-03-23
ररप्लेसमेंट थेरेपी के जलए)
481 जनफे जडजपन गोली 10 मिलीग्राि 1 गोली 1.54 4663(अ) 25-10-23
482 dSIlwy 10 fexzk- 1 dSIlwy 0.95 1577(अ) 31-03-23
483 नाइट्रोफ्यिू न्टाइन गोली 100 मिलीग्राि 1 गोली 8.11 4663(अ) 25-10-23
484 नन टोइन dSIlwy 100 fexzk- 1 dSIlwy 8.64 1577(अ) 31-03-23
vksjy fyD;wbZM 25
485 टोइन fexzk-@5 fefy-
1 fefy- 0.89 4663(अ) 25-10-23
इजं ेक्शन 2 मिलीग्राि/
486 नॉिएड्रेनालाईन 1 मि.ली. 20.17 1574(अ) 31-03-23
मि.ली.
487 नोिे धिस्टिोन गोली 5 मिलीग्राि 1 गोली 5.39 1574(अ) 31-03-23
488 ओमेप्राज़ोल कै प्सूल 20 मिलीग्राि 1 कै प्सूल 2.87 1574(अ) 31-03-23
489 xksyh 20 fexzk- 1 xksyh 4.34 4663(अ) 25-10-23
490 dSIlwy 10 fexzk- 1 dSIlwy 2.41 1577(अ) 31-03-23
vksjy fyD;wbZM ds fy,
491
ikmMj 20 fexzk-
1 xzke 1.51 1577(अ) 31-03-23
492 dSIlwy 40 fexzk- 1 dSIlwy 8.45 1577(अ) 31-03-23
493 ओंडान्िेट्रॉन गोली 4 मिलीग्राि 1 गोली 5.14 4663(अ) 25-10-23
ओरल मलमक्वड 2
494 ओंडान्िेट्रॉन 1 मि.ली. 1.26 4663(अ) 25-10-23
मिलीग्राि/5 मि.ली. (पी)
495 ओंडान्िेट्रॉन इजं ेक्शन 2 मिलीग्राि/मि.ली. 1 मि.ली. 5.96 1574(अ) 31-03-23
496 ओंडान्िेट्रॉन गोली 8 मिलीग्राि 1 गोली 9.06 4663(अ) 25-10-23
497 ykblsal ds :i esa 1 fefy- 0.15 4663(अ) 25-10-23
ऑरमेलोजससफे न
498 गोली 30 जमलीग्राम 1 गोली 8.44 1579(अ) 31-03-23
(सेंटक्रोमन)
इजं ेक्शन 5
499 ऑक्टिक्प्लक्प्टन मिलीग्राि/मि.ली. in 10 1 वाईल 2233.95 4663(अ) 25-10-23
मि.ली. वाईल
500 ऑटिीटोमिन इजं ेक्शन 5 आईय/ू मि.ली. 1 मि.ली. 17.84 4663(अ) 25-10-23
batSD'ku 10
501 1 fefy- 39.87 1577(अ) 31-03-23
vkbZ;w@fefy-
batSD'ku 30 fexzk-@5
502 fefy-batSD'ku 100 1 fefy- 215.44 1577(अ) 31-03-23
fexzk-@16-7 fefy-
503 पैंटोप्राज़ोल इजं ेक्शन 40 मिलीग्राि 1 वाईल 50.45 1574(अ) 31-03-23
504 पेिामिटामोल गोली 650 मिलीग्राि 1 गोली 2.01 4663(अ) 25-10-23
ओरल मलमक्वड 125
505 पेिामिटामोल 1 मि.ली. 0.37 1574(अ) 31-03-23
मिलीग्राि/5 मि.ली. (पी)
ओरल मलमक्वड 250
506 पेिामिटामोल 1 मि.ली. 0.67 1574(अ) 31-03-23
मिलीग्राि/5 मि.ली. (पी)
ओरल मलमक्वड 120
507 पेिामिटामोल 1 मि.ली. 0.61 4663(अ) 25-10-23
मिलीग्राि/5 मि.ली. (पी)
20 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

508 पेिामिटामोल गोली 500 मिलीग्राि 1 गोली 0.90 4663(अ) 25-10-23


509 पेिामिटामोल सपोमसटरी 80 मिलीग्राि 1 सपोमसटरी 6.66 1574(अ) 31-03-23
510 पेिामिटामोल सपोमसटरी 170 मिलीग्राि 1 सपोमसटरी 7.95 4663(अ) 25-10-23
इंजेटशन 150
511 पैिािीटामोल ममलीग्राम / मम.ली. 1 मि.ली. 3.97 2124(अ) 04-05-23
(2 मम.ली.)
इंजेटशन 150
512 पेिामिटामोल मिलीग्राि / मि.ली. (100 1 मि.ली. 1.60 2125(अ) 04-05-23
मि.ली.)
513 Øhe 5% 1 xzke 1.85 1577(अ) 31-03-23
514 yks'ku 1% 1 fefy- 1.00 4663(अ) 25-10-23
515 Øhe 1% 1 xzke 1.50 1577(अ) 31-03-23
1 fefy-
516 yks'ku 5% 1.00 4663(अ) 25-10-23
@xzke
517 पमेधिन जेल 5% 1 ग्राि 1.31 2540(अ) 08-06-23
batSD'ku 22-75 fexzk-
518 1 fefy- 2.76 4663(अ) 25-10-23
@fefy-¼2 fefy-½
batSD'ku 22-75 fexzk-
519 1 fefy- 2.06 1577(अ) 31-03-23
@fefy-¼10 fefy-½
520 फेनोबार्बिटोन गोली 30 मिलीग्राि 1 गोली 1.31 1574(अ) 31-03-23
521 फेनोबार्बिटोन गोली 60 मिलीग्राि 1 गोली 1.89 1574(अ) 31-03-23
इजं ेक्शन 200
522 फेनोबार्बिटोन 1 मि.ली. 22.14 1574(अ) 31-03-23
मिलीग्राि/मि.ली.
ओरल मलमक्वड 20
523 फेनोबार्बिटोन 1 मि.ली. 0.49 1574(अ) 31-03-23
मिलीग्राि / 5 मि.ली. (पी)
524 फेनीटोइन गोली 300 मिलीग्राि 1 गोली 5.48 1574(अ) 31-03-23
इजं ेक्शन 50
525 फ़िनाइटोइन 1 मि.ली. 5.95 1574(अ) 31-03-23
मिलीग्राि/मि.ली.
मोडीफाइड रिलीज
526 1 xksyh 6.57 1577(अ) 31-03-23
xksyh 300 fexzk-
527 xksyh 100 fexzk- 1 xksyh 1.76 1577(अ) 31-03-23
528 xksyh 50 fexzk- 1 xksyh 0.84 1577(अ) 31-03-23
vksjy fyD;wbZM 30
529 1 fefy- 0.35 4663(अ) 25-10-23
fexzk-@5 fefy- (पी)
vksjy fyD;wbZM 125
530 1 fefy- 1.10 4663(अ) 25-10-23
fexzk-@5 fefy- (पी)
531 dSIlwy 300 fexzk- 1 dSIlwy 4.65 1577(अ) 31-03-23
532 dSIlwy 100 fexzk- 1 dSIlwy 1.83 4663(अ) 25-10-23
फाइटोमेनाडडयोन इजं ेक्शन 10
533 1 मि.ली. 53.09 4663(अ) 25-10-23
(ववटाममन मिलीग्राि/मि.ली.
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 21

534 xksyh 10 fexzk- 1 xksyh 14.54 1577(अ) 31-03-23


535 वपलोर्कावपिन ड्रोप 2 % 1 मि.ली. 10.83 1574(अ) 31-03-23

वपपेिामिमलन (ए) + पाउडर फोर इजं ेक्शन 1000


536 मिलीग्राि (ए)+125 1 वाईल 99.66 1574(अ) 31-03-23
टाज़ोबैटटम (बी)
मिलीग्राि (बी)
वपपेिामिमलन (ए) + पाउडर फोर इजं ेक्शन 2000
537 मिलीग्राि (ए) +250 1 वाईल 191.55 4663(अ) 25-10-23
टाज़ोबैटटम (बी)
मिलीग्राि (बी)
वपपेिामिमलन (ए) + पाउडर फोर इजं ेक्शन 4000
538 मिलीग्राि (ए) +500 1 वाईल 399.41 4663(अ) 25-10-23
टाज़ोबैटटम (बी)
मिलीग्राि (बी)
ओरल मलमक्वड 500
539 पोटे मशयम टलोिाइड 1 मि.ली. 0.30 1574(अ) 31-03-23
मिलीग्राि/5 मि.ली.
इजं ेक्शन 150
540 पोटे मशयम टलोिाइड 1 मि.ली. 2.40 4663(अ) 25-10-23
मिलीग्राि/मि.ली.
541 पोवीडोन आयोडीन सोलूशन 5% 1 मि.ली. 0.44 4663(अ) 25-10-23
542 पोवीडोन आयोडीन सोलश
ू न 7.5% 1 मि.ली. 0.82 4663(अ) 25-10-23
543 पोवीडोन आयोडीन सोलूशन 10% 1 मि.ली. 0.96 1574(अ) 31-03-23
544 पोवीडोन आयोडीन िोेयश
ू न 4% 1 मि.ली. 1.74 2168(अ) 11-05-23
प्रैमलडॉक्टिम इजं ेक्शन 25
545 1 मि.ली. 4.56 1574(अ) 31-03-23
टलोिाइड ( पीएएम) मिलीग्राि/मि.ली.
546 प्रेडननिोलोन गोली 40मिलीग्राि 1 गोली 3.41 4663(अ) 25-10-23
ओरल मलमक्वड 5
547 प्रेडननिोलोन 1 मि.ली. 0.49 1574(अ) 31-03-23
मिलीग्राि/5 मि.ली. (पी)
ओरल मलमक्वड 15
548 प्रेडननिोलोन मिलीग्राि/5मि.ली.(पी) 1 मि.ली. 0.86 1574(अ) 31-03-23
549 प्रेडननिोलोन गोली 10 मिलीग्राि 1 गोली 1.20 4663(अ) 25-10-23
550 प्रेडननिोलोन गोली 5 मिलीग्राि 1 गोली 0.68 1574(अ) 31-03-23
551 प्रेडननिोलोन गोली 20 मिलीग्राि 1 गोली 2.40 4663(अ) 25-10-23
552 प्रेडननिोलोन ड्रोप 1% 1 मि.ली. 5.76 1574(अ) 31-03-23
batSD'ku 40
553
vkbZ;w@fefy-
1 fefy- 16.99 4663(अ) 25-10-23

554 प्राइमाटवीन गोली 7.5 मिलीग्राि 1 गोली 2.38 4663(अ) 25-10-23


555 प्राइमाटवीन गोली 15 मिलीग्राि 1 गोली 5.14 4663(अ) 25-10-23
556 xksyh 2-5 fexzk- 1 xksyh 1.75 4663(अ) 25-10-23
557 प्रोपिर्काइन आई ड्रॉप 0.5% 1 मि.ली. 10.25 4663(अ) 25-10-23
इजं ेक्शन 10
558 प्रोपोफोल 1 मि.ली. 6.50 1574(अ) 31-03-23
मिलीग्राि/मि.ली.
559 प्रोप्रानोलोल गोली 40 मिलीग्राि 1 गोली 3.22 4663(अ) 25-10-23
560 प्रोप्रानोलोल गोली 10 मिलीग्राि 1 गोली 1.31 1574(अ) 31-03-23
561 प्रोप्रानोलोल गोली 20 मिलीग्राि 1 गोली 3.20 4663(अ) 25-10-23
22 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

562 dSIlwy 40 fexzk- 1 dSIlwy 4.25 4663(अ) 25-10-23


र्कैप्िल
ू 20
563 प्रोप्रानोलोल 1 र्कैप्िल
ू 2.35 1578(अ) 31-03-23
ममलीग्राम
र्कैप्िल
ू 10
564 प्रोप्रानोलोल 1 र्कैप्िल
ू 2.00 4663(अ) 25-10-23
ममलीग्राम
इजं ेक्शन 10
565 प्रोटामाइन िेफेट 1 मि.ली. 9.78 4663(अ) 25-10-23
मिलीग्राि/मि.ली.
566 पायिाज़ीनामाईड गोली 1000 मिलीग्राि 1 गोली 10.53 4663(अ) 25-10-23
567 पायिाज़ीनामाईड गोली 500 मिलीग्राि 1 गोली 4.89 4663(अ) 25-10-23
568 पायिाज़ीनामाईड गोली 750 मिलीग्राि 1 गोली 7.21 4663(अ) 25-10-23
569 पायिाज़ीनामाईड गोली 1500 मिलीग्राि 1 गोली 11.81 4663(अ) 25-10-23
570 पाइरिडोक्टिन गोली 100 मिलीग्राि 1 गोली 5.98 4663(अ) 25-10-23
571 xksyh 10 fexzk- 1 xksyh 0.11 1577(अ) 31-03-23
572 क्टवननन गोली 300 मिलीग्राि 1 गोली 5.65 1574(अ) 31-03-23
batSD'ku 300 fexzk-@
573 र्कुनेन fefy-
1 fefy- 9.50 4663(अ) 25-10-23
574 िे बीज वैटिीन एज लाइसेंस 1 वाइल 378.71 1574(अ) 31-03-23
575 िाेटे ग्रेववि गोली 400 मिलीग्राि 1 गोली 147.80 4663(अ) 25-10-23
576 िाममवप्रल गोली 2.5 मिलीग्राि 1 गोली 5.21 1574(अ) 31-03-23
577 िाममवप्रल गोली 5 मिलीग्राि 1 गोली 8.18 1574(अ) 31-03-23
578 dSIlwy 2-5 fexzk- 1 dSIlwy 4.66 1577(अ) 31-03-23
579 dSIlwy 5 fexzk- 1 dSIlwy 7.19 4663(अ) 25-10-23
580 रिबावायरिन कै प्सूल 200 मिलीग्राि 1 कै प्सूल 26.49 1574(अ) 31-03-23
581 रिफैक्पपमिन कै प्सूल 600 मिलीग्राि 1 कै प्सूल 11.36 4663(अ) 25-10-23
582 रिफैक्पपमिन कै प्सूल 450 मिलीग्राि 1 कै प्सूल 5.67 1574(अ) 31-03-23
583 रिफैक्पपमिन कै प्सल
ू 150 मिलीग्राि 1 कै प्सल
ू 2.29 4663(अ) 25-10-23
584 रिफैक्पपमिन कै प्सूल 300 मिलीग्राि 1 कै प्सूल 4.61 4663(अ) 25-10-23
ओरल मलमक्वड 100
585 रिफैक्पपमिन 1 मि.ली. 0.47 1574(अ) 31-03-23
मिलीग्राि/5मि.ली.(पी)
586 रििपेिीडोन गोली 1 मिलीग्राि 1 गोली 3.03 4663(अ) 25-10-23
587 रििपेिीडोन गोली 2 मिलीग्राि 1 गोली 4.48 1574(अ) 31-03-23
588 रििपेिीडोन गोली 4 मिलीग्राि 1 गोली 7.36 4663(अ) 25-10-23
ओरल मलमक्वड 1
589 रििपेिीडोन 1 मि.ली. 2.21 4663(अ) 25-10-23
मिलीग्राि/मि.ली.
इजं ेक्शन (लोंगएमक्टंग) 25
590 रििपेिीडोन 1 मि.ली. 1930.30 2125(अ) 04-05-23
मिलीग्राि
इजं ेक्शन (लोंगएमक्टंग)
591 रििपेिीडोन 1 मि.ली. 2649.41 2125(अ) 04-05-23
37.5 मिलीग्राि
592 रिटोनवीि गोली 100 मिलीग्राि 1 गोली 29.21 4663(अ) 25-10-23
इजं ेक्शन 10
593 रिट्कक्टिमैब 1 मि.ली. 761.81 4663(अ) 25-10-23
मिलीग्राि/मि.ली.
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 23

594 िोटा वाईिि वैक्टिन लाईिेंि र्के अनि


ु ाि 1 वाईल 854.58 4663(अ) 25-10-23
595 िैेबट
ु ामोल गोली 4 मिलीग्राि 1 गोली 0.21 1574(अ) 31-03-23
596 िैेबट
ु ामोल गोली 2 मिलीग्राि 1 गोली 0.18 4663(अ) 25-10-23
ओरल मलमक्वड 2
597 िैेबट
ु ामोल 1 मि.ली. 0.18 4663(अ) 25-10-23
मिलीग्राि/5मि.ली.
इनहेलेशन
598 िैेबट
ु ामोल (एिडीआई(*डीपीआई/ 1 एिडीआई 0.49 1574(अ) 31-03-23
100 एिसीजी / डोज
रे मस्परे टर सॉ्यूशन (सॉ्यशू न
599 िैेबट
ु ामोल फोर नेब्लयिंलाइज़र 5 मिलीग्राि / 1 मि.ली. 0.68 1574(अ) 31-03-23
मि.ली.)
600 िैमलमिमलर्क एमिड ओइटं िेंट 3-6% (6%) 1 ग्राि 2.02 4663(अ) 25-10-23
ओइंटमें ट 3-6%
601 िेमलिाईर्कामिड 1 ग्राम 2.06 1579(अ) 31-03-23
(3%)
bugsys'ku र्के मलये
602 1 fefy- 31.17 4663(अ) 25-10-23
मलक़ुड
िोडडयम इजं ेक्शन (एज पर आईपी) -
603 1 मि.ली. 1.35 4663(अ) 25-10-23
बाइर्काबोनेट 8.4%
batSD'ku (आईपी र्के
604 1 fefy- 1.01 4663(अ) 25-10-23
अनि
ु ाि) 7-5%
605 िोडडयम वैेप्रोएट गोली 300 मिलीग्राि 1 गोली 4.46 1574(अ) 31-03-23
ओरल मलमक्वड 200
606 िोडडयम वैेप्रोएट 1 मि.ली. 0.65 1574(अ) 31-03-23
मिलीग्राि/5 मि.ली. (पी)
607 िोडडयम वैेप्रोएट गोली 200 मिलीग्राि 1 गोली 3.59 4663(अ) 25-10-23
िोडीफाइड ररलीज – गोली
608 िोडडयम वैेप्रोएट 1 गोली 9.28 1574(अ) 31-03-23
500 मिलीग्राि
609 िोडडयम वैेप्रोएट गोली 500 मिलीग्राि 1 गोली 8.12 4663(अ) 25-10-23
िोडीफाइड ररलीज – गोली
610 िोडडयम वैेप्रोएट 1 गोली 6.10 4663(अ) 25-10-23
300 मिलीग्राि
इजं ेक्शन
611 िोडडयम वैेप्रोएट 1 मि.ली. 6.75 4663(अ) 25-10-23
100मिलीग्राि/मि.ली.
612 िोफोिबव
ु ीि गोली 400 मिलीग्राि 1 गोली 525.12 4663(अ) 25-10-23
batSD'ku ds fy, ikmMj
613
3 fexzk- 1 वाईल- 1359.00 4663(अ) 25-10-23
614 स्पैिोनोलाटटोंन गोली 50 मिलीग्राि 1 गोली 4.37 1574(अ) 31-03-23
615 स्पैिोनोलाटटोंन गोली 25 मिलीग्राि 1 गोली 2.19 4663(अ) 25-10-23
इजं ेक्शन 15,00,000
616 स्ट्रे प्टोफर्कनेज 1 वाईल 1877.33 1574(अ) 31-03-23
आईयू
पाउडर फोर इजं ेक्शन 750
617 स्ट्रे प्टोमाइमिन 1 वाईल 10.10 1574(अ) 31-03-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 1000
618 स्ट्रे प्टोमाइमिन 1 वाईल 10.86 1574(अ) 31-03-23
मिलीग्राि
इजं ेक्शन 50 मिलीग्राि
619 िक्टिनीर्कोमलन 1 मि.ली. 5.21 2540(अ) 08-06-23
/मि.ली.
620 िेफािालाक्ज़न गोली 500 मिलीग्राि 1 गोली 4.72 1574(अ) 31-03-23
24 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

621 िम
ु ाट्रट्रप्टान गोली 25 मिलीग्राि 1 गोली 32.50 2540(अ) 08-06-23
622 िम
ु ाट्रट्रप्टान गोली 50 मिलीग्राि 1 गोली 55.68 2540(अ) 08-06-23
623 टै क्रोमलमि कै प्सल
ू 0.5 मिलीग्राि 1 कै प्सल
ू 20.66 1574(अ) 31-03-23
624 टै क्रोमलमि कै प्सूल 1 मिलीग्राि 1 कै प्सूल 40.62 1574(अ) 31-03-23
625 टै क्रोमलमि कै प्सूल 2 मिलीग्राि 1 कै प्सूल 84.34 4663(अ) 25-10-23
626 टै क्रोमलमि गोली 1 मिलीग्राि 1 गोली 39.98 4886(अ) 10-11-23
627 टै क्रोमलमि गोली 2 मिलीग्राि 1 गोली 77.69 4886(अ) 10-11-23
628 टै क्रोमलमि गोली 0.5 मिलीग्राि 1 गोली 20.97 4886(अ) 10-11-23
629 टामोटिीफेन गोली 20 मिलीग्राि 1 गोली 2.95 4663(अ) 25-10-23
630 टामोटिीफेन गोली 10 मिलीग्राि 1 गोली 2.21 4663(अ) 25-10-23
631 टे क्ेमिटि न गोली 20 मिलीग्राि 1 गोली 3.88 4663(अ) 25-10-23
632 टे क्ेमिटि न गोली 40 मिलीग्राि 1 गोली 6.76 1574(अ) 31-03-23
633 टे क्ेमिटि न गोली 80 मिलीग्राि 1 गोली 10.40 1574(अ) 31-03-23
634 टे मोज़ोलोमाइड कै प्सूल 20 मिलीग्राि 1 कै प्सूल 441.33 1574(अ) 31-03-23
635 टे मोज़ोलोमाइड कै प्सल
ू 250 मिलीग्राि 1 कै प्सल
ू 4304.01 1574(अ) 31-03-23
636 टे मोज़ोलोमाइड कै प्सूल 100 मिलीग्राि 1 कै प्सूल 1508.70 1574(अ) 31-03-23
637 टे मोज़ोलोमाइड गोली 20 मिलीग्राि 1 गोली 336.65 4886(अ) 10-11-23
638 टे मोज़ोलोमाइड गोली 250 मिलीग्राि 1 गोली 3758.15 4886(अ) 10-11-23
इजं ेक्शन 40 मिलीग्राि /
639 टे नेटटे प्लेि 1 वाईल 50389.69 4663(अ) 25-10-23
वाईल
इजं ेक्शन 30 मिलीग्राि /
640 टे नेटटे प्लेि 1 वाईल 36910.02 4663(अ) 25-10-23
वाईल
641 टे नेमलक्ललक्प्टन गोली 20 ममलीग्राम 1 गोली 11.09 4663(अ) 25-10-23
टे नोफोववि
642 अलाफेनामाइड गोली 25 मिलीग्राि 1 गोली 48.87 1574(अ) 31-03-23
फ्यम
ू िे ट (टीएएफ)
टे नोफोववि
डडिोप्रोटिील गोली 300 मिलीग्राि (ए)
643 1 गोली 45.58 4663(अ) 25-10-23
फ्यम
ू िे ट (ए) + + 300 मिलीग्राि (बी)
लैममवड
ु ाइन (बी)
टे नोफोववि
डडिोप्रॉक्टिल गोली 300 मिलीग्राि (ए)
644 फ्यम
ू िे ट) + + 300 मिलीग्राि (बी) + 1 गोली 102.85 4663(अ) 25-10-23
लैममवड
ु ाइन (बी) + 600 मिलीग्राि (सी)
ए़िावविें ज़ (िी)
टे नोफोववि
डडिप्रॉक्टिल
645 गोली 300 मिलीग्राि 1 गोली 45.84 4663(अ) 25-10-23
फ्यम
ू िे ट (टी डी
एफ)*
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 25

646 टर्बिनाफाईन क्रीम 1% 1 ग्राम 5.26 4663(अ) 25-10-23

647 1 वाईल- 25.53 1577(अ) 31-03-23


( जमली)
1 वाईल -
648 12.47 4663(अ) 25-10-23
(0.5 जमली.) ¼0-5 fefy-½
649 िैमलडोमाइड कै प्सूल 50 मिलीग्राि 1 कै प्सल
ू 31.16 4663(अ) 25-10-23
650 िैमलडोमाइड कै प्सूल 100 मिलीग्राि 1 कै प्सूल 62.01 1574(अ) 31-03-23
651 धियाममन गोली 100 मिलीग्राि 1 गोली 4.46 1574(अ) 31-03-23
इजं ेक्शन 100
652 धियाममन 1 मि.ली. 22.59 1574(अ) 31-03-23
मिलीग्राि/मि.ली.
653 धियोपें टोन पाउडर फोर इजं ेक्शन 1 ग्राि 1 वाईल 55.32 2540(अ) 08-06-23
पाउडर फोर इजं ेक्शन 0.5
654 धियोपें टोन 1 वाईल 45.69 2540(अ) 08-06-23
ग्राि
655 ट्रटमोलोल ड्रॉप 0.5 % 1 मि.ली. 13.40 4663(अ) 25-10-23
इनहेलेशन (एिडीआई( 9
656 ट्रटयोट्रोवपयम 1 एिडीआई 2.78 1574(अ) 31-03-23
एिसीजी डोज /
इनहेलेशन (डीपीआई( 18
657 ट्रटयोट्रोवपयम 1 डीपीआई 10.71 4663(अ) 25-10-23
एिसीजी डोज /
इजं ेक्शन 50
658 ट्रामाडोल मिलीग्राि/मि.ली. 1 मि.ली. 11.78 1574(अ) 31-03-23
( प टू 2 मि.ली. पैक)
659 dSIlwy 50 fexzk- 1 dSIlwy 4.82 1577(अ) 31-03-23
660 dSIlwy 100 fexzk- 1 dSIlwy 9.04 4663(अ) 25-10-23
661 ट्रामाडोल गोली 50 मिलीग्राि 1 गोली 9.70 4886(अ) 10-11-23
662 ट्रामाडोल गोली 100 मिलीग्राि 1 गोली 24.48 4886(अ) 10-11-23
इजं ेक्शन 100
663 ट्रे नेटज़ाममर्क एमिड 1 मि.ली. 13.71 1574(अ) 31-03-23
मिलीग्राि/मि.ली.
664 ट्रे नेटज़ाममर्क एमिड गोली 500 मिलीग्राि 1 गोली 18.54 1574(अ) 31-03-23
इजं ेक्शन 440
665 ट्रस्टुज़ुमाब 1 वाईल 54725.21 4663(अ) 25-10-23
मिलीग्राि/50 मि.ली.
666 ट्राइहे क्टिफेननडाइल गोली 2 मिलीग्राि 1 गोली 1.37 4663(अ) 25-10-23
667 ट्रॉवपर्कैमाइड आई ड्रॉप 1 % 1 मि.ली. 9.43 4663(अ) 25-10-23
668 वेलगैन्िीटलोववि गोली 450 मिलीग्राि 1 गोली 400.73 1574(अ) 31-03-23
पाउडर फोर इजं ेक्शन 500
669 वैनर्कॉमायमिन 1 वाईल 317.64 4663(अ) 25-10-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 1000
670 वैनर्कॉमायमिन 1 वाईल 470.27 4663(अ) 25-10-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 250
671 वैनर्कॉमायमिन 1 वाईल 251.25 1574(अ) 31-03-23
मिलीग्राि
र्कैप्िल
ू 250
672 वैनर्कॉमायमिन 1 र्कैप्िल
ू 152.39 1578(अ) 31-03-23
ममलीग्राम
पाउडर फोर इजं ेक्शन 10
673 वेर्कुिोननयम रत्येक वाईल 117.37 4663(अ) 25-10-23
मिलीग्राि
26 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

पाउडर फोर इजं ेक्शन 4


674 वेर्कुिोननयम रत्येक वाईल 74.40 1574(अ) 31-03-23
मिलीग्राि
675 वेिापाममल गोली 80 मिलीग्राि 1 गोली 1.59 1574(अ) 31-03-23
676 वेिापाममल गोली 40 मिलीग्राि 1 गोली 0.86 1574(अ) 31-03-23
677 ववक्न्क्रस्टाईन इजं ेक्शन 1 मिलीग्राि/मि.ली. 1 मि.ली. 57.52 4663(अ) 25-10-23
xksyh 50000 vkbZ;w
678 (च्यए ू बल गोली 1 xksyh 0.73 4663(अ) 25-10-23
िट्रहत)
batSD'ku 50000
679
vkbZ;w@fefy-
1 fefy- 2.26 1577(अ) 31-03-23
680 वािफरिन गोली 5 मिलीग्राि 1 गोली 2.40 2540(अ) 08-06-23
681 वािफरिन गोली 3 मिलीग्राि 1 गोली 3.18 2540(अ) 08-06-23
682 वारफररन गोली 2 मिलीग्राि 1 गोली 2.72 2540(अ) 08-06-23
683 वारफररन गोली 1 मिलीग्राि 1 गोली 2.46 2540(अ) 08-06-23
684 िाइलोमेटाजोजलन नेजल ड्रोप 0.05 % 1 मि.ली. 4.19 1574(अ) 31-03-23
685 िाइलोमेटाजोजलन नेजल ड्रोप 0.1% 1 मि.ली. 5.12 1574(अ) 31-03-23
जजडोवुडाइन (ए) + गोली 300 मिलीग्राि (ए)
686 लेजमवुडाइन (बी) + + 150 मिलीग्राि (बी) + 1 गोली 21.13 1574(अ) 31-03-23
नेजवरापीन (सी) 200 मिलीग्राि (सी)
जिडोवुडाइन (ए) + गोली 300 मिलीग्राि (ए)
687 1 गोली 21.09 1574(अ) 31-03-23
लेजमवुडाइन (बी) +150 मिलीग्राि (बी)
मडस्पमसमबल गोली 20
688 किंक सल्फे ट 1 गोली 3.41 4886(अ) 10-11-23
मिलीग्राि
पाउडर फोर इजं ेक्शन 4
689 जोलेड्रोजनक एजसड मिलीग्राि
1 वाईल 2392.05 4663(अ) 25-10-23

690 जोल्पीडेम गोली 5 मिलीग्राि 1 गोली 6.21 1574(अ) 31-03-23


691 जोल्पीडेम गोली 10 मिलीग्राि 1 गोली 8.51 1574(अ) 31-03-23
िारुनवीर (ए) + गोली 600 मिलीग्राि + (ए)
692 1 गोली 146.46 939(अ) 28-02-24
ररटोनवीर (बी) 100 मिलीग्राि (बी)
ननर्कोटीन (ननर्कोटीन
ओरल डोसेज 2
693 रिप्लेिमें ट िेिेपी र्के 1 पैक्स्टल 7.12 939(अ) 28-02-24
मिलीग्राि पैमस्टल
मलए)
ननर्कोटीन (ननर्कोटीन
ओरल डोसेज 4
694 रिप्लेिमें ट िेिेपी र्के 1 पैक्स्टल 7.83 939(अ) 28-02-24
मिलीग्राि पैमस्टल
मलए)
695 लेवोनोगेस्ट्रे ल गोली 1.5 मिलीग्राि 1 गोली 75.35 939(अ) 28-02-24
सोमलड ओरल डोसेज
696 र्कॉलेर्कैक्ेिफेिॉलमैल फॉिम 1000 आईयू सैशे / 1 ग्राम 23.14 939(अ) 28-02-24
पाउडर / ग्रेूय्ू स
टे नोफोववि गोली 300 मिलीग्राि +
697 डडिप्रॉक्टिल 300 मिलीग्राि +50 1 गोली 114.99 939(अ) 28-02-24
फ्यम
ू िे ट + मिलीग्राि
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 27

लैममवडु डन +
डोेयट
ू े ग्रेववि
698 xksyh 300 fexzk- 1 xksyh 13.59 938(अ) 28-02-24
batSD'ku ds fy,
699 ikmMj 12 yk[k 1 वाईल 19.81 938(अ) 28-02-24
;wfuV
batSD'ku ds fy,
700 ikmMj 6 yk[k 1 वाईल 11.69 938(अ) 28-02-24
;wfuV
batSD'ku 50
701 1 fefy- 20.96 938(अ) 28-02-24
,elhth@fefy-
702 dSIlwy 5 fexzk- 1 dSIlwy 5.04 938(अ) 28-02-24
batSD'ku 20 fexzk-
703 1 fefy- 11.24 938(अ) 28-02-24
@fefy-
704 dSIlwy 40 fexzk- 1 dSIlwy 5.67 938(अ) 28-02-24
batSD'ku ds fy,
705 1 वाईल 188.65 938(अ) 28-02-24
ikmMj 500 fexzk-
ykbvksfQykftM 1 वाईल
706 ikWyhosysaV ऐज ओफ 10 665.26 938(अ) 28-02-24
लाइिेंि मम.ली.
lksyqcy@fyD;wbM 1 वाईल
707 ikWyhosysaV ऐज ओफ 10 428.67 938(अ) 28-02-24
लाइिेंि मम.ली.
708 xksyh 2 fexzk- 1 xksyh 31.16 938(अ) 28-02-24
709 xksyh 5 fexzk- 1 xksyh 77.21 938(अ) 28-02-24
710 xksyh 2 fexzk- 1 xksyh 91.34 938(अ) 28-02-24
711 xksyh 5 fexzk- 1 xksyh 86.04 938(अ) 28-02-24
batSD'ku 1 fexzk- 1 fefy-
712
@fefy- 30.54 938(अ) 28-02-24
batSD'ku 250 fexzk-@5 1 fefy-
713
fefy- 2.04 938(अ) 28-02-24
कंनवेंसनल / एफिवेिट ें 1 xksyh

/ डडस्पमििबल /
714 एंटरिर्क लेवपत 0.67 938(अ) 28-02-24
गोमलयााँ 325
ममलीग्राम
bugsys”ku ¼,eMhvkbZ½ 1 ehVj Mkst
715
100 ,elhth@Mkst 1.41 938(अ) 28-02-24
bugsys”ku ¼,eMhvkbZ½ 1 ehVj Mkst
716
200 ,elhth@Mkst 2.03 938(अ) 28-02-24
bugsys”ku ¼MhihvkbZ½ 1 Mkst
717
200 ,elhth@Mkst 3.33 938(अ) 28-02-24
usty Lizs 100 1 Mkst
718
,elhth@Mkst 0.81 938(अ) 28-02-24
bugsys”ku ¼,eMhvkbZ½ 1 ehVj Mkst
719 100 ,elhth ¼,½ $ 6 2.12 938(अ) 28-02-24
,elhth ¼ch½
28 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

bugsys”ku ¼MhihvkbZ½ 1 Mkst


720 100 ,elhth ¼,½ $ 6 4.32 938(अ) 28-02-24
,elhth ¼ch½
bugsys”ku ¼MhihvkbZ½ 1 Mkst
721 200 ,elhth ¼,½ $ 6 5.72 938(अ) 28-02-24
,elhth ¼ch½
bugsys”ku ¼MhihvkbZ½ 1 Mkst
722 400 ,elhth ¼,½ $ 6 6.62 938(अ) 28-02-24
,elhth ¼ch½
ऑटिीजन -
मेडडर्कल उद्दे श्य टयर्ू बर्क
723 मलक्टवड मेडडर्कल 17.02 1580(अ) 31-03-23
र्के मलये लाइिेंि मीटि
ऑटिीजन
ऑटिीजन (मिमलंडि मेडडर्कल उद्दे श्य टयर्ू बर्क
724 28.83 1580(अ) 31-03-23
में ) र्के मलये लाइिेंि मीटि
मेडडर्कल उद्दे श्य टयर्ू बर्क
725 नाईट्रि ऑटिाईड 285.98 4663(अ) 25-10-23
र्के मलये लाइिेंि मीटि
डडस्पोजेबल पेन में इंजेटशन 100
726 1 मम.ली. 244.14 1581 (अ) 31-03-23
इंिमु लन ललाधगिन आईयू .ली.मम /

-
(
0.00551% )

11(3)

(5)

a b िे

0.00551

(5)

यदि संिोधन दकया िाता है तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध
में प्रपत्र-।। के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और
इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन नहीं दकया िाना
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 29

माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेने की जतजथ से उस पर ब्याि सजहत पूवच-संिोजधत
अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा।

(4)

(ञ)

(1) u
II I

II III

II IV

[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]


यमिं वका पंवार, सह यक मनदेशक

MINISTRY OF CHEMICALS AND FERTILIZERS


(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 26th March, 2024
S.O. 1547(E).—In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the
Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession
of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical
Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the
National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below
as ceiling prices exclusive of Goods and Services Tax applicable, if any in respect of the Scheduled formulations
specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit
specified respectively in the corresponding entries in columns (3) and (4) thereof:
30 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

TABLE
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Ceiling price Existing S.O., No. & Date
(wef 1.4.2024
Sl. Dosage form and
Medicines Unit with WPI @
No. strength
0.00551%) (in
Rs.)
(1) (2) (3) (4) (5) (6a) (6b)
1 6-Mercaptopurine Tablet 50mg 1 Tablet 5.26 4663(E) 25-10-23
2 Abacavir Tablet 300 mg 1 Tablet 48.59 1574(E) 31-03-23
Abacavir (A) + Lamivudine Tablet 600mg (A) 4663(E) 25-10-23
3 1 Tablet 72.32
(B) +300mg (B)
4 Acetazolamide Tablet 250mg 1 Tablet 4.06 4663(E) 25-10-23
5 Acetazolamide Capsule 250mg 1 Capsule 5.05 4663(E) 25-10-23
Enteric coated 4663(E) 25-10-23
6 Acetylsalicylic acid 1 Tablet 0.35
Tablet 75 mg
Conventional/Effer 4663(E) 25-10-23
vescent/Dispersible/
7 Acetylsalicylic acid 1 Tablet 0.71
Enteric coated
Tablets 150 mg
Powder for 4663(E) 25-10-23
8 Actinomycin D 1 Vial 331.03
Injection 0.5mg
9 Acyclovir Tablet 400mg 1 Tablet 13.66 4663(E) 25-10-23
10 Acyclovir Tablet 200mg 1 Tablet 7.61 1574(E) 31-03-23
Powder for 4663(E) 25-10-23
11 Acyclovir 1 Vial 426.40
Injection 250 mg
Powder for 4663(E) 25-10-23
12 Acyclovir 1 Vial 528.45
Injection 500 mg
13 Acyclovir Tablet 800mg 1 Tablet 37.66 1574(E) 31-03-23
14 Acyclovir Ointment 3% 1 GM 11.67 1574(E) 31-03-23
Oral liquid 4663(E) 25-10-23
15 Acyclovir 1 ML 1.36
400mg/5mL (p)
16 Adenosine Injection 3mg/mL 1 ML 92.86 4663(E) 25-10-23
17 Adrenaline Injection1mg/mL 1 ML 12.23 1574(E) 31-03-23
Oral liquid 1577(E) 31-03-23
18 Albendazole 1 ML 1.79
200mg/5mL(p)
19 Albendazole Tablet 400mg 1 Tablet 7.04 1577(E) 31-03-23
Chewable Tablet 4663(E) 25-10-23
20 Albendazole 1 Tablet 8.13
400mg
21 Allopurinol Tablet 300mg 1 Tablet 5.63 4663(E) 25-10-23
22 Allopurinol Tablet 100mg 1 Tablet 1.89 1574(E) 31-03-23
23 Alprostadil Injection 0.5mg/mL 1 ML 6106.75 1574(E) 31-03-23
Injection 4663(E) 25-10-23
24 Amikacin 1 ML 54.17
250mg/mL
25 Amiodarone Tablet 200mg 1 Tablet 11.51 1574(E) 31-03-23
26 Amiodarone Tablet 100mg 1 Tablet 6.14 1574(E) 31-03-23
27 Amiodarone Injection 50mg/mL 1 ML 21.13 1574(E) 31-03-23
28 Amitriptyline Tablet 50mg 1 Tablet 5.99 4663(E) 25-10-23
29 Amitriptyline Tablet 75mg 1 Tablet 5.45 4663(E) 25-10-23
30 Amitriptyline Tablet 25mg 1 Tablet 2.49 4663(E) 25-10-23
31 Amitriptyline Tablet 10mg 1 Tablet 2.39 4663(E) 25-10-23
32 Amlodipine Tablet 2.5mg 1 Tablet 1.79 1574(E) 31-03-23
33 Amlodipine Tablet 5mg 1 Tablet 2.50 1574(E) 31-03-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 31
34 Amlodipine Tablet 10mg 1 Tablet 5.45 4663(E) 25-10-23
35 Amoxicillin Capsule 250mg 1 Capsule 2.44 1574(E) 31-03-23
36 Amoxicillin Capsule 500mg 1 Capsule 7.36 4663(E) 25-10-23
Oral liquid 250 4663(E) 25-10-23
37 Amoxicillin 1 ML 1.56
mg/5 mL (p)
Powder for 1578(E) 31-03-23
38 Amoxicillin 1 Vial 24.79
Injection 250 mg
Powder for 4663(E) 25-10-23
39 Amoxicillin 1 Vial 54.65
Injection 500 mg
Oral liquid 125 1579(E) 31-03-23
40 Amoxicillin 1 ML 1.02
mg/5 mL (p)
Powder for 4663(E) 25-10-23
Amoxicillin (A) + Clavulanic
41 Injection 1 g (A) 1 Vial 140.66
acid (B)
+200mg (B)
Powder for 4663(E) 25-10-23
Amoxicillin (A) + Clavulanic
42 Injection 500mg 1 Vial 101.35
acid (B)
(A) + 100mg (B)
Dry Syrup 125mg 1574(E) 31-03-23
Amoxicillin (A) + Clavulanic
43 (A) + 31.25 1 ML 2.05
acid (B)
(B)/5mL(p)
Amoxicillin (A) +Clavulanic Tablet 500 mg (A) 4663(E) 25-10-23
44 1 Tablet 18.30
acid (B) + 125 mg (B)
Oral liquid 200 mg 4663(E) 25-10-23
Amoxicillin (A) +Clavulanic
45 (A) + 28.5mg(B)/5 1 ML 2.02
acid (B)
mL(p)
Amphotericin 1577(E) 31-03-23
46 Amphotericin B B(conventional) - 1 Vial 227.40
Injection 50mg/vial
Powder for 1574(E) 31-03-23
47 Ampicillin 1 Vial 14.25
Injection 500 mg
Artemether (A) + Tablet 40 mg (A) + 1574(E) 31-03-23
48 1 Tablet 18.04
Lumefantrine (B) 240 mg (B)
Tablet 4663(E) 25-10-23
Artemether (A)
49 80mg(A)+480mg(B 1 Tablet 25.51
+Lumefantrine(B)
)
Artemether (A) +Lumefantrine Tablet 20 mg (A) + 4663(E) 25-10-23
50 1 Tablet 12.65
(B) 120 mg (B)
Powder for 4663(E) 25-10-23
51 Artesunate 1 Vial 244.73
Injection 60 mg
Powder for 4663(E) 25-10-23
52 Artesunate 1 Vial 454.44
Injection 120mg
Combi pack (A+B) 4663(E) 25-10-23
Artesunate (A) + Sulphadoxine 1 Tablet 50mg (A) 1 Combi
53 22.55
-Pyrimethamine (B) + 1Tablet (500mg + Pack
25mg) (B)
54 Ascorbic acid (Vitamin C) Tablet 100mg 1 Tablet 0.24 4663(E) 25-10-23
55 Ascorbic acid (Vitamin C) Tablet 500mg 1 Tablet 1.48 1577(E) 31-03-23
Tablet 300mg(A) + 1574(E) 31-03-23
56 Atazanavir (A) +Ritonavir(B) 1 Tablet 99.83
Tablet 100mg(B)
57 Atorvastatin Tablet 40mg 1 Tablet 19.30 4663(E) 25-10-23
58 Atorvastatin Tablet 20mg 1 Tablet 12.56 4663(E) 25-10-23
59 Atorvastatin Tablet 10mg 1 Tablet 4.94 1574(E) 31-03-23
60 Atorvastatin Tablet 80mg 1 Tablet 40.58 4663(E) 25-10-23
61 Atracurium Injection 10 mg/ml 1 ML 16.98 4663(E) 25-10-23
62 Atropine Drops 1% 1 ML 3.94 4663(E) 25-10-23
63 Atropine Ointment 1% 1 GM 4.71 4663(E) 25-10-23
32 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

64 Atropine Injection 0.6mg/mL 1 ML 4.57 1574(E) 31-03-23


65 Azathioprine Tablet 50mg 1 Tablet 11.26 4663(E) 25-10-23
66 Azathioprine Tablet 25mg(p) 1 Tablet 7.24 1578(E) 31-03-23
Powder for 1574(E) 31-03-23
67 Azithromycin 1 Vial 204.72
Injection 500mg
68 Azithromycin Tablet 250mg 1 Tablet 11.65 4663(E) 25-10-23
69 Azithromycin Tablet 500mg 1 Tablet 23.57 4663(E) 25-10-23
Oral liquid 200 4663(E) 25-10-23
70 Azithromycin 1 ML 3.41
mg/5 mL (p)
71 Azithromycin Capsule250mg 1 Capsule 10.62 4663(E) 25-10-23
72 Azithromycin Tablet 1000mg 1 Tablet 57.78 4663(E) 25-10-23
73 Azithromycin Capsule 500mg 1 Capsule 19.03 2124(E) 04-05-23
74 Baclofen Tablet 20mg 1 Tablet 16.28 1574(E) 31-03-23
75 Baclofen Tablet 10mg 1 Tablet 11.90 4663(E) 25-10-23
76 Baclofen Tablet 5mg 1 Tablet 6.37 4663(E) 25-10-23
Injection 100 1574(E) 31-03-23
77 Bendamustine hydrochloride 1 Vial 4946.80
mg/vial
78 Benzoyl peroxide Gel 2.5 1 GM 3.62 1574(E) 31-03-23
79 Benzoyl peroxide Gel 5 % 1 GM 7.97 1574(E) 31-03-23
80 Benzoyl peroxide Gel 3.5% 1 GM 10.11 1578(E) 31-03-23
81 Betamethasone Injection 4mg/mL 1 ML 4.74 1577(E) 31-03-23
82 Betamethasone valerate Cream 0.05% 1 GM 0.67 1574(E) 31-03-23
83 Betamethasone valerate Cream 0.1% 1 GM 1.04 1574(E) 31-03-23
84 Bicalutamide Tablet 50mg 1 Tablet 43.30 1574(E) 31-03-23
85 Bisacodyl Tablet 5mg 1 Tablet 1.17 4663(E) 25-10-23
1 4663(E) 25-10-23
86 Bisacodyl Suppository 5mg 9.98
Suppository
Powder for 1574(E) 31-03-23
87 Bleomycin 1 Vial 677.41
Injection 15units
Powder for 4663(E) 25-10-23
88 Bortezomib 1 Vial 5260.50
Injection 2mg
Respirator solution 4663(E) 25-10-23
89 Budesonide for use in nebulizer 1 ML 11.90
0.5mg/mL
Respirator solution 1577(E) 31-03-23
90 Budesonide for use in nebulizer 1 ML 13.14
1mg/mL
Injection 0.5 % 4663(E) 25-10-23
91 Bupivacaine 1 ML 7.39
with 7.5 % glucose
92 Bupivacaine Injection 0.5 % 1 ML 4.42 4663(E) 25-10-23
93 Bupivacaine Injection 0.25% 1 ML 2.83 4663(E) 25-10-23
Tablet (Sub- 4663(E) 25-10-23
94 Buprenorphine 1 Tablet 9.43
lingual)0.4mg
Tablet (Sub- 4663(E) 25-10-23
Buprenorphine (A) +Naloxone
95 lingual) 1 Tablet 36.98
(B)
2mg(A)+0.5mg(B)
Tablet (Sub- 4663(E) 25-10-23
Buprenorphine (A) +Naloxone lingual)
96 1 Tablet 11.82
(B) 0.4mg(A)+0.1mg
(B)
Oral liquid 20 1574(E) 31-03-23
97 Caffeine 1 ML 245.68
mg/mL
98 Caffeine Injection 20mg/mL Per ML 250.50 1577(E) 31-03-23
99 Calamine Lotion (As per IP) 1 ML 0.95 1577(E) 31-03-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 33
100 Calcium folinate Tablet 15mg 1 Tablet 47.54 4663(E) 25-10-23
101 Capecitabine Tablet 500mg 1 Tablet 112.73 4663(E) 25-10-23
Modified Release – 4663(E) 25-10-23
102 Carbamazepine 1 Tablet 2.40
Tablet 200mg
Modified Release – 1574(E) 31-03-23
103 Carbamazepine 1 Tablet 4.66
Tablet 400mg
104 Carbamazepine Tablet 400mg 1 Tablet 3.55 1574(E) 31-03-23
105 Carbamazepine Tablet 200mg 1 Tablet 1.57 4663(E) 25-10-23
Oral liquid 1574(E) 31-03-23
106 Carbamazepine 1 ML 0.31
100mg/5mL(p)
107 Carbamazepine Tablet 100mg 1 Tablet 1.07 4663(E) 25-10-23
108 Carbimazole Tablet 10mg 1 Tablet 4.26 1574(E) 31-03-23
109 Carbimazole Tablet 5mg 1 Tablet 2.19 4663(E) 25-10-23
110 Carbimazole Tablet 20mg 1 Tablet 13.87 4663(E) 25-10-23
111 Carboplatin Injection 10mg/mL 1 ML 59.07 4663(E) 25-10-23
112 Carboxymethyl cellulose Drops 0.5% 1 ML 12.30 4663(E) 25-10-23
113 Carboxymethyl cellulose Drops 1% 1 ML 16.58 1574(E) 31-03-23
114 Cefadroxil Tablet 500mg 1 Tablet 4.47 1574(E) 31-03-23
Oral liquid 1574(E) 31-03-23
115 Cefadroxil 1 ML 0.68
125mg/5mL(p)
116 Cefixime Tablet 400mg 1 Tablet 22.10 4663(E) 25-10-23
117 Cefixime Tablet 200mg 1 Tablet 9.78 4663(E) 25-10-23
Oral liquid 50 mg/5 4663(E) 25-10-23
118 Cefixime 1 ML 1.63
mL (p)
Oral liquid 4663(E) 25-10-23
119 Cefixime 1 ML 2.39
100mg/5mL(p)
120 Cefixime Capsule 200mg 1 Capsule 14.68 4663(E) 25-10-23
Powder for 4663(E) 25-10-23
121 Cefotaxime 1 Vial 17.72
Injection 250 mg
Powder for 4663(E) 25-10-23
122 Cefotaxime 1 Vial 24.38
Injection 500 mg
Powder for 1574(E) 31-03-23
123 Cefotaxime 1 Vial 39.96
Injection 1000mg
Powder for 1574(E) 31-03-23
124 Ceftazidime 1 Vial 227.02
Injection 1000mg
Powder for 4663(E) 25-10-23
125 Ceftazidime 1 Vial 79.07
Injection 250 mg
Powder for 4663(E) 25-10-23
126 Ceftriaxone 1 Vial 50.28
Injection 500 mg
Powder for 1574(E) 31-03-23
127 Ceftriaxone 1 Vial 28.34
Injection 250 mg
Powder for 1574(E) 31-03-23
128 Ceftriaxone 1 Vial 62.38
Injection 1000mg
Powder for 1574(E) 31-03-23
129 Ceftriaxone 1 Vial 138.12
Injection 2000mg
130 Cefuroxime Tablet 500mg 1 Tablet 51.43 1578(E) 31-03-23
131 Cefuroxime Injection 1500 mg 1 Vial 338.76 1579(E) 31-03-23
132 Cetirizine Tablet 10mg 1 Tablet 1.88 1574(E) 31-03-23
Oral liquid 1574(E) 31-03-23
133 Cetirizine 1 ML 0.66
5mg/5mL(p)
134 Chloroquine Tablet 150 mg 1 Tablet 1.17 4663(E) 25-10-23
Oral liquid 4663(E) 25-10-23
135 Chloroquine 1 ML 0.34
50mg/5mL
34 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

136 Cholecalciferol Tablet 1000 IU 1 Tablet 4.31 4663(E) 25-10-23


Oral liquid 400 1574(E) 31-03-23
137 Cholecalciferol 1 ML 2.61
IU/mL
Solid oral dosage 1574(E) 31-03-23
138 Cholecalciferol form 60000 IU 1 Tablet 22.50
Tablets
139 Cholecalciferol Capsule 60000 IU 1 Capsule 30.78 4663(E) 25-10-23
140 Cholecalciferol Capsule 1000 IU 1 Capsule 4.89 4663(E) 25-10-23
Sache t/ Granuels / 1578(E) 31-03-23
141 Cholecalciferol 1 GM 33.98
Powder 60000 IU
142 Ciprofloxacin Tablet 250mg 1 tablet 2.20 4663(E) 25-10-23
143 Ciprofloxacin Tablet 500mg 1 tablet 4.25 4663(E) 25-10-23
144 Ciprofloxacin Drops 0.3 % 1 ML 1.54 4663(E) 25-10-23
Injection 1574(E) 31-03-23
145 Ciprofloxacin 1 ML 0.20
200mg/100mL
Oral liquid 1577(E) 31-03-23
146 Ciprofloxacin 1 ML 0.74
250mg/5mL(p)
147 Ciprofloxacin Ointment 0.3% 1 GM 1.29 4663(E) 25-10-23
148 Cisplatin Injection 1mg/mL 1 ML 7.09 4663(E) 25-10-23
149 Clarithromycin Tablet 250mg 1 Tablet 23.89 1574(E) 31-03-23
150 Clarithromycin Tablet 500mg 1 Tablet 39.84 4663(E) 25-10-23
Oral liquid 4663(E) 25-10-23
151 Clarithromycin 1 ML 4.61
125mg/5mL(p)
152 Clindamycin Capsule 150mg 1 Capsule 16.36 4663(E) 25-10-23
153 Clindamycin Capsule 300mg 1 Capsule 28.37 4663(E) 25-10-23
154 Clindamycin Tablet 300mg 1 Tablet 18.97 1574(E) 31-03-23
155 Clindamycin Injection150mg/mL 1 ML 60.60 1579(E) 31-03-23
156 Clobazam Tablet 5mg 1 Tablet 5.73 4663(E) 25-10-23
157 Clobazam Tablet 10mg 1 Tablet 9.84 1574(E) 31-03-23
158 Clofazimine Capsule100mg 1 Capsule 3.98 2540(E) 08-06-23
159 Clofazimine Capsule 50mg 1 Capsule 2.11 2540(E) 08-06-23
160 Clomiphene citrate Capsule 50mg 1 Capsule 27.37 2124(E) 04-05-23
161 Clomiphene citrate Capsule 100 mg 1 Capsule 51.14 2124(E) 04-05-23
162 Clomiphene citrate Tablet 100 mg 1 Tablet 13.95 4663(E) 25-10-23
163 Clomiphene citrate Tablet 50mg 1 Tablet 8.84 4663(E) 25-10-23
164 Clomipramine Tablet 10 mg 1 Tablet 2.85 4663(E) 25-10-23
165 Clomipramine Tablet 25 mg 1 Tablet 6.22 1577(E) 31-03-23
166 Clomipramine Tablet 75 mg 1 Tablet 16.46 4663(E) 25-10-23
167 Clonazepam Tablet 0.25mg 1 Tablet 2.02 4663(E) 25-10-23
168 Clonazepam Tablet 0.5mg 1 Tablet 3.45 1574(E) 31-03-23
169 Clonazepam Tablet 1mg 1 Tablet 4.77 4663(E) 25-10-23
170 Clopidogrel Tablet 75mg 1 Tablet 6.66 1574(E) 31-03-23
171 Clopidogrel Tablet 150 mg 1 Tablet 20.48 1574(E) 31-03-23
172 Clotrimazole Lotion 1% 1 ML 3.89 1577(E) 31-03-23
173 Clotrimazole Pessary 100mg 1 Pessary 10.01 1577(E) 31-03-23
174 Clotrimazole Drops 1% 1 ML 3.37 1577(E) 31-03-23
175 Clotrimazole Cream1% 1 GM 3.00 1577(E) 31-03-23
176 Clozapine Tablet 25mg 1 Tablet 2.78 1574(E) 31-03-23
177 Clozapine Tablet 50mg 1 Tablet 5.19 1574(E) 31-03-23
178 Clozapine Tablet 100 mg 1 Tablet 8.45 1574(E) 31-03-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 35
179 Colchicine Tablet 0.5mg 1 Tablet 3.26 1574(E) 31-03-23
Co-trimoxazole 4663(E) 25-10-23
Tablet 400 mg (A)
180 [Sulphamethoxazole (A) 1 Tablet 0.90
+ 80 mg (B)
+Trimethoprim(B)]*
Co-trimoxazole 4886(E) 10-11-23
Tablet 800mg (A) +
181 [Sulphamethoxazole 1 Tablet 2.30
160 mg (B)
(A)+Trimethoprim (B)]
Co-trimoxazole Oral liquid 200 mg 4663(E) 25-10-23
182 [Sulphamethoxazole(A) (A) + 40 1 ML 0.35
+Trimethoprim(B)]* mg(B)/5mL(p)
Powder for 1574(E) 31-03-23
183 Cyclophosphamide 1 Vial 73.48
Injection 500mg
184 Cyclophosphamide Tablet 50mg 1 Tablet 3.73 1577(E) 31-03-23
185 Cycloserine Capsule250mg 1 Capsule 59.19 4663(E) 25-10-23
186 Cycloserine Tablet 250mg 1 Tablet 46.01 1577(E) 31-03-23
187 Cyclosporine Capsule 25 mg 1 Capsule 28.04 1574(E) 31-03-23
Oral liquid 1574(E) 31-03-23
188 Cyclosporine 1 ML 80.58
100mg/mL(p)
189 Cyclosporine Capsule 50 mg 1 Capsule 55.11 4663(E) 25-10-23
190 Cyclosporine Capsule 100mg 1 Capsule 103.12 4663(E) 25-10-23
Injection 4663(E) 25-10-23
191 Cytosine arabinoside 1 Vial 1130.33
1000mg/vial
Injection 1574(E) 31-03-23
192 Cytosine arabinoside 1 Vial 139.59
100mg/vial
Injection 1574(E) 31-03-23
193 Cytosine arabinoside 1 Vial 536.33
500mg/vial
194 Dabigatran Capsule 110mg 1 Capsule 31.81 2822(E) 28-06-23
195 Dabigatran Capsule 150mg 1 Capsule 35.59 2822(E) 28-06-23
Powder for 4663(E) 25-10-23
196 Dacarbazine 1 Vial 381.75
Injection 200mg
Powder for 4663(E) 25-10-23
197 Dacarbazine 1 Vial 518.83
Injection 500mg
198 Daclatasvir Tablet 60mg 1 Tablet 199.97 4663(E) 25-10-23
199 Dapsone Tablet 100 mg 1 Tablet 0.41 2540(E) 08-06-23
200 Darunavir Tablet 600mg 1 Tablet 154.44 4663(E) 25-10-23
201 Dexamethasone Tablet 0.5mg 1 Tablet 0.22 1574(E) 31-03-23
202 Dexamethasone Tablet 4 mg 1 Tablet 4.62 4663(E) 25-10-23
Injection 4mg/mL 2124(E) 04-05-23
203 Dexamethasone 1 ML 5.09
(2 ML)
Injection 4mg/mL 2125(E) 04-05-23
204 Dexamethasone 1 ML 2.57
(5 ML)
Injection 4mg/mL 4663(E) 25-10-23
205 Dexamethasone 1 ML 1.57
(Pack of 10ML)
Injection 4mg/mL 4663(E) 25-10-23
206 Dexamethasone 1 ML 1.35
(Pack of 20 ML)
Injection 4mg/mL 4663(E) 25-10-23
207 Dexamethasone 1 ML 0.90
(Pack of 30ML)
208 Diazepam Tablet 5 mg 1 Tablet 1.63 4663(E) 25-10-23
209 Diazepam Injection 5mg/mL 1 ML 5.54 4663(E) 25-10-23
210 Diazepam Tablet 2 mg 1 Tablet 1.44 4663(E) 25-10-23
1 4663(E) 25-10-23
211 Diazepam Suppository 5mg 6.19
Suppository
212 Diclofenac Tablet 50mg 1 Tablet 2.05 1574(E) 31-03-23
213 Diclofenac Injection 25mg/mL 1 ML 1.69 1574(E) 31-03-23
36 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

Injection 10mg/mL 4663(E) 25-10-23


214 Dicyclomine (Less than 10ML 1 ML 3.32
Pack)
Injection 10mg/mL 4663(E) 25-10-23
215 Dicyclomine (10 ML & more 1 ML 2.10
pack))
216 Diethylcarbamazine (DEC) Tablet 100mg 1 Tablet 1.67 1574(E) 31-03-23
217 Diethylcarbamazine (DEC) Tablet 50mg 1 Tablet 0.56 1574(E) 31-03-23
Oral liquid 1574(E) 31-03-23
218 Diethylcarbamazine (DEC) 1 ML 0.48
120mg/5mL(p)
219 Digoxin Tablet 0.25mg 1 Tablet 1.33 1574(E) 31-03-23
Oral 4663(E) 25-10-23
220 Digoxin 1 ML 1.47
liquid0.05mg/mL
Injection 4663(E) 25-10-23
221 Digoxin 1 ML 3.87
0.25mg/mL
222 Diltiazem Tablet 60mg 1 Tablet 5.46 1574(E) 31-03-23
223 Diltiazem Tablet 30mg 1 Tablet 2.68 4663(E) 25-10-23
224 Diltiazem Injection 5mg/mL 1 ML 3.50 4663(E) 25-10-23
225 Dinoprostone Gel 0.5mg 1 GM 84.72 4663(E) 25-10-23
226 Dobutamine Injection 50 mg/ml 1 ML 9.03 4663(E) 25-10-23
Powder for 1574(E) 31-03-23
227 Docetaxel 1 Vial 2868.39
Injection 20mg
Powder for 1574(E) 31-03-23
228 Docetaxel 1 Vial 10333.69
Injection 80mg
229 Dolutegravir Tablet 50mg 1 Tablet 112.79 1574(E) 31-03-23
230 Domperidone Tablet 10mg 1 Tablet 2.31 4663(E) 25-10-23
Oral Liquid 1574(E) 31-03-23
231 Domperidone 1 ML 1.24
1mg/mL
232 Donepezil Tablet 10mg 1 Tablet 17.46 4663(E) 25-10-23
233 Donepezil Tablet 5mg 1 Tablet 12.11 4663(E) 25-10-23
234 Dopamine Injection 40mg/mL 1 ML 4.77 4663(E) 25-10-23
235 Doxorubicin Injection2mg/mL 1 ML 31.75 1577(E) 31-03-23
236 Doxycycline Capsule 100mg 1 Capsule 3.08 1574(E) 31-03-23
237 Doxycycline Tablet100mg 1 Tablet 1.22 1577(E) 31-03-23
Powder for 4663(E) 25-10-23
238 Doxycycline 1 Vial 502.64
Injection 100 mg
239 D-Penicillamine Capsule 250 mg 1 Capsule 15.65 1574(E) 31-03-23
240 DPT+ Hib+ Hep B Vaccine As licensed Per 0.1 ML 75.65 4663(E) 25-10-23
241 Efavirenz Tablet 600mg 1 Tablet 70.59 1574(E) 31-03-23
242 Efavirenz Tablet 200 mg (p) 1 Tablet 22.54 4663(E) 25-10-23
243 Efavirenz Capsule 200 mg 1 Capsule 21.98 2124(E) 04-05-23
244 Enalapril Tablet 5mg 1 Tablet 3.70 1574(E) 31-03-23
245 Enalapril Tablet 2.5mg 1 Tablet 2.19 4663(E) 25-10-23
Injection40mg/0.4 4663(E) 25-10-23
246 Enoxaparin mL , injection 0.10 ML 111.99
60mg/0.6 ml
247 Entecavir Tablet 1mg 1 Tablet 130.24 4663(E) 25-10-23
248 Entecavir Tablet 0.5mg 1 Tablet 84.44 4663(E) 25-10-23
Injection 1574(E) 31-03-23
249 Erythropoietin 1 ML 549.58
2000IU/mL
Injection 10000 1574(E) 31-03-23
250 Erythropoietin 1 ML 1969.11
IU/mL
251 Escitalopram Tablet 5mg 1 Tablet 5.02 1574(E) 31-03-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 37
252 Escitalopram Tablet 10mg 1 Tablet 9.00 1574(E) 31-03-23
253 Escitalopram Tablet 20mg 1 Tablet 14.36 1574(E) 31-03-23
254 Esmolol Injection10 mg/mL 1 ML 26.38 1577(E) 31-03-23
255 Ethambutol Tablet 600mg 1 Tablet 4.08 1574(E) 31-03-23
256 Ethambutol Tablet 800mg 1 Tablet 4.96 4663(E) 25-10-23
257 Ethambutol Tablet 400mg 1 Tablet 2.61 1574(E) 31-03-23
258 Ethambutol Tablet 200mg 1 Tablet 1.14 1577(E) 31-03-23
Ethinylestradiol (A)+ Tablet 0.03mg(A) + 1574(E) 31-03-23
259 1 Tablet 3.17
Levonorgestrel (B) Tablet 0.15mg(B)
260 Ethionamide Tablet 250mg 1 Tablet 14.81 1574(E) 31-03-23
261 Etoposide Capsule 50mg 1 Capsule 56.63 1574(E) 31-03-23
262 Etoposide Injection 20mg/mL 1 ML 34.51 1574(E) 31-03-23
263 Filgrastim Injection 300mcg 1 Vial 1159.97 1574(E) 31-03-23
264 Fluconazole Tablet 400mg 1 Tablet 29.75 4663(E) 25-10-23
265 Fluconazole Tablet 200mg 1 Tablet 17.46 4663(E) 25-10-23
266 Fluconazole Tablet 100mg 1 Tablet 7.62 1574(E) 31-03-23
267 Fluconazole Tablet 150mg 1 Tablet 12.06 1574(E) 31-03-23
268 Fluconazole Tablet 50mg 1 Tablet 9.68 4663(E) 25-10-23
269 Fluconazole Capsule 200mg 1 Capsule 40.11 4663(E) 25-10-23
270 Fluconazole Capsule 150mg 1 Capsule 19.22 4663(E) 25-10-23
Injection Per 100 ML 1577(E) 31-03-23
271 Fluconazole 92.33
200mg/100mL Vial
272 Fluconazole Capsule 100mg 1 Capsule 21.40 2124(E) 04-05-23
273 Fludrocortisone Tablet 0.1mg 1 Tablet 13.20 2541(E) 08-06-23
274 Flunarizine Tablet 5mg 1 Tablet 2.48 4663(E) 25-10-23
275 Flunarizine Tablet 10mg 1 Tablet 4.82 1574(E) 31-03-23
276 Fluoxetine Capsule 20 mg 1 Capsule 3.99 1574(E) 31-03-23
277 Fluoxetine Capsule 60 mg 1 Capsule 11.10 1574(E) 31-03-23
278 Fluoxetine Capsule 40 mg 1 Capsule 6.49 1574(E) 31-03-23
279 Fluoxetine Capsule 10 mg 1 Capsule 3.32 4663(E) 25-10-23
280 Fluoxetine Tablet 10 mg 1 Tablet 2.78 2124(E) 04-05-23
281 Fluoxetine Tablet 40 mg 1 Tablet 5.56 2124(E) 04-05-23
282 Fluoxetine Tablet 60 mg 1 Tablet 8.25 2124(E) 04-05-23
283 Fluoxetine Tablet 20 mg 1 Tablet 4.15 2124(E) 04-05-23
284 Fluphenazine Injection 25mg/mL 1 ML 55.26 1574(E) 31-03-23
285 Folic Acid Tablet 5 mg 1 Tablet 1.51 1574(E) 31-03-23
286 Framycetin Cream 1 % 1 GM 1.66 2541(E) 08-06-23
287 Furosemide Tablet 40mg 1 Tablet 0.91 4663(E) 25-10-23
288 Furosemide Injection 10mg/mL 1 ML 2.99 1574(E) 31-03-23
Oral liquid 4663(E) 25-10-23
289 Furosemide 1 ML 3.32
10mg/mL
290 Fusidic acid Cream 2 % 1 GM 9.83 1574(E) 31-03-23
291 Gefitinib Tablet 250mg 1 Tablet 237.14 4663(E) 25-10-23
Powder for 1574(E) 31-03-23
292 Gemcitabine 1 Vial 5592.55
Injection 1000mg
Powder for 4663(E) 25-10-23
293 Gemcitabine 1 Vial 1299.80
Injection 200 mg
Injection 40mg/mL 2125(E) 04-05-23
294 Gentamicin 1 ML 2.90
(1.5 ml)
295 Gentamicin Injection 10mg/mL 1 ML 2.41 1574(E) 31-03-23
38 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

Injection 40mg/mL 1577(E) 31-03-23


296 Gentamicin 1 ML 1.51
(Pack of 10ml)
Injection 40mg/mL 4663(E) 25-10-23
297 Gentamicin 1 ML 1.55
(Pack of 20ml)
Injection 40mg/mL 1577(E) 31-03-23
298 Gentamicin 1 ML 1.23
Pack of 30ml)
Injection 40mg/mL 2124(E) 04-05-23
299 Gentamicin 1 ML 4.85
(2ml)
300 Glimepiride Tablet 2mg 1 Tablet 5.80 4663(E) 25-10-23
301 Glimepiride Tablet 1mg 1 Tablet 3.70 1574(E) 31-03-23
302 Glucose Injection 25% 1 ML 0.20 1574(E) 31-03-23
Glycerin/glycerol (as 1579(E) 31-03-23
303 Topical - Lotion 1 ML 1.23
mentioned in IP)
Glycerin/glycerol (as 4663(E) 25-10-23
304 Topical - Cream 1 GM 2.37
mentioned in IP)
305 Glyceryl trinitrate Injection 5mg/mL 1 ML 6.19 4663(E) 25-10-23
Sublingual Tablet 4663(E) 25-10-23
306 Glyceryl trinitrate 1 Tablet 1.27
0.5mg
307 Glycopyrrolate Injection 0.2mg/mL 1 ML 14.53 1574(E) 31-03-23
308 Griseofulvin Tablet 250mg 1 Tablet 1.77 1574(E) 31-03-23
309 Haloperidol Tablet 5mg 1 Tablet 3.57 4663(E) 25-10-23
310 Haloperidol Tablet 10mg 1 Tablet 4.78 4663(E) 25-10-23
Oral liquid 1574(E) 31-03-23
311 Haloperidol 1 ML 2.24
2mg/5mL
312 Haloperidol Injection 5mg/mL 1 ML 6.51 1577(E) 31-03-23
313 Haloperidol Tablet 20mg 1 Tablet 5.36 4663(E) 25-10-23
314 Haloperidol Tablet 1.5mg 1 Tablet 1.58 1697(E) 12-04-23
Liquid for 4663(E) 25-10-23
315 Halothane 1 ML 6.10
inhalation
Injection 1574(E) 31-03-23
316 Heparin 1 ML 21.21
1000IU/mL
Injection 1574(E) 31-03-23
317 Heparin 1 ML 59.96
5000IU/mL
318 Hepatitis B immunoglobulin As Licensed 1 Vial 5498.70 4663(E) 25-10-23
319 Hepatitis B vaccine As Licensed 1 ML 78.82 1577(E) 31-03-23
320 Homatropine Drops 2% 1 ML 6.40 1574(E) 31-03-23
Contains 52 mg of 4663(E) 25-10-23
321 Hormone Releasing IUD 1 IUD 4103.53
Levonorgestrel
Human chorionic gonado 1574(E) 31-03-23
322 Injection 5000 IU 1 Vial 417.47
tropin
Human chorionic gonado 4663(E) 25-10-23
323 Injection10000IU 1 Vial 928.30
tropin
Human chorionic gonado 1579(E) 31-03-23
324 Injection2000 IU 1 Vial 343.66
tropin
325 Hydrochlorothiazide Tablet 25 mg 1 Tablet 1.75 4663(E) 25-10-23
326 Hydrochlorothiazide Tablet 12.5mg 1 Tablet 1.04 1574(E) 31-03-23
Powder for 1574(E) 31-03-23
327 Hydrocortisone 1 Vial 44.79
Injection 100mg
328 Hydrocortisone Tablet 10mg 1 Tablet 6.70 1574(E) 31-03-23
Powder for 1574(E) 31-03-23
329 Hydrocortisone 1 Vial 65.60
Injection 200mg
330 Hydrocortisone Tablet 5mg 1 Tablet 3.12 4663(E) 25-10-23
331 Hydrocortisone Tablet 20mg 1 Tablet 14.89 4663(E) 25-10-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 39
Hydroxy propylmethyl 4663(E) 25-10-23
332 Injection 2% 1 ML 29.21
cellulose
333 Hydroxychloroquine Tablet 400mg 1 Tablet 13.80 1574(E) 31-03-23
334 Hydroxychloroquine Tablet 200mg 1 Tablet 6.36 4663(E) 25-10-23
335 Hydroxyurea Capsule 500mg 1 Capsule 12.12 1574(E) 31-03-23
336 Ibuprofen Tablet 200mg 1 Tablet 0.71 4663(E) 25-10-23
337 Ibuprofen Tablet 400mg 1 Tablet 1.20 4663(E) 25-10-23
Oral liquid 1574(E) 31-03-23
338 Ibuprofen 1 ML 0.22
100mg/5mL(p)
Powder for 4663(E) 25-10-23
339 Ifosfamide 1 Vial 643.16
Injection 2000mg
Powder for 1577(E) 31-03-23
340 Ifosfamide 1 Vial 318.96
Injection 1000mg
341 Imatinib Tablet 100mg 1 Tablet 69.75 1574(E) 31-03-23
342 Imatinib Tablet 400mg 1 Tablet 199.62 1574(E) 31-03-23
343 Imatinib Capsule 100mg 1 Capsule 73.48 1577(E) 31-03-23
344 Insulin (Soluble) Injection 40 IU/ml 1 ml 16.99 4663(E) 25-10-23
345 Insulin Glargine Injection 100 IU/ml 1 ML 203.46 4663(E) 25-10-23
Insulin Intermediate Acting 4663(E) 25-10-23
346 Injection 40IU/mL 1 ML 16.99
(NPH)
Injection 300mg 4663(E) 25-10-23
347 Iohexol 1 ML 16.90
iodine/mL
Injection 350mg 4663(E) 25-10-23
348 Iohexol 1 ML 14.24
iodine/mL
Solution for 1579(E) 31-03-23
349 Irinotecan HCltrihydrate 1 ML 964.89
injection 20mg/mL
350 Iron sucrose Injection 20mg/mL 1 ML 57.41 4663(E) 25-10-23
Liquid for 1574(E) 31-03-23
351 Isoflurane 1 ML 9.65
inhalation
352 Isoniazid Tablet 300mg 1 Tablet 1.29 2540(E) 08-06-23
353 Isoniazid Tablet 100mg 1 Tablet 0.65 2540(E) 08-06-23
354 Isosorbide dinitrate Tablet 5mg 1 Tablet 0.82 4663(E) 25-10-23
355 Isosorbide dinitrate Tablet 10mg 1 Tablet 0.81 4663(E) 25-10-23
Granules/Husk/Pow 1574(E) 31-03-23
356 Ispaghula 1 GM 0.94
der
Oral liquid 1574(E) 31-03-23
357 Itraconazole 1 ML 4.94
10mg/mL
358 Itraconazole Capsule 100mg 1 Capsule 16.67 1579(E) 31-03-23
359 Itraconazole Capsule 200mg 1 Capsule 22.12 1579(E) 31-03-23
360 IUD containing Copper As licensed 1 IUD 281.02 4663(E) 25-10-23
361 Ivermectin Tablet 6 mg 1 Tablet 21.58 1578(E) 31-03-23
362 Ivermectin Tablet 12 mg 1 Tablet 37.37 1578(E) 31-03-23
As licensed (4mcg 2124(E) 04-05-23
363 Japanese encephalitis vaccine 1 Vial 677.17
to 6 mcg)
As licensed (upto 3 2124(E) 04-05-23
364 Japanese encephalitis vaccine 1 Vial 518.66
mcg)
365 Ketamine Injection 50mg/mL 1 ML 12.12 1574(E) 31-03-23
366 Labetalol Injection 5mg/mL 1 ML 49.98 1574(E) 31-03-23
367 Labetalol Tablet 100 mg 1 Tablet 15.16 4663(E) 25-10-23
Oral liquid 10 1574(E) 31-03-23
368 Lactulose 1 ML 1.23
g/15mL
369 Lamivudine Tablet 100mg 1 Tablet 10.40 1574(E) 31-03-23
40 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

370 Lamivudine Tablet 150mg 1 Tablet 10.86 1574(E) 31-03-23


Powder for 4663(E) 25-10-23
371 L-Asparaginase 1 Vial 1034.88
Injection 5000 KU
Powder for 4663(E) 25-10-23
372 L-Asparaginase 1 Vial 1707.74
Injection 10000KU
373 Latanoprost Drops 0.005% 1 ML 232.58 2542(E) 08-06-23
374 Lenalidomide Capsule 5mg 1 Capsule 67.25 1574(E) 31-03-23
375 Lenalidomide Capsule 25 mg 1 Capsule 292.28 4663(E) 25-10-23
376 Letrozole Tablet 2.5mg 1 Tablet 29.32 4663(E) 25-10-23
Powder for 4663(E) 25-10-23
377 Leuprolide acetate 1 Vial 17081.50
injection 22.5 mg
Powder for 4663(E) 25-10-23
378 Leuprolide acetate 1 Vial 9294.48
injection 11.25mg
Powder for 1574(E) 31-03-23
379 Leuprolide acetate 1 Vial 3112.67
injection 3.75 mg
380 Levetiracetam Tablet 250mg 1 Tablet 6.30 1574(E) 31-03-23
381 Levetiracetam Tablet 500mg 1 Tablet 12.98 1574(E) 31-03-23
Modified Release 4663(E) 25-10-23
382 Levetiracetam 1 Tablet 18.30
Tablet 750mg
383 Levetiracetam Tablet 750mg 1 Tablet 19.34 1574(E) 31-03-23
Oral liquid 100 4663(E) 25-10-23
384 Levetiracetam 1 ML 3.97
mg/mL (p)
Injection 4663(E) 25-10-23
385 Levetiracetam 1 ML 23.02
100mg/mL
Modified Release– 1574(E) 31-03-23
386 Levodopa (A) + Carbidopa (B) Tablet 200mg (A) + 1 Tablet 4.73
50mg (B)
Tablet 100 mg (A) 4663(E) 25-10-23
387 Levodopa (A) +Carbidopa(B) 1 Tablet 2.58
+ 25 mg (B)
Tablet 100 mg (A) 1574(E) 31-03-23
388 Levodopa (A) +Carbidopa(B) 1 Tablet 1.76
+ 10 mg (B)
Tablet 250mg(A) 4663(E) 25-10-23
389 Levodopa (A) +Carbidopa(B) 1 Tablet 4.42
+25mg(B)
Modified Release– 1574(E) 31-03-23
390 Levodopa (A) +Carbidopa(B) Tablet 100 mg (A) 1 Tablet 2.79
+ 25 mg (B)
391 Levofloxacin Tablet 750mg 1 Tablet 12.45 4663(E) 25-10-23
392 Levofloxacin Tablet 250mg 1 Tablet 4.82 1697(E) 12-04-23
393 Levofloxacin Tablet 500mg 1 Tablet 8.99 1697(E) 12-04-23
394 Levothyroxine Tablet 50mcg 1 Tablet 1.03 1574(E) 31-03-23
395 Levothyroxine Tablet 75mcg 1 Tablet 1.44 4663(E) 25-10-23
396 Levothyroxine Tablet 88 mcg 1 Tablet 1.65 4663(E) 25-10-23
397 Levothyroxine Tablet 112 mcg 1 Tablet 1.66 4663(E) 25-10-23
398 Levothyroxine Tablet 25 mcg 1 Tablet 1.45 4663(E) 25-10-23
399 Levothyroxine Tablet 62.5mcg 1 Tablet 1.61 1574(E) 31-03-23
400 Levothyroxine Tablet 12.5mcg 1 Tablet 1.48 1574(E) 31-03-23
401 Levothyroxine Tablet 100mcg 1 Tablet 1.32 1574(E) 31-03-23
402 Levothyroxine Tablet 125mcg 1 Tablet 1.69 1574(E) 31-03-23
403 Levothyroxine Tablet 150 mcg 1 Tablet 1.70 1577(E) 31-03-23
Topical forms 2-5 1574(E) 31-03-23
404 Lignocaine 1 GM/ML 1.13
%
405 Lignocaine Injection 2% 1 ML 1.04 1574(E) 31-03-23
406 Lignocaine Injection 1% 1 ML 8.87 4663(E) 25-10-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 41
Injection 5% with 4663(E) 25-10-23
407 Lignocaine 1 ML 3.50
7.5% glucose
Injection2%(A)+1:2 1577(E) 31-03-23
Lignocaine (A)
408 00000(5 1 ML 1.05
+Adrenaline(B)
mcg/mL)(B)
409 Linezolid Tablet 600mg 1 Tablet 35.67 4663(E) 25-10-23
410 Linezolid Tablet 300 mg 1 Tablet 22.65 4663(E) 25-10-23
411 Lithium Tablet 300mg 1 Tablet 1.63 4663(E) 25-10-23
412 Loperamide Tablet 2mg 1 Tablet 2.28 4663(E) 25-10-23
413 Loperamide Capsule 2mg 1 Capsule 3.79 4663(E) 25-10-23
Tablet 200 mg (A) 4663(E) 25-10-23
414 Lopinavir (A) + Ritonavir(B) 1 Tablet 47.97
+ 50mg (B)
415 Lorazepam Tablet 1 mg 1 Tablet 2.31 4663(E) 25-10-23
416 Lorazepam Tablet 2 mg 1 Tablet 2.81 1574(E) 31-03-23
417 Lorazepam Injection 2mg/mL 1 ML 8.10 4663(E) 25-10-23
Injection 4663(E) 25-10-23
418 Magnesium sulphate 1 ML 4.87
500mg/mL
419 Mannitol Injection 20 % 1 ML 0.35 4663(E) 25-10-23
420 Mannitol Injection 10 % 1 ML 0.19 1577(E) 31-03-23
421 Mebendazole Tablet 100 mg 1 Tablet 2.90 1574(E) 31-03-23
Oral liquid 1574(E) 31-03-23
422 Mebendazole 1 ML 0.84
100mg/5mL(p)
423 Medroxyprogesterone acetate Tablet 10 mg 1 Tablet 6.25 4663(E) 25-10-23
Injection 4663(E) 25-10-23
424 Medroxyprogesterone acetate 1 ML 289.77
150mg/mL
Oral liquid 1574(E) 31-03-23
425 Mefenamic acid 1 ML 0.56
100mg/5mL(p)
426 Mefenamic acid Tablet 250 mg 1 Tablet 2.11 4663(E) 25-10-23
427 Mefloquine Tablet 250 mg 1 Tablet 52.16 4663(E) 25-10-23
428 Meglumine diatrizoate Injection 60%w/v 1 ML 9.47 1574(E) 31-03-23
429 Meglumine diatrizoate Injection 76%w/v 1 ML 10.20 1574(E) 31-03-23
Powder for 1579(E) 31-03-23
430 Meropenem Injection 500 mg 1 Vial 723.02
(as trihydrate)
Powder for 4663(E) 25-10-23
431 Meropenem Injection1000mg 1 Vial 952.74
(as trihydrate)
Injection 4663(E) 25-10-23
432 Mesna 1 ML 15.51
100mg/mL
433 Metformin Tablet 1000mg 1 Tablet 3.49 4663(E) 25-10-23
434 Metformin Tablet 500mg 1 Tablet 2.02 4663(E) 25-10-23
Modified release 4663(E) 25-10-23
435 Metformin 1 Tablet 4.05
Tablet 1000mg
436 Methotrexate Tablet 10mg 1 tablet 13.29 4663(E) 25-10-23
437 Methotrexate Tablet 2.5mg 1 tablet 5.31 1574(E) 31-03-23
438 Methotrexate Tablet 5mg 1 Tablet 9.43 4663(E) 25-10-23
439 Methylergometrine Tablet 0.125mg 1 Tablet 8.94 4663(E) 25-10-23
440 Methylergometrine Injection 0.2mg/mL 1 ML 14.95 4663(E) 25-10-23
441 Methylprednisolone Injection 40mg/mL 1 ML 45.67 4663(E) 25-10-23
442 Metoclopramide Tablet 10mg 1 Tablet 1.35 4663(E) 25-10-23
Injection 5mg/mL 4663(E) 25-10-23
443 Metoclopramide (Less than 10ML 1 ML 2.67
Pack)
42 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

Injection 5mg/mL 4663(E) 25-10-23


444 Metoclopramide (10 ML & More 1 ML 1.63
Pack)
Oral liquid 1577(E) 31-03-23
445 0.50
Metoclopramide 5mg/5mL(p) 1 ML
446 Metoprolol Tablet 25mg 1 Tablet 4.20 1574(E) 31-03-23
447 Metoprolol Tablet 50mg 1 Tablet 5.84 1574(E) 31-03-23
Modified Release 1574(E) 31-03-23
448 Metoprolol 1 Tablet 14.99
Tablet 100 mg
449 Metoprolol Tablet 100 mg 1 Tablet 11.13 1574(E) 31-03-23
450 Metoprolol Capsule 25mg 1 Capsule 4.14 4663(E) 25-10-23
451 Metoprolol Capsule 50mg 1 Capsule 5.82 4663(E) 25-10-23
452 Metoprolol Injection 1mg/ML 1 ML 3.40 4663(E) 25-10-23
453 Metronidazole Tablet 200mg 1 Tablet 0.82 4663(E) 25-10-23
454 Metronidazole Tablet 400mg 1 Tablet 1.52 1574(E) 31-03-23
Injection 1574(E) 31-03-23
455 Metronidazole 1 ML 0.21
500mg/100mL
Oral liquid 4663(E) 25-10-23
456 Metronidazole 1 ML 0.52
200mg/5mL(p)
Nasal Spray 4663(E) 25-10-23
457 Midazolam 1 ML 216.82
1.25mg/ actuation
Nasal Spray 0.5 1574(E) 31-03-23
458 Midazolam 1 ML 79.93
mg/actuation
459 Midazolam Injection 1mg/mL 1 ML 5.92 1574(E) 31-03-23
460 Midazolam Injection 5mg/mL 1 ML 10.88 4663(E) 25-10-23
461 Mifepristone Tablet 200mg 1 Tablet 350.92 4663(E) 25-10-23
462 Misoprostol Tablet 200mcg 1 Tablet 18.97 1574(E) 31-03-23
463 Misoprostol Tablet 100mcg 1 Tablet 9.92 1574(E) 31-03-23
464 Montelukast Tablet 4 mg 1 Tablet 10.03 1574(E) 31-03-23
465 Montelukast Tablet 10 mg 1 Tablet 16.44 4663(E) 25-10-23
466 Morphine Injection 10mg/mL 1 ML 19.60 4663(E) 25-10-23
467 Morphine Injection 15mg/mL 1 ML 14.93 1574(E) 31-03-23
468 Moxifloxacin Tablet 400mg 1 Tablet 25.82 1574(E) 31-03-23
469 Mupirocin Ointment 2% 1 GM 20.29 1579(E) 31-03-23
470 Mycophenolate mofetil Tablet 250mg 1 Tablet 49.60 1574(E) 31-03-23
Injection 200 4663(E) 25-10-23
471 N-acetylcysteine 1 ML 23.64
mg/mL
472 Naloxone Injection 0.4mg/mL 1 ML 92.73 1574(E) 31-03-23
473 Natamycin Drops 5% 1 ML 23.38 4663(E) 25-10-23
474 Neostigmine Injection 0.5mg/mL 1 ML 5.01 1574(E) 31-03-23
475 Neostigmine Tablet 15mg 1 Tablet 4.59 4663(E) 25-10-23
476 Nevirapine Tablet 200 mg 1 Tablet 15.80 4663(E) 25-10-23
Nicotine (for nicotine 4663(E) 25-10-23
477 Lozenge 2mg 1 Lozenges 7.92
replacement therapy)
Nicotine (for nicotine 4663(E) 25-10-23
478 Gum 2 mg 1 Gum 8.59
replacement therapy)
Nicotine (for nicotine 1579(E) 31-03-23
479 Gum 4 mg 1 Gum 10.64
replacement therapy)
Nicotine (for nicotine 1579(E) 31-03-23
480 Lozenge 4mg 1 Lozenges 9.75
replacement therapy)
481 Nifedipine Tablet 10mg 1 Tablet 1.54 4663(E) 25-10-23
482 Nifedipine Capsule10mg 1 Capsule 0.95 1577(E) 31-03-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 43
483 Nitrofurantoin Tablet 100 mg 1 Tablet 8.11 4663(E) 25-10-23
484 Nitrofurantoin Capsule 100 mg 1 Capsule 8.64 1577(E) 31-03-23
Oral liquid 4663(E) 25-10-23
485 Nitrofurantoin 1 ML 0.89
25mg/5mL(p)
486 Noradrenaline Injection 2mg/mL 1 ML 20.17 1574(E) 31-03-23
487 Norethisterone Tablet 5mg 1 Tablet 5.39 1574(E) 31-03-23
488 Omeprazole Capsule 20 mg 1 Capsule 2.87 1574(E) 31-03-23
489 Omeprazole Tablet 20 mg 1 Tablet 4.34 4663(E) 25-10-23
490 Omeprazole Capsule 10 mg 1 Capsule 2.41 1577(E) 31-03-23
Powder for oral 1577(E) 31-03-23
491 Omeprazole 1 GM 1.51
liquid 20mg
492 Omeprazole Tablet 40 mg 1 Tablet 8.45 1577(E) 31-03-23
493 Ondansetron Tablet 4 mg 1 Tablet 5.14 4663(E) 25-10-23
Oral liquid 4663(E) 25-10-23
494 Ondansetron 1 ML 1.26
2mg/5mL(p)
495 Ondansetron Injection 2mg/mL 1 ML 5.96 1574(E) 31-03-23
496 Ondansetron Tablet 8 mg 1 Tablet 9.06 4663(E) 25-10-23
497 Oral rehydration salts As licensed 1 ML 0.15 4663(E) 25-10-23
498 Ormeloxifene (Centchroman) Tablet 30mg 1 Tablet 8.44 1579(E) 31-03-23
Injection 5 mg/mL 4663(E) 25-10-23
499 Oxaliplatin 1 Vial 2233.95
in 10 mL vial
500 Oxytocin Injection 5 IU/mL 1 ML 17.84 4663(E) 25-10-23
501 Oxytocin Injection 10IU/mL 1 ML 39.87 1577(E) 31-03-23
Injection 30 mg/5 1577(E) 31-03-23
502 Paclitaxel mL, injection 100 1 ML 215.44
mg/16.7 ml
503 Pantoprazole Injection 40mg 1 Vial 50.45 1574(E) 31-03-23
504 Paracetamol Tablet 650mg 1 Tablet 2.01 4663(E) 25-10-23
Oral Liquid 125 1574(E) 31-03-23
505 Paracetamol 1 ML 0.37
mg/5 mL (p)
Oral Liquid 250 1574(E) 31-03-23
506 Paracetamol 1 ML 0.67
mg/5 mL (p)
Oral liquid 120 4663(E) 25-10-23
507 Paracetamol 1 ML 0.61
mg/5 mL (p)
508 Paracetamol Tablet 500mg 1 Tablet 0.90 4663(E) 25-10-23
1 1574(E) 31-03-23
509 Paracetamol Suppository 80mg 6.66
Suppository
1 4663(E) 25-10-23
510 Paracetamol Suppository 170mg 7.95
Suppository
Injection 2124(E) 04-05-23
511 Paracetamol 1 ML 3.97
150mg/mL (2ML)
Injection150mg/mL 2125(E) 04-05-23
512 Paracetamol 1 ML 1.60
(100 ML)
513 Permethrin Cream 5% 1 GM 1.85 1577(E) 31-03-23
514 Permethrin Lotion 1% 1 ML 1.00 4663(E) 25-10-23
515 Permethrin Cream 1% 1 GM 1.50 1577(E) 31-03-23
516 Permethrin Lotion 5% 1 ML/GM 1.00 4663(E) 25-10-23
517 Permethrin Gel 5% 1 GM 1.31 2540(E) 08-06-23
Injection 4663(E) 25-10-23
518 Pheniramine 1 ML 2.76
22.75mg/mL (2ml)
Injection 1577(E) 31-03-23
519 Pheniramine 22.75mg/mL 1 ML 2.06
(10ml)
44 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

520 Phenobarbitone Tablet 30mg 1 Tablet 1.31 1574(E) 31-03-23


521 Phenobarbitone Tablet 60mg 1 Tablet 1.89 1574(E) 31-03-23
Injection 1574(E) 31-03-23
522 Phenobarbitone 1 ML 22.14
200mg/mL
Oral liquid 1574(E) 31-03-23
523 Phenobarbitone 1 ML 0.49
20mg/5mL (p)
524 Phenytoin Tablet 300mg 1 Tablet 5.48 1574(E) 31-03-23
525 Phenytoin Injection 50mg/mL 1 ML 5.95 1574(E) 31-03-23
Modified Release 1577(E) 31-03-23
526 Phenytoin 1 Tablet 6.57
Tablet 300mg
527 Phenytoin Tablet 100mg 1 Tablet 1.76 1577(E) 31-03-23
528 Phenytoin Tablet 50mg 1 Tablet 0.84 1577(E) 31-03-23
Oral liquid 30mg/5 4663(E) 25-10-23
529 Phenytoin 1 ML 0.35
mL(p)
Oral liquid 4663(E) 25-10-23
530 Phenytoin 1 ML 1.10
125mg/5mL(p)
531 Phenytoin Capsule 300mg 1 Capsule 4.65 1577(E) 31-03-23
532 Phenytoin Capsule 100mg 1 Capsule 1.83 4663(E) 25-10-23
533 Phytomenadione (Vitamin K1) Injection 10mg/mL 1 ML 53.09 4663(E) 25-10-23
534 Phytomenadione (Vitamin K1) Tablet 10mg 1 Tablet 14.54 1577(E) 31-03-23
535 Pilocarpine Drops 2 % 1 ML 10.83 1574(E) 31-03-23
Powder for 1574(E) 31-03-23
Piperacillin (A) Injection
536 1 Vial 99.66
+Tazobactam(B) 1000mg(A)+125mg
(B)
Powder for 4663(E) 25-10-23
Piperacillin (A) Injection
537 1 Vial 191.55
+Tazobactam(B) 2000mg(A)+250mg
(B)
Powder for 4663(E) 25-10-23
Piperacillin (A) Injection
538 1 Vial 399.41
+Tazobactam(B) 4000mg(A)+500mg
(B)
Oral liquid 1574(E) 31-03-23
539 Potassium chloride 1 ML 0.30
500mg/5mL
Injection 4663(E) 25-10-23
540 Potassium chloride 1 ML 2.40
150mg/mL
541 Povidone iodine Solution 5% 1 ML 0.44 4663(E) 25-10-23
542 Povidone iodine Solution 7.5% 1 ML 0.82 4663(E) 25-10-23
543 Povidone iodine Solution 10% 1 ML 0.96 1574(E) 31-03-23
544 Povidone iodine Solution 4% 1 ML 1.74 2168(E) 11-05-23
545 Pralidoxime chloride (2-PAM) Injection 25mg/mL 1 ML 4.56 1574(E) 31-03-23
546 Prednisolone Tablet 40mg 1 Tablet 3.41 4663(E) 25-10-23
Oral liquid 1574(E) 31-03-23
547 Prednisolone 1 ML 0.49
5mg/5mL(p)
Oral liquid 1574(E) 31-03-23
548 Prednisolone 1 ML 0.86
15mg/5mL(p)
549 Prednisolone Tablet 10mg 1 Tablet 1.20 4663(E) 25-10-23
550 Prednisolone Tablet 5mg 1 Tablet 0.68 1574(E) 31-03-23
551 Prednisolone Tablet 20mg 1 Tablet 2.40 4663(E) 25-10-23
552 Prednisolone Drops 1% 1 ML 5.76 1574(E) 31-03-23
Premix Insulin 30:70 Injection Injection 40 IU /ml 1 ml 4663(E) 25-10-23
553 16.99
(Regular:NPH)
554 Primaquine Tablet 7.5mg 1 Tablet 2.38 4663(E) 25-10-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 45
555 Primaquine Tablet 15mg 1 Tablet 5.14 4663(E) 25-10-23
556 Primaquine Tablet 2.5mg 1 Tablet 1.75 4663(E) 25-10-23
557 Proparacaine Eye Drops0.5% 1 ML 10.25 4663(E) 25-10-23
558 Propofol Injection 10mg/mL 1 ML 6.50 1574(E) 31-03-23
559 Propranolol Tablet 40mg 1 Tablet 3.22 4663(E) 25-10-23
560 Propranolol Tablet 10mg 1 Tablet 1.31 1574(E) 31-03-23
561 Propranolol Tablet 20mg 1 Tablet 3.20 4663(E) 25-10-23
562 Propranolol Capsule 40mg 1 Capsule 4.25 4663(E) 25-10-23
563 Propranolol Capsule 20 mg 1 Capsule 2.35 1578(E) 31-03-23
564 Propranolol Capsule 10 mg 1 Capsule 2.00 4663(E) 25-10-23
565 Protamine Sulphate Injection 10mg/mL 1 ML 9.78 4663(E) 25-10-23
566 Pyrazinamide Tablet 1000mg 1 Tablet 10.53 4663(E) 25-10-23
567 Pyrazinamide Tablet 500mg 1 Tablet 4.89 4663(E) 25-10-23
568 Pyrazinamide Tablet 750mg 1 Tablet 7.21 4663(E) 25-10-23
569 Pyrazinamide Tablet 1500mg 1 Tablet 11.81 4663(E) 25-10-23
570 Pyridoxine Tablet 100 mg 1 Tablet 5.98 4663(E) 25-10-23
571 Pyridoxine Tablet 10mg 1 Tablet 0.11 1577(E) 31-03-23
572 Quinine Tablet 300 mg 1 Tablet 5.65 1574(E) 31-03-23
Injection 300 4663(E) 25-10-23
573 Quinine 1 ML 9.50
mg/mL
574 Rabies vaccine As licensed 1 Vial 378.71 1574(E) 31-03-23
575 Raltegravir Tablet 400mg 1 Tablet 147.80 4663(E) 25-10-23
576 Ramipril Tablet 2.5 mg 1 Tablet 5.21 1574(E) 31-03-23
577 Ramipril Tablet 5mg 1 Tablet 8.18 1574(E) 31-03-23
578 Ramipril Capsule 2.5mg 1 Capsule 4.66 1577(E) 31-03-23
579 Ramipril Capsule 5mg 1 Capsule 7.19 4663(E) 25-10-23
580 Ribavirin Capsule 200 mg 1 Capsule 26.49 1574(E) 31-03-23
581 Rifampicin Capsule 600mg 1 Capsule 11.36 4663(E) 25-10-23
582 Rifampicin Capsule 450mg 1 Capsule 5.67 1574(E) 31-03-23
583 Rifampicin Capsule 150mg 1 Capsule 2.29 4663(E) 25-10-23
584 Rifampicin Capsule 300mg 1 Capsule 4.61 4663(E) 25-10-23
Oral liquid 1574(E) 31-03-23
585 Rifampicin 1 ML 0.47
100mg/5mL(p)
586 Risperidone Tablet 1 mg 1 Tablet 3.03 4663(E) 25-10-23
587 Risperidone Tablet 2 mg 1 Tablet 4.48 1574(E) 31-03-23
588 Risperidone Tablet 4 mg 1 Tablet 7.36 4663(E) 25-10-23
589 Risperidone Oral liquid 1mg/mL 1 ML 2.21 4663(E) 25-10-23
Injection 2125(E) 04-05-23
590 Risperidone 1 ML 1930.30
(Longacting) 25mg
Injection 2125(E) 04-05-23
591 Risperidone (Longacting) 37.5 1 ML 2649.41
mg
592 Ritonavir Tablet 100mg 1 Tablet 29.21 4663(E) 25-10-23
593 Rituximab Injection 10mg/mL 1 ML 761.81 4663(E) 25-10-23
594 Rota virus vaccine As licensed 1 Vial 854.58 4663(E) 25-10-23
595 Salbutamol Tablet 4 mg 1 Tablet 0.21 1574(E) 31-03-23
596 Salbutamol Tablet 2 mg 1 Tablet 0.18 4663(E) 25-10-23
Oral liquid 4663(E) 25-10-23
597 Salbutamol 1 ML 0.18
2mg/5mL
598 Salbutamol Inhalation 1 Dose 0.49 1574(E) 31-03-23
46 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

(MDI/DPI)
100mcg/dose
Respirator Solution 1574(E) 31-03-23
599 Salbutamol (Solution for 1 ML 0.68
Nebulizer 5mg/mL)
Ointment 3-6% 4663(E) 25-10-23
600 Salicylic acid 1 GM 2.02
(6%)
601 Salicylicacid Ointment 3% 1 GM 2.06 1579(E) 31-03-23
Liquid for 4663(E) 25-10-23
602 Sevoflurane 1 ML 31.17
inhalation
Injection (as per IP) 4663(E) 25-10-23
603 Sodium bicarbonate 1 ML 1.35
- 8.4%
Injection (as per IP) 4663(E) 25-10-23
604 Sodium bicarbonate 1 ML 1.01
- 7.5%
605 Sodium Valproate Tablet 300mg 1 Tablet 4.46 1574(E) 31-03-23
Oral liquid 1574(E) 31-03-23
606 Sodium Valproate 1 ML 0.65
200mg/5mL(p)
607 Sodium Valproate Tablet 200mg 1 Tablet 3.59 4663(E) 25-10-23
Modified Release – 1574(E) 31-03-23
608 Sodium Valproate 1 Tablet 9.28
Tablet 500mg
609 Sodium Valproate Tablet 500mg 1 Tablet 8.12 4663(E) 25-10-23
Modified Release – 4663(E) 25-10-23
610 Sodium Valproate 1 Tablet 6.10
Tablet 300mg
Injection 4663(E) 25-10-23
611 Sodium Valproate 1 ML 6.75
100mg/mL
612 Sofosbuvir Tablet 400mg 1 Tablet 525.12 4663(E) 25-10-23
Powder for 4663(E) 25-10-23
613 Somatostatin 1 Vial 1359.00
Injection 3mg
614 Spironolactone Tablet 50mg 1 Tablet 4.37 1574(E) 31-03-23
615 Spironolactone Tablet 25mg 1 Tablet 2.19 4663(E) 25-10-23
Injection 1574(E) 31-03-23
616 Streptokinase 1 Vial 1877.33
15,00,000IU
Powder for 1574(E) 31-03-23
617 Streptomycin 1 Vial 10.10
Injection 750 mg
Powder for 1574(E) 31-03-23
618 Streptomycin 1 Vial 10.86
Injection 1000mg
619 Succinylcholine Injection 50mg/mL 1 ML 5.21 2540(E) 08-06-23
620 Sulfasalazine Tablet 500 mg 1 Tablet 4.72 1574(E) 31-03-23
621 Sumatriptan Tablet 25mg 1 Tablet 32.50 2540(E) 08-06-23
622 Sumatriptan Tablet 50mg 1 Tablet 55.68 2540(E) 08-06-23
623 Tacrolimus Capsule 0.5mg 1 Capusle 20.66 1574(E) 31-03-23
624 Tacrolimus Capsule 1mg 1 Capusle 40.62 1574(E) 31-03-23
625 Tacrolimus Capsule 2mg 1 Capusle 84.34 4663(E) 25-10-23
626 Tacrolimus Tablet 1mg 1 Tablet 39.98 4886(E) 10-11-23
627 Tacrolimus Tablet 2mg 1 Tablet 77.69 4886(E) 10-11-23
628 Tacrolimus Tablet 0.5mg 1 Tablet 20.97 4886(E) 10-11-23
629 Tamoxifen Tablet 20mg 1 Tablet 2.95 4663(E) 25-10-23
630 Tamoxifen Tablet 10mg 1 Tablet 2.21 4663(E) 25-10-23
631 Telmisartan Tablet 20mg 1 Tablet 3.88 4663(E) 25-10-23
632 Telmisartan Tablet 40mg 1 Tablet 6.76 1574(E) 31-03-23
633 Telmisartan Tablet 80mg 1 Tablet 10.40 1574(E) 31-03-23
634 Temozolomide Capsule 20 mg 1 Capsule 441.33 1574(E) 31-03-23
635 Temozolomide Capsule 250mg 1 Capsule 4304.01 1574(E) 31-03-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 47
636 Temozolomide Capsule 100mg 1 Capsule 1508.70 1574(E) 31-03-23
637 Temozolomide Tablet 20 mg 1 Tablet 336.65 4886(E) 10-11-23
638 Temozolomide Tablet 250 mg 1 Tablet 3758.15 4886(E) 10-11-23
639 Tenecteplase Injection 40mg/vial 1 Vial 50389.69 4663(E) 25-10-23
640 Tenecteplase Injection 30mg/vial 1 Vial 36910.02 4663(E) 25-10-23
641 Teneligliptin Tablet 20mg 1 Tablet 11.09 4663(E) 25-10-23
Tenofovir Alafenamide 1574(E) 31-03-23
642 Tablet 25mg 1 Tablet 48.87
Fumarate (TAF)
Tenofovir Disproxil Fumarate Tablet 300mg (A) + 4663(E) 25-10-23
643 1 Tablet 45.58
(A) + Lamivudine (B) 300mg(B)
Tenofovir Disproxil Fumarate Tablet 300mg(A)+ 4663(E) 25-10-23
644 (A) +Lamivudine (B) + 300mg (B) + 1 Tablet 102.85
Efavirenz(C) 600mg(C)
Tenofovir Disproxil Fumarate 4663(E) 25-10-23
645 Tablet 300mg 1 Tablet 45.84
(TDF)*
646 Terbinafine Cream 1% 1 GM 5.26 4663(E) 25-10-23
647 Tetanus toxoid As licensed (5ml) 1 Vial 25.53 1577(E) 31-03-23
1 Vial 4663(E) 25-10-23
648 Tetanus toxoid As licensed (0.5ml) 12.47
(0.5ML)
649 Thalidomide Capsule 50 mg 1 Capsule 31.16 4663(E) 25-10-23
650 Thalidomide Capsule 100mg 1 Capsule 62.01 1574(E) 31-03-23
651 Thiamine Tablet 100 mg 1 Tablet 4.46 1574(E) 31-03-23
Injection 100 1574(E) 31-03-23
652 Thiamine 1 ML 22.59
mg/mL
Powder for 2540(E) 08-06-23
653 Thiopentone 1 Vial 55.32
injection 1g
Powder for 2540(E) 08-06-23
654 Thiopentone 1 Vial 45.69
injection 0.5g
655 Timolol Drops 0.5 % 1 ML 13.40 4663(E) 25-10-23
Inhalation (MDI) 9 1574(E) 31-03-23
656 Tiotropium 1 MD 2.78
mcg/dose
Inhalation (DPI) 4663(E) 25-10-23
657 Tiotropium 1 DP 10.71
18mcg/dose
Injection 50mg/mL 1574(E) 31-03-23
658 Tramadol 1 ML 11.78
(upto 2ml pack)
659 Tramadol Capsule 50mg 1 Capsule 4.82 1577(E) 31-03-23
660 Tramadol Capsule 100mg 1 Capsule 9.04 4663(E) 25-10-23
661 Tramadol Tablet 50mg 1 Tablet 9.70 4886(E) 10-11-23
662 Tramadol Tablet 100mg 1 Tablet 24.48 4886(E) 10-11-23
Injection 100 1574(E) 31-03-23
663 Tranexamic acid 1 ML 13.71
mg/mL
664 Tranexamic acid Tablet 500 mg 1 Tablet 18.54 1574(E) 31-03-23
Injection 4663(E) 25-10-23
665 Trastuzumab 1 Vial 54725.21
440mg/50mL
666 Trihexyphenidyl Tablet 2mg 1 Tablet 1.37 4663(E) 25-10-23
667 Tropicamide Eye drop 1 % 1 ML 9.43 4663(E) 25-10-23
668 Valganciclovir Tablet 450 mg 1 Tablet 400.73 1574(E) 31-03-23
Powder for 4663(E) 25-10-23
669 Vancomycin 1 Vial 317.64
Injection 500 mg
Powder for 4663(E) 25-10-23
670 Vancomycin 1 Vial 470.27
Injection 1000mg
Powder for 1574(E) 31-03-23
671 Vancomycin 1 Vial 251.25
Injection 250 mg
48 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

672 Vancomycin Capsule 250 mg 1 Capsule 152.39 1578(E) 31-03-23


Powder for 4663(E) 25-10-23
673 Vecuronium Each Vial 117.37
injection 10mg
Powder for 1574(E) 31-03-23
674 Vecuronium Each Vial 74.40
injection 4 mg
675 Verapamil Tablet 80 mg 1 Tablet 1.59 1574(E) 31-03-23
676 Verapamil Tablet 40mg 1 Tablet 0.86 1574(E) 31-03-23
677 Vincristine Injection 1mg/mL 1 ML 57.52 4663(E) 25-10-23
Tablet 50000IU 4663(E) 25-10-23
678 Vitamin A (including 1 Tablet 0.73
Chewable Tablet)
Injection 1577(E) 31-03-23
679 Vitamin A 1 ML 2.26
50000IU/mL
680 Warfarin Tablet 5 mg 1 Tablet 2.40 2540(E) 08-06-23
681 Warfarin Tablet 3 mg 1 Tablet 3.18 2540(E) 08-06-23
682 Warfarin Tablet 2 mg 1 Tablet 2.72 2540(E) 08-06-23
683 Warfarin Tablet 1 mg 1 Tablet 2.46 2540(E) 08-06-23
684 Xylometazoline Nasal drops 0.05 % 1 ML 4.19 1574(E) 31-03-23
685 Xylometazoline Nasal drops 0.1% 1 ML 5.12 1574(E) 31-03-23
Tablet 1574(E) 31-03-23
Zidovudine (A) +Lamivudine
686 300mg(A)+150mg( 1 Tablet 21.13
(B) +Nevirapine(C)
B)+200mg (c)
Tablet 1574(E) 31-03-23
Zidovudine (A)
687 300mg(A)+150mg( 1 Tablet 21.09
+Lamivudine(B)
B)
Dispersible Tablet 4886(E) 10-11-23
688 Zinc Sulphate 1 Tablet 3.41
20mg
Powder for 4663(E) 25-10-23
689 Zoledronic acid 1 Vial 2392.05
Injection 4mg
690 Zolpidem Tablet 5mg 1 Tablet 6.21 1574(E) 31-03-23
691 Zolpidem Tablet 10mg 1 Tablet 8.51 1574(E) 31-03-23
Tablet 600mg (A) + 939(E) 28-02-24
692 Darunavir (A) +Ritonavir (B) 1 Tablet 146.46
100mg (B)
Nicotine (for nicotine Oral Dosage forms 939(E) 28-02-24
693 1 Pastille 7.12
replacement therapy) 2mg Pastille
Nicotine (for nicotine Oral Dosage forms 939(E) 28-02-24
694 1 Pastille 7.83
replacement therapy) 4mg Pastille
695 Levonorgestrel Tablet 1.5mg 1 Tablet 75.35 939(E) 28-02-24
Solid oral dosage 939(E) 28-02-24
form 1000 IU
696 Cholecalciferol 1 Gram 23.14
Sachet/ Granuels /
Powder
Tenofovir Disproxil Fumarate Tablet 300mg + 939(E) 28-02-24
697 1 Tablet 114.99
+ Lamivudine + Dolutegravir 300mg + 50 mg
698 Zidovudine Tablet 300 mg 1 Tablet 13.59 938(E) 28-02-24
Powder for 938(E) 28-02-24
699 Benzathine benzylpenicillin Injection 12 lac 1 Vial 19.81
units
Powder for 938(E) 28-02-24
700 Benzathine benzylpenicillin 1 Vial 11.69
Injection 6 lac units
701 Fentanyl Injection 50mcg/ml 1 ml 20.96 938(E) 28-02-24
702 Folic Acid Capsule 5 mg 1 Capsule 5.04 938(E) 28-02-24
703 Hyoscine butylbromide Injection 20 mg/ml 1 ml 11.24 938(E) 28-02-24
704 Omeprazole Capsule 40 mg 1 Capsule 5.67 938(E) 28-02-24
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 49
Powder for 938(E) 28-02-24
705 Desferrioxamine 1 Vial 188.65
Injection 500mg
Lyophilized 938(E) 28-02-24
1 Vial of 10
706 Snake venom antiserum polyvalent - As 665.26
ml
Licensed
Soluble/ Liquid 938(E) 28-02-24
1 Vial of 10
707 Snake Venom Antiserum Polyvalent - As 428.67
ml
Licensed
708 Chlorambucil Tablet 2 mg 1 Tablet 31.16 938(E) 28-02-24
709 Chlorambucil Tablet 5 mg 1 Tablet 77.21 938(E) 28-02-24
710 Melphalan Tablet 2 mg 1 Tablet 91.34 938(E) 28-02-24
711 Melphalan Tablet 5 mg 1 Tablet 86.04 938(E) 28-02-24
712 Arsenic Trioxide Injection 1mg/ml 1 ml 30.54 938(E) 28-02-24
Injection 250 mg/5 938(E) 28-02-24
713 5-Fluorouracil 1 ml 2.04
ml
Conventional / 938(E) 28-02-24
Effervescent /
714 Acetylsalicylic acid Dispersible / 1 Tablet 0.67
Enteric coated
Tablets 325 mg
Inhalation (MDI) 1 Metered 938(E) 28-02-24
715 Budesonide 1.41
100 mcg/dose Dose
Inhalation (MDI) 1 Metered 938(E) 28-02-24
716 Budesonide 2.03
200 mcg/dose Dose
Inhalation (DPI) 938(E) 28-02-24
717 Budesonide 1 Dose 3.33
200 mcg/dose
Nasal Spray 100 938(E) 28-02-24
718 Budesonide 1 Dose 0.81
mcg/dose
Inhalation (MDI) 938(E) 28-02-24
Budesonide (A)+ Formoterol 1 Metered
719 100 mcg (A) + 6 2.12
(B) Dose
mcg (B)
Inhalation (DPI) 938(E) 28-02-24
Budesonide (A)+ Formoterol
720 100 mcg (A) + 6 1 Dose 4.32
(B)
mcg (B)
Inhalation (DPI) 938(E) 28-02-24
Budesonide (A)+ Formoterol
721 200 mcg (A) + 6 1 Dose 5.72
(B)
mcg (B)
Inhalation (DPI) 938(E) 28-02-24
Budesonide (A)+ Formoterol
722 400 mcg (A) + 6 1 Dose 6.62
(B)
mcg (B)
Oxygen – Liquid Medical As licensed for 1580(E) 31-03-23
723 Cubic Meter 17.02
Oxygen medical purpose
As licensed for 1580(E) 31-03-23
724 Oxygen (in cylinder) Cubic Meter 28.83
medical purpose
As licensed for 4663(E) 25-10-23
725 Nitrous oxide Cubic Meter 285.98
medical purpose
Disposable Pen containing 1581(E) 31-03-23
726 Injection 100 IU/ml 1 ML 244.14
Insulin Glargine

Notes: -
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) In respect of formulation where pack wise ceiling price is notified, for any other pack size manufactured, the
manufacturer shall approach NPPA under para 11(3) of DPCO, 2013 for specific price approval for its
formulations. The formulation of Sodium Valproate includes combination of Sodium Valproate and Valproic
Acid both together corresponding to Sodium Valproate of the stated strength.
50 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

(c) In respect of any other scheduled formulation, for which ceiling price is not mentioned above, the
manufacturer shall approach NPPA for specific price approval for its formulations.
(d) All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled
formulations at price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any.
(e) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the
ceiling price notified vide S.O. & date as specified in column 6 (a) & 6 (b) in the above table (plus Goods and
Services Taxes as applicable, if any), may revise the existing MRP of their formulations, on the basis of WPI
@ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013.
(f) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a
copy to State Drug Controller and dealers.
(i) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to NPPA in Form I as specified under Schedule-II of the
DPCO, 2013.
(k) The manufacturers of above said scheduled formulations shall furnish quarterly return to NPPA, in respect of
production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013
through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation
shall furnish information to NPPA, in respect of discontinuation of production and / or import of scheduled
formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
discontinuation.
(l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director

नई दिल्ली, 26 मार्च, 2024


का. आ. 1548(अ).—
vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022
4, 6, 10, 11, 14, 16, 17 18

a b
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 51

@ (0.00551%)

0.00551%

(1) (2) (3) (4) (5) 6(a) 6(b)


1 5&,feukslsyhflfyd lqIiksftVªh 500 fexzk- fjVsu'ku 1 lqIiksftVªh 21.05 4663 (अ) 25.10.2023
,flM ,fuek
2 5&,feukslsyhflfyd xksyh 400 fexzk- 1 xksyh 9.31 4663 (अ) 25.10.2023
,flM
3 ,cdkohj ¼,½ $ xksyh 60 fexzk- ¼,½ $ 30 fexzk- 1 xksyh 25.00 1573 (अ) 31.03.2023
ysfeoqMhu ¼ch½ ¼ch½
4 ,lhVkbylSyhflfyd bQsjoslsVa @fMLijflcy@,afVªd 1 xksyh 0.22 1573 (अ) 31.03.2023
,flM dksfVM xksyh 100 fexzk-
5 ,lhVkbylSyhflfyd xksyh 100 fexzk- 1 xksyh 0.21 1573 (अ) 31.03.2023
,flM
6 ,lhVkbylSyhflfyd xksyh 150 fexzk- 1 xksyh 0.50 1573 (अ) 31.03.2023
,flM
7 ,lhVkbylSyhflfyd xksyh 350 fexzk- 1 xksyh 0.38 1573 (अ) 31.03.2023
,flM
8 ,lhVkbylSyhflfyd xksyh 75 fexzk- 1 xksyh 0.38 1573 (अ) 31.03.2023
,flM
9 vkWy&Vªkal jsVhukWbd dSIlwy 10 fexzk- 1 dSIlwy 101.85 1573 (अ) 31.03.2023
,flM
10 ,EQksVsfjflu ch ¼fyfiM½ batSD'ku ds fy, ikmMj 50 izfr iSd 3990.62 1573 (अ) 31.03.2023
fexzk-
11 ,EQksVsfjflu ch batSD'ku ds fy, ikmMj 50 izfr iSd 9295.41 4663 (अ) 25.10.2023
¼fyikslksey½ fexzk-
12 ,Eihflfyu batSD'ku ds fy, ikmMj 1 xzke izfr iSd 26.56 1573 (अ) 31.03.2023
13 ,aVh&Mh bEequksXykscfq yu batSD'ku 300 ,elhth izfr iSd 2657.47 1573 (अ) 31.03.2023
14 ,aVh&Mh bEequksXykscfq yu batSD'ku 150 ,elhth izfr ok;y 2071.40 1573 (अ) 31.03.2023

15 ,aVh&jscht batSD'ku 150 vkbZ;w@fefy- 1 fefy- 3454.06 4663 (अ) 25.10.2023


bEequksXykscqfyu
16 ,aVh&jscht batSD'ku 300 vkbZ;w@fefy- 1 fefy- 121.77 1573 (अ) 31.03.2023
bEequksXykscqfyu
17 ,aVh&VsVul 250 vkbZ;w izfr iSd 1383.57 1573 (अ) 31.03.2023
bEequksXykscqfyu
18 vVslZ quVs ¼,½ $ xksyh 100 fexzk- ¼,½ $ 1 xksyh dksEch iSd 36.72 4663 (अ) 25.10.2023
lYQkMkWDlhu & ¼750 fexzk- $ 37-5 fexzk-½ ¼ch½
fifjesFkkekbu ¼ch½
19 vVslZ quVs ¼,½ $ xksyh 150 fexzk- ¼,½ $ 2 xksyh dksEch iSd 49.85 4663 (अ) 25.10.2023
lYQkMkWDlhu & ¼500 fexzk- $ 25 fexzk-½ ¼ch½
fifjesFkkekbu ¼ch½
20 vVslZ quVs ¼,½ $ xksyh 200 fexzk- ¼,½ $ 2 xksyh dksEch iSd 45.45 1573 (अ) 31.03.2023
lYQkMkWDlhu & ¼750 fexzk- $ 37-5 fexzk-½ ¼ch½
fifjesFkkekbu ¼ch½
21 vVslZ quVs ¼,½ $ xksyh 25 fexzk- ¼,½ $ 1 xksyh dksEch iSd 24.48 4663 (अ) 25.10.2023
lYQkMkWDlhu & ¼250 fexzk- $ 12-5 fexzk-½ ¼ch½
fifjesFkkekbu ¼ch½
22 chlhth oSDlhu izfr Mkst 11.12 1573 (अ) 31.03.2023
23 csutks,y isjkDlkbM Øhe 2-5% 1 xzke 2.90 1573 (अ) 31.03.2023
24 csutkby isfuflfyu batSD'ku ds fy, ikmMj 10 izfr iSd 9.71 4663 (अ) 25.10.2023
yk[k ;wfuV
25 chVkesFklksu tSy 0-05% 1 xzke 0.66 1573 (अ) 31.03.2023
52 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

26 chVkesFklksu yks'ku 0-1% 1 fefy- 1.02 1573 (अ) 31.03.2023


27 chVkesFklksu yks'ku 0-5% 1 fefy- 0.66 1573 (अ) 31.03.2023
28 cqMslksukbM usty Lizs 50 ,elhth@Mkst 1 Mkst 1.27 4663 (अ) 25.10.2023
29 cqMslksukbM bugsys'ku ¼MhihvkbZ½ 100 2.49 4663 (अ) 25.10.2023
,elhth@Mkst
30 cqMslksukbM ¼,½ $ bugsys'ku ¼,eMhvkbZ½ 200 3.33 1573 (अ) 31.03.2023
QkseksVZ sjksy ¼ch½ ,elhth ¼,½ $ 6 ,elhth ¼ch½
31 cqMslksukbM ¼,½ $ bugsys'kku ¼,eMhvkbZ½ 400 3.80 1573 (अ) 31.03.2023
QkseksVZ sjksy ¼ch½ ,elhth ¼,½ $ 6 ,elhth ¼ch½
32 dSfY'k;e dkWcksZusV Xksyh 500 fexzk- 1 xksyh 2.15 1573 (अ) 31.03.2023
33 dSfY'k;e XyqdksuVs batSD'ku 100 fexzk-@fefy- 1 fefy- 0.68 1573 (अ) 31.03.2023
34 lsQkMªksDlhy dSIlwy 500 fexzk- 1 dSIlwy 8.90 1573 (अ) 31.03.2023
35 lsQktksfyu batSD'ku ds fy, ikmMj 1 xzke izfr iSd 30.56 1573 (अ) 31.03.2023
36 lsQktksfyu batSD'ku ds fy, ikmMj 500 izfr iSd 19.37 1573 (अ) 31.03.2023
fexzk-
37 lsfQDlhe dSIlwy 400 fexzk- 1 dSIlwy 36.41 4663 (अ) 25.10.2023
38 lsfVªftu dSIlwy 10 fexzk- 1 dSIlwy 2.96 1573 (अ) 31.03.2023
39 DyksjgsDlkMhu lksy'q ku 5% ¼da'kuVªsV QkWj 1 fefy- 0.19 1573 (अ) 31.03.2023
fMyq'ku½
40 DyksDlkflfyu dSIlwy 250 fexzk- 1 dSIlwy 1.41 1573 (अ) 31.03.2023
41 DyksDlkflfyu dSIlwy 500 fexzk- 1 dSIlwy 2.38 4663 (अ) 25.10.2023
42 DyksDlkflfyu xksyh 250 fexzk- 1 xksyh 2.15 1573 (अ) 31.03.2023
43 DyksDlkflfyu batSD'ku ds fy, ikmMj 250 izfr iSd 5.53 4663 (अ) 25.10.2023
fexzk-
44 dksxqys'ku QSDVj IX batSD'ku ds fy, ikmMj 600 izfr iSd 15339.76 1573 (अ) 31.03.2023
vkbZ;w
45 dksx
s qys'ku QSDVj VIII batSD'ku ds fy, ikmMj 250 izfr iSd 4650.15 1573 (अ) 31.03.2023
vkbZ;w
46 dksxqys'ku QSDVj VIII batSD'ku ds fy, ikmMj 500 izfr iSd 11411.13 1573 (अ) 31.03.2023
vkbZ;w
47 lkbDyksLiksfju batSD'ku 50 fexzk-@fefy- 1 fefy- 335.80 1573 (अ) 31.03.2023
48 MkSuk:fclhu I.V. batSD'ku ds fy, ikmMj izfr iSd 302.76 1573 (अ) 31.03.2023
20 fexzk- ¼5 fexzk-@fefy-½
49 MsDlkVªku&40 batSD'ku 10% 1 fefy- 1.05 1573 (अ) 31.03.2023
50 vksjy fyD;wbZM 2 fexzk-@5 3.40 4663 (अ) 25.10.2023
Mk;tsike 1 fefy-
fefy-
51 fMDyksQus d dSIlwy 50 fexzk- 1 dSIlwy 0.76 1573 (अ) 31.03.2023
52 vksjy lksyq'ku 10 fexzk-@5 0.20 1573 (अ) 31.03.2023
fMlkbDyksekbu 1 fefy-
fefy-
53 fMlkbDyksekbu xksyh 10 fexzk- 1 xksyh 0.13 1573 (अ) 31.03.2023
54 MkbuksizksLVksu xksyh 0-5 fexzk- 1 xksyh 62.31 4663 (अ) 25.10.2023
55 MkbQFksfj;k ,VhaVksDlhu 10000 vkbZ;w izfr iSd 1631.70 4663 (अ) 25.10.2023
56 izfr 0-5 17.64 4663 (अ) 25.10.2023
MhihVh oSDlhu
fefy-
57 bQkohjst
a dSIlwy 600 fexzk- 1 dSIlwy 78.09 1573 (अ) 31.03.2023
58 bFkkbZy ,Ydksgy 0.53 4663 (अ) 25.10.2023
lksY;q'ku 70 izfr'kr 1 fefy-
¼MhuspjM½
59 Xkksyh 100 fexzk- byhesuVy
Qsjl lkYV ¼,½ $
Qksfyd ,flM ¼ch½
vk;ju ¼,½ $ 500 ,elhth 1 xksyh 0.28 1573 (अ) 31.03.2023
¼ch½
60 vksjy fyD;wbZM 50 fexzk-@5 3.25 1573 (अ) 31.03.2023
¶ywdksuktksy 1 fefy-
fefy-
61 xkMkscsusV batSD'ku 529 fexzk-@fefy- 1 fefy- 135.69 4663 (अ) 25.10.2023
62 Xywdkst batSD'ku 50% 1 fefy- 0.61 4663 (अ) 25.10.2023
63 1000 fefy- 79.95 1573 (अ) 31.03.2023
Xywdkst batSD'ku 5% Xykl
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 53
64 1000 fefy- 64.55 4663 (अ) 25.10.2023
Xywdkst batSD'ku 5% ukWu Xykl
65 100 fefy- 22.45 4663 (अ) 25.10.2023
Xywdkst batSD'ku 5% Xykl
66 100 fefy- 20.32 4663 (अ) 25.10.2023
Xywdkst batSD'ku 5% ukWu Xykl
67 250 fefy- 31.01 1573 (अ) 31.03.2023
Xywdkst batSD'ku 5% Xykl
68 250 fefy- 28.02 4663 (अ) 25.10.2023
Xywdkst batSD'ku 5% ukWu Xykl
69 500 fefy- 44.02 4663 (अ) 25.10.2023
Xywdkst batSD'ku 5% Xykl
70 500 fefy- 37.98 4663 (अ) 25.10.2023
Xywdkst batSD'ku 5% ukWu Xykl
71 izfr iSd 32.16 4663 (अ) 25.10.2023
Xywdkst batSD'ku 10% ¼1000 fefy-½
72 izfr iSd 34.97 1573 (अ) 31.03.2023
Xywdkst batSD'ku 10% ¼500 fefy-½
73 Xywdkst ¼,½ $ lksfM;e 1000 fefy- 80.48 1573 (अ) 31.03.2023
DyksjkbM ¼ch½ batSD'ku 5% ¼,½ $ 0-9% ¼ch½ Xykl
74 Xywdkst ¼,½ $ lksfM;e 1000 fefy- 65.03 1573 (अ) 31.03.2023
DyksjkbM ¼ch½ batSD'ku 5% ¼,½ $ 0-9% ¼ch½ ukWu Xykl
75 Xywdkst ¼,½ $ lksfM;e 100 fefy- 22.50 1573 (अ) 31.03.2023
DyksjkbM ¼ch½ batSD'ku 5% ¼,½ $ 0-9% ¼ch½ Xykl
76 Xywdkst ¼,½ $ lksfM;e 100 fefy- 20.34 4663 (अ) 25.10.2023
DyksjkbM ¼ch½ batSD'ku 5% ¼,½ $ 0-9% ¼ch½ ukWu Xykl
77 Xywdkst ¼,½ $ lksfM;e 250 fefy- 31.14 4663 (अ) 25.10.2023
DyksjkbM ¼ch½ batSD'ku 5% ¼,½ $ 0-9% ¼ch½ Xykl
78 Xywdkst ¼,½ $ lksfM;e 250 fefy- 28.12 1573 (अ) 31.03.2023
DyksjkbM ¼ch½ batSD'ku 5% ¼,½ $ 0-9%¼ch½ ukWu Xykl
79 Xywdkst ¼,½ $ lksfM;e 500 fefy- 44.23 1573 (अ) 31.03.2023
batSD'ku 5% ¼,½ $ 0-9% ¼ch½
DyksjkbM ¼ch½ Xykl
80 Xywdkst ¼,½ $ lksfM;e 500 fefy- 38.21 1573 (अ) 31.03.2023
DyksjkbM ¼ch½ batSD'ku 5% ¼,½ $ 0-9% ¼ch½ ukWu Xykl
81 XywVkjkyMsgkbM lksy'q ku 2% 1 fefy- 0.08 4663 (अ) 25.10.2023
82 xzhlksQqyfou xksyh 125 fexzk- 1 xksyh 1.02 1573 (अ) 31.03.2023
83 xzhlksQqyfou xksyh 375 fexzk- 1 xksyh 5.35 4663 (अ) 25.10.2023
84 gseksMk;ylhl ¶ywM ykblsal ds vuqlkj 1 fefy- 0.04 1573 (अ) 31.03.2023
85 g~;qeu ukWeZy lksyq'ku QkWj buQ~;wtu 5 192.07 1573 (अ) 31.03.2023
1 fefy-
bEequksXykscqfyu izfr'kr
86 g~;qeu ukWeZy lksyq'ku QkWj buQ~;wtu 10 260.04 1573 (अ) 31.03.2023
1 fefy-
bEequksXykscqfyu izfr'kr
87 g~;qeu ukWeZy lksyq'ku QkWj buQ~;wtu 494.52 1573 (अ) 31.03.2023
1 fefy-
bEequksXykscqfyu 16.5 izfr'kr
88 gkbMªksDyksjksFkkbtkbM xksyh 50 fexzk- 1 xksyh 0.10 1573 (अ) 31.03.2023
89 gkbMªkstu isjksDlkbM lksy'q ku 6% 1 fefy- 0.04 1573 (अ) 31.03.2023
90
इं िेसिन 1 12.31 1573 (अ) 31.03.2023
हाइड्रोससोकोबालाजमन 1 जम.ली.
जमलीग्रामएमएल/
91 vkbZcqizksQuq dSIlwy 400 fexzk- 1 dSIlwy 1.31 1573 (अ) 31.03.2023
92 1 lkWQ~V 3.33 1573 (अ) 31.03.2023
vkbZcqizksQuq dSIlwy 200 fexzk- tsyVs kbu
dSIlwy
93 besfVuhc dSIlwy 400 fexzk- 1 dSIlwy 318.01 4663 (अ) 25.10.2023
94 bugsy's ku ¼,eMhvkbZ@MhihvkbZ½ 0.76 1573 (अ) 31.03.2023
vkbZizkVªksfi;e 1 Mkst
20 ,elhth@Mkst
95 jslfijsVkWjh lksyq'ku QkWj ;wt 3.15 1573 (अ) 31.03.2023
vkbZizkVªksfi;e bu uscqykbtj 250 1 fefy-
,elhth@fefy-
96 dSVkekbu batSD'ku 10 fexzk-@fefy- 1 fefy- 13.19 4663 (अ) 25.10.2023
97 ysoksuksxsLZ Vªsy xksyh 0-75 fexzk- 1 xksyh 28.65 4663 (अ) 25.10.2023
54 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

98 ysoksFkkbjksDlhu xksyh 37.50 ,elhth 1 xksyh 1.47 4663 (अ) 25.10.2023


99
fyXuksdus ¼,½ $ batSD'ku 1%¼,½ $ 0.56 1573 (अ) 31.03.2023
1%200000¼5 ,elhth@fefy-½ 1 fefy-
,Mªsukykbu ¼ch½
¼ch½
100 yksfiukohj ¼,½ xksyh 100 fexzk- ¼,½ $ 25 29.28 4663 (अ) 25.10.2023
1 xksyh
$fjVksukohj ¼ch½ fexzk- ¼ch½
101 izfr iSd ¼0-5 110.07 4663 (अ) 25.10.2023
fetyl :csyk oSDlhu
fefy-½
102 izfr iSd ¼0-5 63.47 1573 (अ) 31.03.2023
fetyl oSDlhu oSDlhu
fefy-½
103 esFkksVªsDlsV batSD'ku 50 fexzk-@fefy- 1 fefy- 49.86 1573 (अ) 31.03.2023
104 ममिाईलिोिाननमल
ननयम टलोिईड पैंन्ट 1% 1 fefy- 0.10 1573 (अ) 31.03.2023
(जेंमिया वाइलेट)
105 ममिाइलधिओनननन
इंजेटशन 10
यम टलोिाइड 1 मम.ली. 27.13 1573 (अ) 31.03.2023
ममलीग्राम/मम.ली.
(मेधिलीन ब्लू )
106 feMktksye xksyh 7-5 fexzk- 1 xksyh 27.94 1573 (अ) 31.03.2023
107 eksQhZu ,lvkj xksyh 30 fexzk- 1 xksyh 6.78 1573 (अ) 31.03.2023
108 eksQhZu xksyh 10 fexzk- 1 xksyh 6.63 4663 (अ) 25.10.2023
109 ,u&,flVkbyflLVsu lpsV 200 fexzk- 1 xzke 11.20 1573 (अ) 31.03.2023
110 vksjy fyD;wbZM 50 fexzk-@5 1.04 1573 (अ) 31.03.2023
usohjkikbu 1 fefy-
fefy-
111 vksesikz tksy xksyh 10 fexzk- 1 xksyh 5.52 4663 (अ) 25.10.2023
112 ओिल
पोमलओमाईमलट्रटि 1 fefy- 127.67 1573 (अ) 31.03.2023
वेटिीन
113 vksjy fjgkbMªs'ku 1.11 1573 (अ) 31.03.2023
ykblsal ds :i esa 1 xzke
lkYVl
114 batSD'ku 100 fexzk-¼ykblsal ds 5563.91 4663 (अ) 25.10.2023
vksDlkyhIykVhu izfr iSd
:i esa½
115 ikjk&,feukslkfyflfyd 3.54 1573 (अ) 31.03.2023
xzsU;wyl ¼ykblsl
a ds :i es½a 1 xzke
,flM
116 izfr iSd ¼0-5 3.82 1573 (अ) 31.03.2023
isjkflVkeksy batSD'ku 150 fexzk-@fefy-
fefy-½
117 izfr iSd 5.22 1573 (अ) 31.03.2023
isjkflVkeksy batSD'ku 150 fexzk-@fefy-
¼1 fefy-½
118 izfr iSd 10.84 1573 (अ) 31.03.2023
isjkflVkeksy batSD'ku 150 fexzk-@fefy-
¼3 fefy-½
119 izfr iSd 13.65 4663 (अ) 25.10.2023
isjkflVkeksy batSD'ku 150 fexzk-@fefy-
¼4 fefy-½
120 izfr iSd 16.46 4663 (अ) 25.10.2023
isjkflVkeksy batSD'ku 150 fexzk-@fefy-
¼5 fefy-½
121 izfr iSd 22.07 4663 (अ) 25.10.2023
isjkflVkeksy batSD'ku 150 fexzk-@fefy-
¼7 fefy-½
122 isfuflykekbu dSIlwy 250 fexzk- 1 dSIlwy 18.50 1573 (अ) 31.03.2023
123 QsuhysQjhu MªksIl 10% 1 fefy- 10.06 4663 (अ) 25.10.2023
124 QsuhysQjhu MªksIl 5% 1 fefy- 4.64 1573 (अ) 31.03.2023
125 QsuhVksbu bZvkj dSIlwy 300 fexzk- 1 dSIlwy 4.74 1573 (अ) 31.03.2023
126 QsuhVksbu batSD'ku 25 fexzk-@fefy- 1 fefy- 3.13 4663 (अ) 25.10.2023
127 fiyksdkjfiu MªksIl 4% 1 fefy- 14.54 1573 (अ) 31.03.2023
128 iksVsf'k;e ijesaxusV fØLVy QkWj VkWfidy lksyq'ku 1 xzke 0.55 4663 (अ) 25.10.2023
129 ikWfoMu vk;ksMhu स्क्रब 7-5% 1 fefy- 2.00 4663 (अ) 25.10.2023
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 55
130 ikWfoMu vk;ksMhu vksbuVesaV 10% 1 xzke 6.48 1573 (अ) 31.03.2023
131 izkftD;wuVsy xksyh 600 fexzk 1 xksyh 43.25 4663 (अ) 25.10.2023
132 izsMfulksyksu batSD'ku 20 fexzk-@2 fefy- 1 fefy- 4.46 1573 (अ) 31.03.2023
133 vksjy fyD;wbZM 250 fexzk-@5 0.76 1573 (अ) 31.03.2023
ikbjkftukekbM 1 fefy-
fefy-
134 fjQefiflu xksyh 150 fexzk- 1 xksyh 2.01 4663 (अ) 25.10.2023
135 fjQefiflu xksyh 300 fexzk- 1 xksyh 3.66 4663 (अ) 25.10.2023
136 fjaxj ySDVsV batSD'ku 1000 fefy- izfr iSd 99.32 4663 (अ) 25.10.2023
137 fjaxj ySDVsV batSD'ku 100 fefy- izfr iSd 26.00 1573 (अ) 31.03.2023
138 fjaxj ySDVsV batSD'ku 250 fefy- izfr iSd 44.33 1573 (अ) 31.03.2023
139 fjaxj ySDVsV batSD'ku 500 fefy- izfr iSd 56.50 4663 (अ) 25.10.2023
140 fjVksukohj dSIlwy 100 fexzk- 1 dSIlwy 35.14 4663 (अ) 25.10.2023
141 lsycqVkeksy dSIlwy 4 fexzk- 1 dSIlwy 0.74 1573 (अ) 31.03.2023
142 flYoj lYQkMkbftu Øhe 1% 1 xzke 0.63 4663 (अ) 25.10.2023
143 1000 fefy- 73.88 4663 (अ) 25.10.2023
lksfM;e DyksjkbM batSD'ku 0-9% Xykl
144 1000 fefy- 58.27 4663 (अ) 25.10.2023
lksfM;e DyksjkbM batSD'ku 0-9% ukWu Xykl
145 100 fefy- 21.84 1573 (अ) 31.03.2023
lksfM;e DyksjkbM batSD'ku 0-9% Xykl
146 100 fefy- 19.68 4663 (अ) 25.10.2023
lksfM;e DyksjkbM batSD'ku 0-9% ukWu Xykl
147 250 fefy- 29.47 4663 (अ) 25.10.2023
lksfM;e DyksjkbM batSD'ku 0-9% Xykl
148 250 fefy- 26.45 4663 (अ) 25.10.2023
lksfM;e DyksjkbM batSD'ku 0-9% ukWu Xykl
149 500 fefy- 40.97 4663 (अ) 25.10.2023
lksfM;e DyksjkbM batSD'ku 0-9% Xykl
150 500 fefy- 34.87 4663 (अ) 25.10.2023
lksfM;e DyksjkbM batSD'ku 0-9% ukWu Xykl
151 lksfM;e ukbZVªsV batSD'ku 30 fexzk-@fefy- 1 fefy- 32.35 4663 (अ) 25.10.2023
152 lksfM;e ukbVªksi:lkbM batSD'ku 10 fexzk-@fefy- 1 fefy- 32.15 4663 (अ) 25.10.2023
153 LVªsIVksfdukl batSD'ku 7]50]000 vkbZ;w izfr iSd 1567.42 4663 (अ) 25.10.2023
154 izfr iSd esa
lLis'a ku QkWj buVªkVªkpsy
izfr fefy-
ljQsDVkaV buLVkbys'ku ¼ykblsl a ds :i
QksLQksfyfiM~ 83.27 1573 (अ) 31.03.2023
es½a
l
155 प्रत्येर्क 0.5 ममली. डोिेि
मे: डडप्िेरिया टोटिाइड
प्रत्येर्क
≤ 5 एलएफ (≥
टी डी वैक्टिन 0.5 ममली. 23.33 1573 (अ) 31.03.2023
2आईयू) टे ट्कनि
पैर्क
टोटिाइड ≥ 5 एलएफ
(≥ 40 आईयू)
156 प्रत्येर्क 0.5 ममली. डोिेि
मे: डडप्िेरिया टोटिाइड
≤ 5 एलएफ (≥ 2 प्रत्येर्क 5
टी डी वैक्टिन 219.25 1573 (अ) 31.03.2023
आईयू) टे ट्कनि टोटिाइड ममली. पैर्क
≥ 5 एलएफ (≥ 40
आईयू)
157 प्रत्येर्क 0.5 ममली. डोिेि प्रत्येर्क
टी डी वैक्टिन 20.00 1573 (अ) 31.03.2023
मे: डडप्िेरिया टोटिाइड 0.5 ममली.
56 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

≤ 25 एलएफ (≥ 30 पैर्क
आईयू) टे ट्कनि टोटिाइड
≥ 5 एलएफ (≥ 40
आईयू)
158 VsekstksyksekbM xksyh 100 fexzk- 1 xksyh 1925.59 4663 (अ) 25.10.2023
159 fVeksyksy MªksIl 0-25% 1 fefy- 6.44 4663 (अ) 25.10.2023
160 batSD'ku 50 fexzk-@fefy- ¼20 1.55 4663 (अ) 25.10.2023
VªkekMksy 1 fefy-
fefy- iSd½
161 osjkikfey batSD'ku 2-5 fexzk-@fefy- 1 fefy- 1.46 4663 (अ) 25.10.2023
162 fouOykLVhu batSD'ku 1 fexzk-@fefy- 1 fefy- 25.54 1573 (अ) 31.03.2023
163 foVkfeu , dSIlwy 50000 vkbZ;w 1 dSIlwy 0.68 1573 (अ) 31.03.2023
164 izfr iSd ¼10 2.89 1573 (अ) 31.03.2023
okVj QkWj batSD'ku batSD'ku
fefy-½
165 izfr iSd 2.79 1573 (अ) 31.03.2023
okVj QkWj batSD'ku batSD'ku
¼5 fefy-½
166 izfr iSd 57.40 4663 (अ) 25.10.2023
okVj QkWj batSD'ku batSD'ku
¼500 fefy-½
167 izfr iSd 100.74 1573 (अ) 31.03.2023
okVj QkWj batSD'ku batSD'ku
¼1000 fefy-½
168 ftMksoqMkbu dSIlwy 300 fexzk- 1 dSIlwy 2.57 4663 (अ) 25.10.2023
169 tksyfiMse dSIlwy 5 fexzk- 1 dSIlwy 9.15 4663 (अ) 25.10.2023

-
(
0.00551% )

11(3)

(5)

a b िे

0.00551

(5)
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 57

यदि संिोधन दकया िाता है तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की
अवजध में प्रपत्र-II के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की
िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन
नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेने की जतजथ से उस पर ब्याि सजहत
पूवच-संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा।

(4)

(ञ)

(1) u
II I

II III

II IV

[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]


यमिं वका पंवार, सह यक मनदेशक
ORDER
New Delhi, the 26th March, 2024
S.O. 1548(E).—In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the
Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession
of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical
58 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the
National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below
as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulations
specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit
specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date
No. Strength 1.4.2024 with WPI
@ 0.00551%) (in
Rs.)
(1) (2) (3) (4) (5) 6(a) 6(b)
1 5-aminosalicylic Acid Suppository 500 mg 1 Suppository 4663(E) 25.10.2023
21.05
Retention Enema
2 5-aminosalicylic Acid Tablet 400 mg 1 Tablet 9.31 4663(E) 25.10.2023
3 Abacavir (A) + Tablet 60 mg(A) + 1 Tablet 1573(E) 31.03.2023
25.00
Lamivudine (B) 30 mg(B)
4 Acetylsalicylic acid Effervescent/
Dispersible/ Enteric
1 Tablet 0.22 1573(E) 31.03.2023
coated Tablet 100
mg
5 Acetylsalicylic acid Tablet 100 mg 1 Tablet 0.21 1573(E) 31.03.2023
6 Acetylsalicylic acid Tablet 150 mg 1 Tablet 0.50 1573(E) 31.03.2023
7 Acetylsalicylic acid Tablet 350mg 1 Tablet 0.38 1573(E) 31.03.2023
8 Acetylsalicylic acid Tablet 75 mg 1 Tablet 0.38 1573(E) 31.03.2023
9 All-trans Retinoic Acid Capsule 10 mg 1 Capsule 1573(E) 31.03.2023
101.85

10 Amphotericin B (Lipid) Powder for Each Pack 1573(E) 31.03.2023


3990.62
Injection 50 mg
11 Amphotericin B Powder for Each Pack 4663(E) 25.10.2023
9295.41
(Liposomal) Injection 50 mg
12 Ampicillin Powder for Each Pack 1573(E) 31.03.2023
26.56
Injection 1 gm
13 Anti-D immunoglobulin Injection 300mcg Each Pack 2657.47 1573(E) 31.03.2023
14 Anti-D Immunoglobulin Injection 150mcg Each Vial 2071.40 1573(E) 31.03.2023
15 Anti-rabies Injection 150 IU/ml 1 ml 4663(E) 25.10.2023
3454.06
immunoglobulin
16 Anti-rabies
Injection 300 IU/ml 1 ml 121.77 1573(E) 31.03.2023
immunoglobulin
17 Anti-tetanus
250IU Each Pack 1383.57 1573(E) 31.03.2023
immunoglobulin
18 Artesunate (A) + Tablet 100 mg(A) + Combi pack 4663(E) 25.10.2023
Sulphadoxine - 1 Tablet (750 mg+ 36.72
Pyrimethamine (B) 37.5 mg) (B)
19 Artesunate (A) + Tablet 150 mg(A) + Combi pack 4663(E) 25.10.2023
Sulphadoxine - 2 Tablet (500 mg+ 49.85
Pyrimethamine (B) 25 mg) (B)
20 Artesunate (A) + Tablet 200 mg(A) + Combi pack 1573(E) 31.03.2023
Sulphadoxine - 2 Tablet (750 mg+ 45.45
Pyrimethamine (B) 37.5 mg) (B)
21 Artesunate (A) + Tablet 25 mg(A) + Combi pack 4663(E) 25.10.2023
Sulphadoxine - 1 Tablet (250 mg+ 24.48
Pyrimethamine (B) 12.5 mg) (B)
22 BCG vaccine Each Dose 11.12 1573(E) 31.03.2023
23 Benzoyl Peroxide Cream 2.5% 1 gm 2.90 1573(E) 31.03.2023
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 59
Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date
No. Strength 1.4.2024 with WPI
@ 0.00551%) (in
Rs.)
(1) (2) (3) (4) (5) 6(a) 6(b)
24 Benzyl penicillin Powder for
Injection 10 Lac Each Pack 9.71 4663(E) 25.10.2023
Units
25 Betamethasone Gel 0.05% 1 gm 0.66 1573(E) 31.03.2023
26 Betamethasone Lotion 0.1% 1 ml 1.02 1573(E) 31.03.2023
27 Betamethasone Lotion 0.5% 1 ml 0.66 1573(E) 31.03.2023
28 Budesonide Nasal Spray 50 1 Dose 4663(E) 25.10.2023
1.27
mcg/dose
29 Budesonide Inhalation (DPI) Per Dose 4663(E) 25.10.2023
2.49
100 mcg/dose
30 Budesonide (A)+ Inhalation (MDI)
Per Metered
Formoterol (B) 200 mcg (A) + 6 3.33 1573(E) 31.03.2023
Dose
mcg (B)
31 Budesonide (A)+ Inhalation (MDI)
Per Metered
Formoterol (B) 400 mcg (A) + 6 3.80 1573(E) 31.03.2023
Dose
mcg (B)
32 Calcium Carbonate Tablet 500mg 1 Tablet 2.15 1573(E) 31.03.2023
33 Calcium gluconate Injection 100 mg/ml 1 ml 0.68 1573(E) 31.03.2023
34 Cefadroxil Capsule 500 mg 1 Capsule 8.90 1573(E) 31.03.2023
35 Cefazolin Powder for Each Pack 1573(E) 31.03.2023
30.56
Injection 1 gm
36 Cefazolin Powder for Each Pack 1573(E) 31.03.2023
19.37
Injection 500 mg
37 Cefixime Capsule 400 mg 1 Capsule 36.41 4663(E) 25.10.2023
38 Cetirizine Capsule 10 mg 1 Capsule 2.96 1573(E) 31.03.2023
39 Chlorhexidine Solution 5% 1 ml 1573(E) 31.03.2023
(Concentrate for 0.19
dilution)
40 Cloxacillin Capsule 250mg 1 Capsule 1.41 1573(E) 31.03.2023
41 Cloxacillin Capsule 500mg 1 Capsule 2.38 4663(E) 25.10.2023
42 Cloxacillin Tablet 250mg 1 Tablet 2.15 1573(E) 31.03.2023
43 Cloxacillin Powder for Each Pack 4663(E) 25.10.2023
5.53
Injection250mg
44 Coagulation factor IX Powder for Each Pack 1573(E) 31.03.2023
15339.76
Injection 600 IU
45 Coagulation factor VIII Powder for Each pack 1573(E) 31.03.2023
4650.15
Injection 250 IU
46 Coagulation factor VIII Powder for Each Pack 1573(E) 31.03.2023
11411.13
Injection 500 IU
47 Cyclosporine Injection 50 mg/ml 1 ml 335.80 1573(E) 31.03.2023
48 Daunarubicin Powder for I.V. Each pack 1573(E) 31.03.2023
Injection 20 mg (5 302.76
mg/ml)
49 Dextran-40 Injection 10% 1 ml 1.05 1573(E) 31.03.2023
50 Diazepam Oral Liquid 2 1 ml 4663(E) 25.10.2023
3.40
mg/5ml
51 Diclofenac Capsule 50 mg 1 Capsule 0.76 1573(E) 31.03.2023
52 Dicyclomine Oral Solution 1 ml 1573(E) 31.03.2023
0.20
10mg/5ml
53 Dicyclomine Tablet 10mg 1 Tablet 0.13 1573(E) 31.03.2023
60 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date
No. Strength 1.4.2024 with WPI
@ 0.00551%) (in
Rs.)
(1) (2) (3) (4) (5) 6(a) 6(b)
54 Dinoprostone Tablet 0.5mg 1 Tablet 62.31 4663(E) 25.10.2023
55 Diphtheria antitoxin 10000 IU Each Pack 1631.70 4663(E) 25.10.2023
56 DPT vaccine Per 0.5 ml 17.64 4663(E) 25.10.2023
57 Efavirenz Capsule 600 mg 1 Capsule 78.09 1573(E) 31.03.2023
58 Ethyl Alcohol (Denatured) Solution 70% 1 ml 0.53 4663(E) 25.10.2023
59 Ferrous Salt (A) + Folic Tablet 100mg
Acid (B) elemental iron (A) + 1 Tablet 0.28 1573(E) 31.03.2023
500mcg (B)
60 Fluconazole Oral Liquid
1 ml 3.25 1573(E) 31.03.2023
50mg/5ml
61 Gadobenate Injection 529 mg/ml 1 ml 135.69 4663(E) 25.10.2023
62 Glucose Injection 50% 1 ml 0.61 4663(E) 25.10.2023
63 Glucose Injection 5% 1000ml Glass 79.95 1573(E) 31.03.2023
64 Glucose Injection 5% 1000ml Non- 4663(E) 25.10.2023
64.55
Glass
65 Glucose Injection 5% 100ml Glass 22.45 4663(E) 25.10.2023
66 Glucose Injection 5% 100ml Non- 4663(E) 25.10.2023
20.32
Glass
67 Glucose Injection 5% 250ml Glass 31.01 1573(E) 31.03.2023
68 Glucose Injection 5% 250ml Non- 4663(E) 25.10.2023
28.02
Glass
69 Glucose Injection 5% 500ml Glass 44.02 4663(E) 25.10.2023
70 Glucose Injection 5% 500ml Non- 4663(E) 25.10.2023
37.98
Glass
71 Glucose Injection 10% Each Pack 4663(E) 25.10.2023
32.16
(1000 ml)
72 Glucose Injection 10% Each Pack 1573(E) 31.03.2023
34.97
(500 ml)
73 Glucose (A) + Sodium Injection 5% (A) + 1000ml Glass 1573(E) 31.03.2023
80.48
Chloride (B) 0.9% (B)
74 Glucose (A) + Sodium Injection 5% (A) + 1000ml Non- 1573(E) 31.03.2023
65.03
Chloride (B) 0.9% (B) Glass
75 Glucose (A) + Sodium Injection 5% (A) + 100ml Glass 1573(E) 31.03.2023
22.50
Chloride (B) 0.9% (B)
76 Glucose (A) + Sodium Injection 5% (A) + 100ml Non- 4663(E) 25.10.2023
20.34
Chloride (B) 0.9% (B) Glass
77 Glucose (A) + Sodium Injection 5% (A) + 250ml Glass 4663(E) 25.10.2023
31.14
Chloride (B) 0.9% (B)
78 Glucose (A) + Sodium Injection 5% (A) + 250ml Non- 1573(E) 31.03.2023
28.12
Chloride (B) 0.9% (B) Glass
79 Glucose (A) + Sodium Injection 5% (A) + 500ml Glass 1573(E) 31.03.2023
44.23
Chloride (B) 0.9% (B)
80 Glucose (A) + Sodium Injection 5% (A) + 500ml Non- 1573(E) 31.03.2023
38.21
Chloride (B) 0.9% (B) Glass
81 Glutaraldehyde Solution 2% 1 ml 0.08 4663(E) 25.10.2023
82 Griseofulvin Tablet 125mg 1 Tablet 1.02 1573(E) 31.03.2023
83 Griseofulvin Tablet 375 mg 1 Tablet 5.35 4663(E) 25.10.2023
84 Haemodialysis fluid As license 1 ml 0.04 1573(E) 31.03.2023
85 Human Normal Solution for 1 ml 192.07 1573(E) 31.03.2023
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 61
Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date
No. Strength 1.4.2024 with WPI
@ 0.00551%) (in
Rs.)
(1) (2) (3) (4) (5) 6(a) 6(b)
Immunoglobulin infusion 5%
86 Human Normal Solution for
1 ml 260.04 1573(E) 31.03.2023
Immunoglobulin infusion 10%
87 Human Normal Solution for
1 ml 494.52 1573(E) 31.03.2023
Immunoglobulin infusion 16.5%
88 Hydrochlorothiazide Tablet 50 mg 1 Tablet 0.10 1573(E) 31.03.2023
89 Hydrogen peroxide Solution 6% 1 ml 0.04 1573(E) 31.03.2023
90 Hydroxocobalamin Injection 1 mg/ml 1 ML 12.31 1573(E) 31.03.2023
91 Ibuprofen Capsule 400 mg 1 Capsule 1.31 1573(E) 31.03.2023
92 Ibuprofen Capsule 200 mg 1 soft gelatin 1573(E) 31.03.2023
3.33
capsule
93 Imatinib Capsule 400 mg 1 Capsule 318.01 4663(E) 25.10.2023
94 Ipratropium Inhalation
(MDI/DPI) 20 1 Dose 0.76 1573(E) 31.03.2023
mcg/dose
95 Ipratropium Respirator solution
for use in Nebulizer 1 ml 3.15 1573(E) 31.03.2023
250 mcg/ml
96 Ketamine Injection 10 mg/ml 1 ml 13.19 4663(E) 25.10.2023
97 Levonorgestrel Tablet 0.75 mg 1 Tablet 28.65 4663(E) 25.10.2023
98 Levothyroxine Tablet 37.50 mcg 1 Tablet 1.47 4663(E) 25.10.2023
99 Lignocaine (A) + Injection 1% (A) + 1 ml 1573(E) 31.03.2023
Adrenaline (B) 1:200000 (5 0.56
mcg/ml) (B)
100 Lopinavir (A) + Ritonavir Tablet 100 mg(A) + 1 Tablet 4663(E) 25.10.2023
29.28
(B) 25 mg(B)
101 Measles Rubbela Vaccine Each Pack 4663(E) 25.10.2023
110.07
(0.5ml)
102 Measles vaccine Vaccine Each Pack 1573(E) 31.03.2023
63.47
(0.5ml)
103 Methotrexate Injection 50 mg/ml 1 ml 49.86 1573(E) 31.03.2023
104 Methylrosanilinium Paint 1% 1 ml 1573(E) 31.03.2023
0.10
chloride (Gentian Violet)
105 Methylthioninium Injection 10mg/ml 1 ML 1573(E) 31.03.2023
27.13
chloride (Methylene blue)
106 Midazolam Tablet 7.5mg 1 Tablet 27.94 1573(E) 31.03.2023
107 Morphine SR Tablet 30 mg 1 Tablet 6.78 1573(E) 31.03.2023
108 Morphine Tablet 10 mg 1 Tablet 6.63 4663(E) 25.10.2023
109 N-acetylcysteine Sachet 200mg 1 gm 11.20 1573(E) 31.03.2023
110 Nevirapine Oral Liquid 50 1 ml 1573(E) 31.03.2023
1.04
mg/5ml
111 Omeprazole Tablet 10 mg 1 Tablet 5.52 4663(E) 25.10.2023
112 Oral poliomyelitis vaccine 1 ml 127.67 1573(E) 31.03.2023
113 Oral Rehydration Salts As Licensed 1 gm 1.11 1573(E) 31.03.2023
114 Oxaliplatin Injection 100mg(as
Each Pack 5563.91 4663(E) 25.10.2023
licensed)
115 Para-aminosalicylic acid Granules (As
1 gm 3.54 1573(E) 31.03.2023
licensed)
116 Paracetamol Injection 150 mg/ml Each Pack 1573(E) 31.03.2023
3.82
( 0.5 ml)
62 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date
No. Strength 1.4.2024 with WPI
@ 0.00551%) (in
Rs.)
(1) (2) (3) (4) (5) 6(a) 6(b)
117 Paracetamol Injection 150 mg/ml Each Pack 1573(E) 31.03.2023
5.22
(1 ml)
118 Paracetamol Injection 150 mg/ml Each Pack 1573(E) 31.03.2023
10.84
(3 ml)
119 Paracetamol Injection 150 mg/ml Each Pack 4663(E) 25.10.2023
13.65
(4 ml)
120 Paracetamol Injection 150 mg/ml Each Pack 4663(E) 25.10.2023
16.46
(5 ml)
121 Paracetamol Injection 150 mg/ml Each Pack 4663(E) 25.10.2023
22.07
(7 ml)
122 Penicillamine Capsule 250 mg 1 Capsule 18.50 1573(E) 31.03.2023
123 Phenylephrine Drop 10% 1 ml 10.06 4663(E) 25.10.2023
124 Phenylephrine Drops 5% 1 ml 4.64 1573(E) 31.03.2023
125 Phenytoin ERCapsule 300 mg 1 Capsule 4.74 1573(E) 31.03.2023
126 Phenytoin injection 25 mg/ml 1 ml 3.13 4663(E) 25.10.2023
127 Pilocarpine Drops 4% 1 ml 14.54 1573(E) 31.03.2023
128 Potassium permanganate Crystals for topical 1 gm 4663(E) 25.10.2023
0.55
solution
129 Povidone iodine Scrub 7.5% 1 ml 2.00 4663(E) 25.10.2023
130 Povidone iodine Ointment 10% 1 gm 6.48 1573(E) 31.03.2023
131 Praziquantel Tablet 600 mg 1 tablet 43.25 4663(E) 25.10.2023
132 Prednisolone Injection 20 mg/2ml 1 ml 4.46 1573(E) 31.03.2023
133 Pyrazinamide Oral Liquid 250 1 ml 1573(E) 31.03.2023
0.76
mg/5ml
134 Rifampicin Tablet 150 mg 1 Tablet 2.01 4663(E) 25.10.2023
135 Rifampicin Tablet 300 mg 1 Tablet 3.66 4663(E) 25.10.2023
136 Ringer Lactate Injection 1000ml Each Pack 99.32 4663(E) 25.10.2023
137 Ringer Lactate Injection 100ml Each Pack 26.00 1573(E) 31.03.2023
138 Ringer Lactate Injection 250ml Each Pack 44.33 1573(E) 31.03.2023
139 Ringer Lactate Injection 500ml Each Pack 56.50 4663(E) 25.10.2023
140 Ritonavir Capsule 100 mg 1 Capsule 35.14 4663(E) 25.10.2023
141 Salbutamol Capsule 4 mg 1 Capsule 0.74 1573(E) 31.03.2023
142 Silver Sulphadiazine Cream 1% 1 gm 0.63 4663(E) 25.10.2023
143 Sodium Chloride Injection 0.9% 1000ml Glass 73.88 4663(E) 25.10.2023
144 Sodium Chloride Injection 0.9% 1000ml Non- 4663(E) 25.10.2023
58.27
Glass
145 Sodium Chloride Injection 0.9% 100ml Glass 21.84 1573(E) 31.03.2023
146 Sodium Chloride Injection 0.9% 100ml Non- 4663(E) 25.10.2023
19.68
Glass
147 Sodium Chloride Injection 0.9% 250ml Glass 29.47 4663(E) 25.10.2023
148 Sodium Chloride Injection 0.9% 250ml Non- 4663(E) 25.10.2023
26.45
Glass
149 Sodium Chloride Injection 0.9% 500ml Glass 40.97 4663(E) 25.10.2023
150 Sodium Chloride Injection 0.9% 500ml Non- 4663(E) 25.10.2023
34.87
Glass
151 Sodium nitrite Injection 30 mg/ml 1 ml 32.35 4663(E) 25.10.2023
152 Sodium Nitroprusside Injection 10 mg/ml 1 ml 32.15 4663(E) 25.10.2023
153 Streptokinase Injection 7,50,000 Each Pack 4663(E) 25.10.2023
1567.42
IU
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 63
Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date
No. Strength 1.4.2024 with WPI
@ 0.00551%) (in
Rs.)
(1) (2) (3) (4) (5) 6(a) 6(b)
154 Surfactant Suspension for
Per mg of
intratracheal
Phospholipids 83.27 1573(E) 31.03.2023
instillation (As
in the pack
liensed)
155 TD Vaccine Each dose of 0.5ml
contains: Diphtheria
Toxoid ≤5Lf (≥ Each 0.5ml
23.33 1573(E) 31.03.2023
2IU) Tetanus Pack
Toxoid ≥ 5Lf (≥
40IU)
156 TD Vaccine Each dose of 0.5ml
contains: Diphtheria
Toxoid ≤5Lf (≥
Each 5ml Pack 219.25 1573(E) 31.03.2023
2IU) Tetanus
Toxoid ≥ 5Lf (≥
40IU)
157 TD Vaccine Each dose of 0.5ml
contains: Diphtheria
Toxoid ≤25Lf (≥ Each 0.5ml
20.00 1573(E) 31.03.2023
30IU) Tetanus Pack
Toxoid ≥ 5Lf (≥
40IU)
158 Temozolomide Tablet 100 mg 1 Tablet 1925.59 4663(E) 25.10.2023
159 Timolol Drops 0.25% 1 ml 6.44 4663(E) 25.10.2023
160 Tramadol Injection 50 mg/ml
1 ml 1.55 4663(E) 25.10.2023
(20 ml Pack)
161 Verapamil Injection 2.5 mg/ml 1 ml 1.46 4663(E) 25.10.2023
162 Vinblastine Injection 1mg/ml 1 ml 25.54 1573(E) 31.03.2023
163 Vitamin A Capsule 50000 IU 1 Capsule 0.68 1573(E) 31.03.2023
164 Water for Injection Injection Each Pack (10
2.89 1573(E) 31.03.2023
ml)
165 Water for Injection Injection Each Pack (5
2.79 1573(E) 31.03.2023
ml)
166 Water for Injection Injection Per 500 ml
57.40 4663(E) 25.10.2023
Pack
167 Water for Injection Injection Per 1000 ml
100.74 1573(E) 31.03.2023
Pack
168 Zidovudine Capsule 300 mg 1 Capsule 2.57 4663(E) 25.10.2023
169 Zolpidem Capsule 5 mg 1 Capsule 9.15 4663(E) 25.10.2023

Notes: -
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale
Price Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) In respect of formulation where pack wise ceiling price is notified, for any other pack size manufactured the
manufacturer shall approach NPPA under para 11(3) of DPCO, 2013 for specific price approval for its
formulations.
(c) In respect of any other scheduled formulation for which ceiling price is not mentioned above,
themanufacturer shall approach NPPA for specific price approval for its formulations.
(d) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of
scheduled formulations at a price higher than the ceiling price (plus Goods and Services Taxes as
applicable) so fixed and notified by the Government, shall revise the prices of all such formulations
downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and
Services Taxes as applicable, if any.
64 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

(e) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the
ceiling price notified vide S.O. No. & date as specified in column 6 (a)& 6 (b) in the above table (plus
Goods and Services Taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on
the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013.
(f) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to
the Government on the ceiling price mentioned in column (5) of the above said table.
(g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer
in accordance with the ceiling price specified in column (5) of the above table as per provisions contained
in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in
Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and
submit a copy to State Drug Controller and dealers.
(i) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries
on business in a manner so as to be easily accessible to any person wishing to consult the same.
(j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II
of the DPCO, 2013.
(k) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or
import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to
the intended date of discontinuation.
(l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table
in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date
of notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director

नई दिल्ली, 26 मार्च, 2024


का. आ. 1549(अ).—
नवम्बर
4, 6, 10, 11, 14, 17 ,16 ,4 18

a
b
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 65

@ 0.00551% बढाकर

0.00551%
01.04.2024 से प्रभावी) ( )

(1) (2) (3) (4) (5) 6(a) 6(b)


1 ,lhVkby xksyh 300 fexzk 1568(अ)
1 xksyh 0.28 31-03-23
lkfyflfyd ,flM
2 dSfY'k;e dkcksuZ Vs xksyh 250 fexzk 1 xksyh 2.43 1568(अ) 31-03-23
3 daMksel 1 daMkse 11.37 4663(अ) 25-10-23
4 Msilksu xksyh 50 fexzk 1 xksyh 0.29 1568(अ) 31-03-23
5 esMªksDlh izkx
s Ls Vsjksu xksyh 5 fexzk 1568(अ)
1 xksyh 3.72 31-03-23
,flVsV
6 fjQefiflu xksyh 450 fexzk 1 xksyh 5.52 4663(अ) 25-10-23
-
(
0.00551% )

(5)

0.00551%

घ (5)

ङ यदि संिोधन दकया िाता है तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध
में प्रपत्र-II के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस
उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन नहीं दकया िाना
माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेने की जतजथ से उस पर ब्याि सजहत पूवच-संिोजधत
अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा।

(4)
66 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

1 u
II I


II III

II IV

(ट)

[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]


यमिं वका पंवार, सह यक मनदेशक
ORDER
New Delhi, the 26th March, 2024
S.O. 1549(E).—In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the
Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession
of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical
Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the
National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below
as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulations
specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit
specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Sl. No. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date
Strength 01.04.2024 with WPI @
0.00551%) (in Rs.)
(1) (2) (3) (4) (5) 6(a) 6(b)
1 Acetyl Salicylic Tablet 300mg 1 Tablet
0.28 1568 (E) 31-03-23
Acid
2 Calcium carbonate Tablet 250 mg 1 Tablet 2.43 1568 (E) 31-03-23
3 Condoms 1 Condom 11.37 4663(E) 25-10-23
4 Dapsone Tablet 50 mg 1 Tablet 0.29 1568 (E) 31-03-23
5 Medroxy Tablet 5mg 1 Tablet
Progesterone 3.72 1568 (E) 31-03-23
Acetate
6 Rifampicin Tablet 450mg 1 Tablet 5.52 4663(E) 25-10-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 67
Notes: -
a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
b) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled
formulations at a price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed
and notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any.
c) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the
ceiling price notified vide S.O. No. & date as specified in column 6 (a)& 6 (b) in the above table (plus Goods
and Services Taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis
of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013.
d) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
e) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a
copy to State Drug Controller and dealers.
g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of
the DPCO, 2013.
i) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or
import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to
the intended date of discontinuation.
j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
k) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director
68 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

नई दिल्ली, 26 मार्च, 2024


का. आ. 1550(अ).—

, नवम्बर
4, 6, 10, 11, 14, 16, 17 18

a b

एनएलईए
म, आदे श र्के
0.00551%
र्के अनि
ु ाि िंशोधित
अंतगित अधिर्कतम र्कीमत

(1) (2) (3) (4) (5) (6) (7) (8) 9(a) 9(b)
ओरल
मलमक्वड 31015/21/202
सेफ्यूरोमक्स 125 3-
1. ि मिलीग्राि / 1 मि.ली. 5.31 5.31 1574(अ) 31-03-23
5.28
5 मि.ली. 08.02.2024
(पी)
गोली 5
मिलीग्राि 31015/12/202
3-
2. िोंटेलक
िं ास्ट (चबाने 1 गोली 12.01 12.01 4663(अ) 25-10-23
योग्य समहत 11.72
19.02.2024
गोली)

िायकोफे नो गोली 31015/13/202


3-
3. लेट 500 1 गोली 74.59 74.59 4663(अ) 25-10-23
िोफे मटल मिलीग्राि 73.88
22.02.2024

(6)

के

.03. तक बनाए रखना जारी रखेंगे ।


सारणी के कॉलि (7) िे मनमदमष्ट (
@0.00551%
)
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 69

िे . . को
या बराबर

0.00551

(6) /या (7)

यदि संिोधन दकया िाता है तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध
में प्रपत्र-।। के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और
इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन नहीं दकया
िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेने की जतजथ से उस पर ब्याि सजहत पूवच-संिोजधत
अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा।

(6) /या (7)

(4)

(1) u
II I

II III

II
IV

[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]


यमिं वका पवं ार, सह यक मनदेशक
70 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

ORDER
New Delhi, the 26th March, 2024
S.O. 1550(E).—In implementation of directions of review orders issued by the Department of
Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control) Order, 2013 vide order(s) specified in column (8) of
the table below and in exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs
(Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession
of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical
Pricing Authority) S.O. Number and date specified in column no. 9(a) & 9(b) mentioned in the table below, the
National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified in column (6) and further
revised the prices w. e. f. 01.04.2024 specified in column (7) of the table herein below as ceiling prices exclusive of
Goods and Services Tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding
entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the
corresponding entries in columns (3) and (4) thereof:
TABLE
Ceiling
Revised
Ceiling price
ceiling
Price (wef
price as Review Order
Sl. Dosage form & under 1.4.2024 Existing SO
Medicines Unit per number and
No. Strength NLEM, with WPI number and date
review date
2022 @
order
(Rs.) 0.00551%)
(in Rs.)
(in Rs.)
(1) (2) (3) (4) (5) (6) (7) (8) 9(a) 9(b)
31015/21/2023
Oral liquid 1574
1. Cefuroxime 1 ML 5.31 5.31 -Pricing dated 31-03-23
125mg/5mL(p) 5.28 (E)
08.02.2024
Tablet 5 mg 31015/12/2023
1 4663
2. Montelukast (including 12.01 12.01 -Pricing dated 25-10-23
Tablet 11.72 (E)
chewable Tablet s) 19.02.2024
31015/13/2023
Mycophenol 1 4663
3. Tablet 500mg 74.59 74.59 -Pricing dated 25-10-23
ate mofetil Tablet 73.88 (E)
22.02.2024

Notes: -
(a) All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled
formulations at price higher than the ceiling price (plus Goods and Services Taxes as applicable) as fixed and
notified by the Government as specified in column (6) of the above table, shall revise the prices of all such
formulations downward not exceeding the ceiling price specified in column (6) plus Goods and Services
Taxes as applicable, if any.
(b) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the
ceiling price as specified in column (6) in the above table (plus Goods and Services Taxes as applicable, if
any) shall continue to maintain the existing MRP in accordance with para 13(2) of DPCO,2013 till
31.03.2024.
(c) The ceiling prices as specified in column (7) of the table are applicable with effect from 01.04.2024 (ceiling
prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). All the
existing manufacturers of above-mentioned scheduled formulations having MRP lower or equal than the
ceiling price as specified in column (6), as on 31.03.2024, in the above table (plus Goods and Services Taxes
as applicable, if any) may revise the MRP on the basis of WPI @ 0.00551% for year 2023 over 2022 in
accordance with paragraph 16(2) of DPCO, 2013.
(d) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (6) and/or (7) of the above said table.
(e) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 71
(f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (6) and/or (7) applicable of the above table as per
provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall
issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA
through IPDMS and submit a copy to State Drug Controller and dealers.
(g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to NPPA in Form I as specified under Schedule-II of
the DPCO, 2013.
(i) The manufacturers of above said scheduled formulations shall furnish quarterly return to NPPA, in respect of
production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013
through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation
shall furnish information to NPPA, in respect of discontinuation of production and / or import of scheduled
formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
discontinuation.
(j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(k) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director

का. आ. 1551(अ).—

, ,
. . , . . , . . ,
. . , . . . .

@ 0.00551%
, ,

0.00551%
I 01.04.2024 िे
प्रभावी

10509.79

38267.18
72 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

13(2)

@ 0.00551%

(4)

[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]


यमिं वका पवं ार, सह यक मनदेशक

ORDER
New Delhi, the 26th March, 2024
S.O. 1551(E).—In continuation of the notifications issued by National Pharmaceutical Pricing Authority,
Department of Pharmaceuticals, Ministry of Chemical and Fertilizers vide S.O. 639(E) dated 12.02.2018, S.O.
1464(E) dated 02.04.2018, S.O. 1488(E) dated 29.03.2019, SO. 1217(E) dated 25.03.2020, S.O. 1334(E) dated
25.03.2021, 1502(E) dated 30.03.2022, 5249(E) dated 11.11.2022, 1572(E) dated 31.03.2023 and 4663(E) dated
25.10.2023 regarding the fixation of ceiling price of the Coronary Stents as specified in column no. (2) mentioned in
the table below; after considering the Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022, it
has been decided to revise the ceiling prices of Coronary Stents as mentioned in column no. (4) in the table below,
exclusive of Goods and Services Tax as applicable,and unit specified in column (3) with effect from 01.04.2024, as
under:
TABLE
Sl. No. Coronary Stents Unit Ceiling price
(Sl. No. 28 in Schedule-I of the DPCO, 2013) (in Number) (wef 1.4.2024
with WPI @0.00551%)
(in Rs.)
(1) (2) (3) (4)
1 Bare Metal Stents 1 10509.79
Drug Eluting Stents (DES) including metallic DES and
2 Bioresorbable Vascular Scaffold (BVS)/ Biodegradable 1 38267.18
Stents
Notes: -
(a) All the existing manufacturers/importers of Coronary Stents having MRP lower than the ceiling price
specified in column (4) in the above table (plus Goods and Services Taxes as applicable, if any), may
revise the existing MRP of Coronary Stent, on the basis of WPI @ 0.00551% for the year 2023 over
2022 in accordance with Paragraph 16(2) of DPCO, 2013, read with Para 13(2) of DPCO, 2013.
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 73
(b) The manufacturers/importers of Coronary Stents may add Goods and Services Taxes only if they have
paid actually or if it is payable to the Government on the ceiling price mentioned in column (4) of the
aforesaid table.
(c) As per Para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer/importers, on a conspicuous part of the premises
where he carries on business in a manner so as to be easily accessible to any person wishing to consult
the same.

(d) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable
to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955

[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]


YUVIKA PANWAR, Assistant Director

नई दिल्ली, 26 मार्च, 2024


का. आ. 1552(अ).—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30
ebZ] 2013] dk-vk- 1192¼v½ rkjh[k 22 ekpZ] 2016 vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr
vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½, iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ksa dk
iz;ksx djrs gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds
'kqf)&i= vkns'k dk- vk- 1500¼v½ fnukad 30 ekpZ] 2022, dk-vk- 4591¼v½ fnukad 29.09.2022, dk-vk-
1571¼v½ fnukad 31.03.2023, dk-vk- 4663¼v½ fnukad 25.10.2023, dk-vk- 4887¼v½ fnukad
10.11.2023 vkSj dk-vk- 424¼v½ fnukad 02.02.2024 vkns'k ds vf/kØe.k esa tgk¡ rd mldk lEcU/k uhps
dh lkj.kh ^d* esa fofufeZr iSd] uhps nh xbZ lkj.kh [k esa fofufnZ"V fuekZrk ds fo'ks”k mRikn ,oa iSsd vkdkj] mu
ckrksa ds flok; vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS]
jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd ewY; lwpdkad ¼MCY;wihvkbZ½] 2023 ij vk/kkfjr la”kks/ku
djrk gS] tSlk fd uhps dh lkj.kh ^d* ds LraHk ¼5½ esa fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½
vkSj ¼4½ esa dh xbZ Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSds ftax
lfgr ml lkj.kh ds LraHk ¼2½ esa dh xbZ rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh
oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksMd + j vf/kdre dher ds #i esa fu;r djrh gSA

@ 0.00551% बढाकर

@ 0.00551%

(1) (2) (3) (4) (5)


1 Xywdkst batsD”ku 5% 1000 fefy xSj&dk¡p fo'ks"k
fo'ks’krkvksa lfgr 95.11
2 Xywdkst batsD”ku 5% 500 fefy xSj&dk¡p fo'ks"k 82.27
fo'ks’krkvksa lfgr
3 Xywdkst ¼,½$lksfM;e batsD”ku 5% ¼,½$0-9% 1000 fefy xSj&dk¡p fo'ks"k
DyksjkbM ¼ch½ fo'ks’krkvksa lfgr 99.94
¼ch½
4 Xywdkst ¼,½$lksfM;e batsD”ku 5% ¼,½$ 0- 500 fefy xSj&dk¡p fo'ks"k
DyksjkbM ¼ch½ fo'ks’krkvksa lfgr 85.52
9% ¼ch½
5 lksfM;e DyksjkbM batsD”ku 0-9% 100 fefy xSj&dk¡p fo'ks"k
fo'ks’krkvksa lfgr 42.06
6 lksfM;e DyksjkbM batsD”ku 0-9% 250 fefy xSj&dk¡p fo'ks"k
fo'ks”krkvksa lfgr 62.10
74 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

7 lksfM;e DyksjkbM batsD”ku 0-9% 500 fefy xSj&dk¡p fo'ks"k


fo'ks’krkvksa lfgr 87.94
8 lksfM;e DyksjkbM batsD”ku 0-9% 1000 fefy xSj&dk¡p fo'ks"k
fo'ks’krkvksa lfgr 98.51

मैससच अससा पैरेंटल्स जलजमटेड यूरोहेड के साथ स्ट्टेरी जड्रप बोतल


मैससच श्री कृ ष्णा के िव लेबोरे टरीि जलजमटेड यूरोहेड के साथ ईजीपोटच बोतल
मैससच रुसोमा लेबोरे टरीि प्रा०जलजमटेड प्यूराड्रीप
मैससच आर .के .लेबोरे टरीि प्रा०जलजमटेड यूरोहेड बाटल
मैससच यूरोलाइफ हेल्थके यर प्रा०जलजमटेड लाइफ पोटच
मैससच ररयलके ड लाईफसाइं स प्रा०जलजमटेड यूरोहेड बाटल
मैससच पुजनस्ट्का हेल्थके यर प्रा०जलजमटेड (नीर्े नोन पीवीसी बेग
मैससच अबैररस हेल्थके यर प्रा० जलजमटेड डु ओ पोटच
मैससच जहलस हेल्थके यर (नीर्े एिा जड्रप
मैससच रूसोमा लेबोरे टरीि प्रा०जलजमटेड यूरोहेड बोटल ब्ांड नाम ड्यूजड्रप के साथ
मैससच प्यूटो लाइफ साइं सेि प्राइवेट जलजमटेड नीर्े यूरोहेड बोटल

मैससच सजर्न पैरेंटेरल प्रा .जलजमटेड नीर्े सेफ पोटच

मैससच बायोजसनिी लाइफके यर प्राइवेट जलजमटेड जलजमटेड बायोपोटच


नीर्े
मैससच प्रोजमया थेरेप्यूरटसस प्राइवेट जलजमटेड नीर्े एलडीपीई बोतल/नोन-ललास कं टेनर जविेि
सुजवधाओं के साथ - यूरोहेड कै प
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 75

0.00551%
र्के 5, 6, 7 औि 8 मे दशािई गई र्कीमते र्केवल मैससच
पुजनस्ट्का हेल्थके यर प्रा०जलजमटेड ( र्के 19) पर लागू होंगी.
र्के 1, 2, 3, 4, 5, 7 औि 8 मे दशािई गई र्कीमते र्केवल
मैससच जहलस हेल्थके यर ( र्के 21) पर लागू होंगी.
र्के 2, 4, 5 औि 7 मे दशािई गई र्कीमते र्केवल मैससच प्यूटो
लाइफ साइं सेि प्राइवेट जलजमटेड ( र्के 23) पर लागू होंगी.
र्के 2, 4, 5, 6 औि 7 मे दशािई गई र्कीमते र्केवल मैससच
सजर्न पैरेंटेरल प्रा .जलजमटेड ( र्के 24) पर लागू होंगी.
र्के 1, 2, 3, 4, 5, 7 औि 8 मे दशािई गई र्कीमते र्केवल
मैििि बायोमिनजी लाइफर्केयि प्राइवेट मलममटे ड ( र्के 25) पि
लागू होंगी.
र्के 2, 4, 5 औि 7 मे दशािई गई र्कीमते र्केवल मैििि
प्रोममया िेिेप्यूट्रटटि प्राइवेट मलममटे ड ( र्के 26) पि लागू होंगी.

(5)

dk- vk- 1571¼v½ fnukad 31.03.2023, dk-vk- 4663¼v½ fnukad 25.10.2023, dk-
vk- 4887¼v½ fnukad 10.11.2023 vkSj dk-vk- 424¼v½ fnukad 02.02.2024

0.00551%

ञ (5)

ठ यदि संिोधन दकया िाता है तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की
अवजध में प्रपत्र-।। के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की
िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन
नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेने की जतजथ से उस पर ब्याि सजहत
पूवच-संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा।
76 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

(4)

(1) u
II I

(त)
II III

II IV

( द)

[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]


यमिं वका पंवार, सह यक मनदेशक

ORDER
New Delhi, the 26th March, 2024
S.O. 1552(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of
the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22 nd
March, 2016, S.O. 5249(E) dated 11 th November, 2022 issued by the Government of India in the Ministry of
Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals
and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 1571(E) dated 31.03.2023, 4663(E) dated
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 77
25.10.2023, 4887(E) dated 10.11.2023 and 424(E) dated 02.02.2024 in so far as they relate to formulation packs
mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and
pack-sizes, except in respect of things done or omitted to be done before such supersession, the National
Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index (WPI) of 2023 as
specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax
applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the
said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in
columns (3) and (4) thereof:
TABLE A
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase
Sl. No. Medicines Dosage form and Unit Ceiling price
Strength (w.e.f.01.04.2024 with WPI
@ 0.00551%) (in Rs.)
(1) (2) (3) (4) (5)
1 Glucose Injection 5% 1000ml NonGlass with special
95.11
features
2 Glucose Injection 5% 500ml Non Glass with special
82.27
features
3 Glucose (A) + Sodium Injection 5% (A) + 1000ml Non Glass with special
99.94
Chloride (B) 0.9% (B) features
4 Glucose (A) + Sodium Injection 5% (A) + 500ml Non Glass with special
85.52
Chloride (B) 0.9% (B) features
5 Sodium Chloride Injection 0.9% 100ml Non Glass with special
42.06
features
6 Sodium Chloride Injection 0.9% 250ml Non Glass with special
62.10
features
7 Sodium Chloride Injection 0.9% 500ml Non Glass with special
87.94
features
8 Sodium Chloride Injection 0.9% 1000ml Non Glass with special
98.51
features

TABLE B
Sl. No. Name of Manufacturer Product /Brand Name
(1) (2) (3)
1 M/s B.Braun Medical (I) Pvt Ltd. Ecoflac Plus bottle with Eurohead
2 M/s Amanta Healthcare Ltd. Steriport bottle
3 M/s Aculife Healthcare Pvt Ltd. Aculife bottle with Eurohead
4 M/s Albert David Limited Albert David bottle with Eurohead
5 M/s Denis Chem Limited Aquapulse with Eurohead
6 M/s Claris Life Sciences Limited Claris bottle with Eurohead
7 M/s Fresenius Kabi India Pvt Limited Freeflex bags
8 M/s Otsuka Pharmaceutical India Private Ltd. Unibag
(previously known as Claris Otsuka Private Limited)
9 M/s Aishwarya Lifesciences LifusionEurohead bottle
10 M/s Baxter (India) Pvt. Ltd. Viaflex bags
11 M/s Otsuka Pharmaceutical India Private Ltd. Eurohead bottle
(previously known as Claris Otsuka Private Limited)
12 M/s Fresenius Kabi India Pvt Limited Eurohead bottle
13 M/s Axa Parenterals Ltd Steri Drip bottle with Eurohead
14 M/s Shree Krishna Keshav Laboratories Ltd Easyport bottle with Eurohead
15 M/s Rusoma Laboratories Pvt. Ltd. Puradrip
16 M/s R. K. Laboratories Pvt. Ltd. Eurohead bottle
78 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

17 M/s Eurolife Healthcare Pvt. Ltd. Life port


18 M/s RealcadeLifesciencePvt. Ltd. Euro head bottle
19 M/s Puniska Healthcare Pvt. Ltd [Note (b) below] Non –PVC bag
20 M/s Abaris Healthcare Pvt. Ltd Duo Port
21 M/s Higgs Healthcare [Note (c) below] Aqua Drip
22 M/s Rusoma Laboratories Pvt. Ltd. Eurohead Bottles with Brand name “Dewdrip”

23 M/s Puerto life Sciences Private Limited [Note (d) Euro head bottle
below]
24 M/s Sachin Parenteral Pvt. Ltd. [Note (e) below] “SAFE PORT”
25 M/s Biosynergy Lifecare Pvt. Ltd. [Note (f) below] “BIOPORT”
26. M/s Promea Therapeutics Pvt. Ltd. [Note (g) below] LDPE Bottle/ Non-Glass container with special features
Euro head Cap

Note:
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) In case of M/s Puniska Healthcare Pvt. Ltd.mentioned in Sl. No. 19 of Table B, only the prices of the
formulations specified in Sl. No. 5, 6, 7 & 8 of Table A are applicable.
(c) In case of M/s Higgs Healthcare mentioned in Sl. No. 21 of Table B, only the prices of the formulations specified
in Sl. No. 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable.
(d) In case of M/s Puerto life Sciences Private Limited mentioned in Sl. No. 23 of Table B, only the prices of the
formulations specified in Sl. No. 2, 4, 5 & 7 of Table A are applicable.
(e) In case of M/s Sachin Parenteral Pvt. Ltd. mentioned in Sl. No. 24 of Table B, only the prices of the formulations
specified in Sl. No. 2, 4, 5, 6 & 7 of Table A are applicable.
(f) In case of M/s Biosynergy Lifecare Pvt. Ltd. mentioned in Sl. No. 25 of Table B, only the prices of the
formulations specified in Sl. No. 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable.
(g) In case of M/s Promea Therapeutics Pvt. Ltd. mentioned in Sl. No. 26 of Table B, only the prices of the
formulations specified in Sl. No. 2, 4, 5 & 7 of Table A are applicable.
(h) The manufacturers of scheduled formulations, selling abovesaid products/brandnameof scheduled formulations
at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the
Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified
in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(i) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified
vide S.O. No. 1571(E) dated 31.03.2023, S.O. 4663(E) dated 25.10.2023, S.O. No. 4887(E) dated 10.11.2023
and S.O. No. 424(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the
existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance
with paragraph 16(2) of DPCO, 2013.
(j) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(k) Any other manufacturer claiming separate ceiling price for Non-Glass with special feature shall apply to NPPA
for separate ceiling price approval with details and demonstrate, that such pack alongwith documentation and
demonstration.
(l) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned
manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price
(MRP), alongwith interest thereon from the date of overcharging.
(m) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 79
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to
State Drug Controller and dealers.
(n) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business
in a manner so as to be easily accessible to any person wishing to consult the same.
(o) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall
apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the
DPCO, 2013.
(p) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of
production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through
IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish
information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in
Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(q) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit
the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order,
2013 read with Essential Commodities Act, 1955.
(r) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this
notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.

[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]


YUVIKA PANWAR, Assistant Director

नई दिल्ली, 26 मार्च, 2024


का. आ. 1553(अ).—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30
ebZ] 2013] dk-vk- 1192¼v½ rkjh[k 22 ekpZ] 2016 vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr
vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½, iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ksa dk
iz;ksx djrs gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds
vkns'k dk- vk- 1570¼v½ fnukad 31 ekpZ] 2023, dk- vk- 4663¼v½ fnukad 25.10.2023, dk- vk- 4888¼v½
fnukad 10.11.2023 vkSj dk- vk- 425¼v½ fnukad 02.02.2024, vkns'k ds vf/kØe.k esa tgk¡ rd, uhps nh
xbZ lkj.kh [k esa fofufnZ"V fuekZrk ds fo'ks”k mRikn ,oa iSsd vkdkj] mu ckrksa ds flok; vf/kØkUr djrs gq,
ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k]
,rn~}kjk] Fkksd ewY; lwpdkad ¼MCY;wihvkbZ½] 2023 ij vk/kkfjr la”kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d*
ds LraHk ¼5½ esa fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh xbZ Øe'k% rRLFkkuh
izfof"V;ksa esa fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½ esa dh
xbZ rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks
NksM+dj vf/kdre dher ds #i esa fu;r djrh gSA

@ 0.00551% बढा

@ 0.00551%

(1) (2) (3) (4) (5)


1 ररं गर लैसटेट इं िेसिन 100 जमली प्रत्येक 100 जमलीलीटर पैक में
29.90
जविेि जविेिताएं हैं
2 ररं गर लैसटेट इं िेसिन 250 जमली प्रत्येक 250 जमलीलीटर पैक में 50.99
80 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

जविेि जविेिताएं हैं


3 ररं गर लैसटेट इं िेसिन 500 जमली प्रत्येक 500 जमलीलीटर पैक में
64.96
जविेि जविेिताएं हैं
4 ररं गर लैसटेट इं िेसिन 1000 जमली प्रत्येक 1000 जमलीलीटर पैक में
114.21
जविेि जविेिताएं हैं

(1) (2) 3
1 मैििि अेबटि डेववड मल. यिू ोहे ड
2 मैििि एटयल
ू ाइफ हे ेिर्केयि प्रा. मलममटे ड यिू ोहे ड
3 मैििि बी। ब्रौन मेडडर्कल प्रा (इंडडया). मलममटे ड यिू ोहे ड र्के िाि इर्कोफ्लैर्क प्लि बोतल
4 मैििि फ्रेिेननयि र्काबी इंडडया प्रा. मलममटे ड फ़्रीफ़्लेटि बैग
5 मैििि ओस्तर्क
ु ा फामािस्यट्रू टर्केि इंडडया प्रा. यिू ोहे ड बोतल
मलममटे ड

6 मैििि डेननि र्केम लेब मलममटे ड यिू ोहे ड प्रोपलीन बोतल

7 मैििि अमान्ता हे ेिर्केयि मलममटे ड एफएफएि/बीएफएि

8 मैििि श्री र्कृष्णा र्केशव लेबोिे टिीज मलममटे ड यिू ोहे ड

9 मैििि अटिा पैिेंटेि मलममटे ड यिू ोहे ड र्के िाि स्टे रिडडप

10 मैििि रुिोमा लेबोिे टिीज मलममटे ड यिू ोहे ड एफएफएि बोतल

11 मैििि आि. र्के. लेबोिे टिीज प्रा० मलममटे ड यिू ोहे ड बोतल

12 मैििि रियलर्केड लाईफिाइंि प्रा० मलममटे ड ववशेष िवु विाओं र्के िाि गैि-ललाि

13. मैििि अबैरिि हे ेिर्केयि प्रा० मलममटे ड (नीर्े ववशेष िवु विाओं र्के िाि गैि-ललाि

14. मैििि ट्रहलि हे ेिर्केयि (नीर्े ववशेष िवु विाओं र्के िाि गैि-ललाि

15. मैििि रूिोमा लेबोिे टिीज प्रा०मलममटे ड (नीर्े यिू ोहे ड बोटल ड्यडू ड्रप र्के िाि

16. मैससच प्यूटो लाइफ साइं सेि प्राइवेट जलजमटेड (नीर्े यिू ोहे ड बोतल

17. मैससच सजर्न पैरेंटेरल प्रा .जलजमटेड (नीर्े "िेफ पोटि "

18. मै ससस बायोससनर्जी लाइफकेयर प्राइवेट सलसमटे ड "बायोपोटस "


(नीर्े
19. मै ससस प्रोसमया थे रेप्यूसटक्स प्राइवेट सलसमटे ड (नीर्े प्रोकैप-आरएल
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 81

0.00551%
र्के 2, 3 औि 4 मे दशािई गई र्कीमते र्केवल मैससच मैििि अबैरिि
हे ेिर्केयि प्रा० मलममटे ड ( र्के 13) औि मैििि रूिोमा लेबोिे टिीज
प्रा०मलममटे ड ( र्के 15) पि लागू होंगी .
र्के औि 4 मे दशािई गई र्कीमते र्केवल मैििि ट्रहलि हे ेिर्केयि
( र्के 14) पर लागू होंगी.
र्के 3 मे दशािई गई र्कीमते र्केवल मैससच प्यूटो लाइफ साइंसेि
प्राइवेट जलजमटेड ( र्के 16), मैससच सजर्न पैरेंटेरल प्रा .जलजमटेड (
र्के 17) औि मैससस प्रोसमया थेरेप्यूसटक्स प्राइवेट सलसमटे ड ( र्के 19)
पि लागू होंगी .
र्के औि 4 मे दशािई गई र्कीमते र्केवल मैससस बायोससनर्जी
लाइफकेयर प्राइवेट सलसमटे ड ( र्के 18) पि लागू होंगी.

(5)

dk-
vk- 1570¼v½ fnukad 31 ekpZ] 2023, dk- vk- 4663¼v½ fnukad 25.10.2023, dk- vk- 4888¼v½ fnukad
10.11.2023 vkSj dk- vk- 425¼v½ fnukad 02.02.2024

0.00551%

(5)

(ञ) यदि संिोधन दकया िाता है तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर
की अवजध में प्रपत्र-।। के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को
अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम
खुिरा मूल्य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेने की
जतजथ से उस पर ब्याि सजहत पूव-च संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की
राजि िमा करने के जलए उत्तरिायी होगा।

V
82 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

(4)

(1) u
II I


II III

II IV

[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]


यमिं वका पंवार, सह यक मनदेशक

ORDER
New Delhi, the 26th March, 2024
S.O. 1553(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11 of the Drugs
(Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30 th May, 2013, S.O. 1192(E) dated 22nd March, 2016,
S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and
Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers
(National Pharmaceutical Pricing Authority) S.O. 1570(E) dated 31.03.2023, S.O. 4663(E) dated 25.10.2023, S.O.
4888(E) dated 10.11.2023 and S.O. 425(E) dated 02.02.2024 in so far as it relates to formulation packs mentioned in
the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes,
except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing
Authority, hereby revises the price based on Wholesale price index(WPI) of 2023 as specified in column (5) of the
Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of
the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form
and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE A
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Sl. Medicines Dosage form and Unit Ceiling price
No. Strength (w.e.f.01.04.2024 with WPI
@ 0.00551%) (in Rs.)
(1) (2) (3) (4) (5)
1 Ringer lactate Injection100 ml Each 100 ml pack having special
29.90
features
2 Ringer lactate Injection 250 ml Each 250 ml pack having special
50.99
features
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 83
3 Ringer lactate Injection 500 ml Each 500 ml pack having special
64.96
features
4 Ringer lactate Injection 1000 ml Each 1000 ml pack having special
114.21
features

TABLE ‘B’
Sl. No. Name of Manufacturer Product /Brand Name

(1) (2) (3)

1 M/s Albert David Ltd. Eurohead

2 M/s Aculife Healthcare Pvt. Ltd. Eurohead

3 M/s B. Braun Medical (India) Pvt. Ltd. Ecoflac Plus bottle with Eurohead

4 M/s Fresenius Kabi India Pvt. Ltd. Freeflex bags

5 M/s Ostuka Pharmaceuticals India Pvt. Ltd. Eurohead bottle

6 M/s Denis Chem lab Ltd. Eurohead Propylene Bottle

7 M/s Amanta Healthcare Ltd. FFS/BFS

8 M/s Shree Krishna Keshav Laboratories Ltd. Eurohead

9 M/s AxaParenterals Ltd. Steridip with Eurohead

10 M/s Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle

11 M/s R. K. Laboratories Pvt. Ltd. Eurohead Bottle

12 M/s Realcade Lifescience Pvt. Ltd. Non-glass with special features

13 M/s Abaris Healthcare Pvt. Ltd (Note (b) below) Non-glass with special features

14 M/s Higgs Healthcare (Note (c) below) Non-glass with special features

15 M/s Rusoma Laboratories Pvt. Ltd. (Note (b) below) “Dewdrip”

16 M/s Puerto life Sciences Private Limited (Note (d) below) Eurohead bottle

17 M/s Sachin Parenteral Pvt. Ltd. (Note (d) below) “SAFE PORT”

18 M/s Biosynergy Lifecare Pvt. Ltd. (Note (e) below) “BIOPORT”

19 M/s Promea Therapeutics Pvt. Ltd. (Note (d) below) PROCAP-RL

Notes:
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) In case of M/s Abaris Healthcare Pvt. Ltd. (Sl. No. 13 of Table B) & M/s Rusoma Laboratories Pvt. Ltd. (Sl.
No. 15 of Table B), only the prices of the formulations specified in Sl. No. 2, 3 & 4 of Table A are applicable.
(c) In case of M/s Higgs Healthcare mentioned in Sl. No. 14 of Table B, only the prices of the formulations
specified in Sl. No. 3 & 4 of Table A are applicable.
(d) In case of M/s Puerto life Sciences Private Limited (Sl. No. 16 of Table B), M/s Sachin Parenteral Pvt. Ltd.
(Sl. No. 17 of Table B) & M/s Promea Therapeutics Pvt. Ltd. (Sl. No. 19 of Table B), only the prices of the
formulations specified in Sl. No. 3 of Table A are applicable.
(e) In case of M/s Biosynergy Lifecare Pvt. Ltd. mentioned in Sl. No. 18 of Table B, only the prices of the
formulations specified in Sl. No. 3 & 4 of Table A are applicable
(f) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled
formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and
84 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(g) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price
notified vide S.O. 1570(E) dated 31.03.2023, S.O. 4663(E) dated 25.10.2023, S.O. 4888(E) dated 10.11.2023
and S.O. 425(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing
M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over the year 2022 in accordance
with paragraph 16(2) of DPCO, 2013.
(h) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(i) Any other manufacturer claiming separate ceiling price for ringer lactate injection in pack having special
features shall apply to NPPA for separate ceiling price approval.
(j) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(k) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy
to State Drug Controller and dealers.
(l) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(m) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall
apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the
DPCO, 2013.
(n) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect
of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013
through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation
shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled
formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
discontinuation.
(o) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control)
Order, 2013 read with Essential Commodities Act, 1955.
(p) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.

[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]


YUVIKA PANWAR, Assistant Director
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 85

ubZ fnYyh] 26 ekpZ] 2024


¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ]
2013 vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 11 ds
mi&iSjk ¼3½ vkSj ¼4½ iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd
ea=ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds vkns'k dk-vk- 4077¼v½ fnukad 15.09.2023 vkns'k ds vf/kØe.k esa tgk¡
rd mldk lEcU/k uhps dh lkj.kh ^d* esa fofufeZr से gSA uhps nh xbZ lkj.kh [k esa fofufnZ"V fuekZrk ds fo"ks'k mRikn ,oa
iSsd vkdkj] mu ckrksa ds flok; vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k
gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd ewY; lwpdkad ¼MCY;wihvkbZ½] 2023 ij vk/kkfjr la'kks/ku djrk gS]
tSlk fd uhps dh lkj.kh ^d* ds LraHk ¼5½ esa fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh xbZ
Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½
esa dh xbZ rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj
vf/kdre dher ds #i esa fu;r djrh gSA

@ 0.00551%
(@ 0.00551%

(1) (2) (3) (4) (5)


1 पििेरपसपिन (ए) + इजं ेक्शन के पिए िाउडर 2 ग्राम (ए) + प्रत्येक‍दोहरे ‍चैम्बर‍बैग
250 पमिीग्राम(बी) fo'ks"k fo'ks’krkvksa lfgr 220.27
ताज़ोबैक्टम (बी)
2 पििेरपसपिन (ए) + इजं ेक्शन के पिए िाउडर 4 ग्राम (ए)+ प्रत्येक द़ोहरे चैम्बर बैग fo'ks"k
500 पमिीग्राम(बी) fo'ks’krkvksa lfgr 459.31
ताज़ोबैक्टम (बी)

(3)
मैससस गुपिक बाय़ोसाइसं ेज पिपमटेड टैज़ोपिक इजं ेक्शन (डीसीबी)

0.00551%

15.09.2023

0.00551%
86 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

कोई‍अन्य‍विविर्ााता‍जो‍विशेष‍सुविधाओं‍िाले‍पैकेजों‍र्ें‍वपपेरवसवलि‍(ए)‍+‍ताजोबैक्टर्‍(बी)‍इं जेक्शि‍के ‍वलए‍पाउडर‍


(i) 2‍ग्रार्‍(ए)‍+‍ 250‍वर्लीग्रार्‍(बी)‍(ii) 4‍ग्रार्‍(ए)+‍ 500‍वर्लीग्रार्(बी)‍प्रत्येक‍दोहरे ‍ चैम्बर‍ बैग, के ‍वलए‍अलग‍
अवधकतर्‍र्ूल्य‍का‍दािा‍करता‍है‍तो‍िह‍अलग‍अवधकतर्‍र्ूल्य‍अिुर्ोदि‍के ‍वलए‍एिपीपीए‍को‍आिेदि‍करे गा।

यदद‍संशोधि‍दकया‍जाता‍है‍तो, इसकी‍सूचिा‍ऐसे‍संशोधिों‍को‍दकए‍जािे‍के ‍पंद्रह‍ददिों‍के ‍भीतर‍की‍अिवध‍र्ें‍प्रपत्र-II‍


के ‍रूप‍र्ें‍इलेक्रॉविक‍अथिा‍िास्तविक‍दकसी‍भी‍तौर‍पर‍सरकार‍को‍अग्रेवषत‍की‍जाएगी‍और‍इस‍उप-पैराग्राफ‍के ‍तहत‍
सूचिा‍प्रस्तुत‍िहीं‍दकए‍जािे‍को‍अवधकतर्‍खुदरा‍र्ूल्य‍र्ें‍संशोधि‍िहीं‍दकया‍जािा‍र्ािा‍जाएगा‍और‍संबंवधत‍विर्ााता‍
अवधक‍शुल्क‍लेिे‍ की‍वतवथ‍से‍ उस‍पर‍ब्याज‍सवहत‍पूिा -संशोवधत‍अवधकतर्‍खुदरा‍र्ूल्य‍(एर्आरपी)‍से‍ अवधक‍की‍रावश‍
जर्ा‍करिे‍के ‍वलए‍उत्तरदायी‍होगा।

u
II I


II III

II IV

[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]


युविका‍पंिार, सहायक‍विदेशक

ORDER
New Delhi, the 26th March, 2024
S.O. 1554(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11,14 and 16 of
the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession
of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing
Authority) S.O. No. 4077(E) dated 15.09.2023 in so far as it relate to formulation packs mentioned in the Table A
below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in
respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority,
hereby revises the price based on Wholesale price index (WPI) of 2023 as specified in column (5) of the Table A
herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 87
scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and
strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE A
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Sl. Medicines Dosage form and Strength Unit Ceiling price (wef
No. 01.04.2024 with WPI
@ 0.00551%) (in Rs.)
(1) (2) (3) (4) (5)
1 Piperacillin (A) + Powder for Per Dual chamber bag with
special feature
Tazobactam (B) Injection 2 g (A) + 220.27
250 mg(B)
2 Piperacillin (A) + Powder for Per Dual chamber bag with
special feature
Tazobactam (B) Injection 4 g (A) + 459.31
500 mg(B)

TABLE ‘B’
Sl. No. Name of Manufacturer Product /Brand Name
(1) (2) (3)
1 M/s Gufic Biosciences Limited Tazofic Injection (DCB)

Note:
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled
formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price
notified vide S.O. No. 4077(E) dated 15.09.2023 (plus Goods and Services Tax as applicable, if any), may
revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in
accordance with paragraph 16(2) of DPCO, 2013.
(d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(e) Any other manufacturer claiming separate ceiling price for Piperacillin (A) + Tazobactam (B) Injection (i)
Powder for injection 2g (A) + 250gm (B) (ii) 4g (A) + 500gm (B) Per Dual chamber bag having special
features shall apply to NPPA for separate ceiling price approval.
(f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a
copy to State Drug Controller and dealers.
(h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
88 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

(i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of
the DPCO, 2013.
(j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import
of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the
intended date of discontinuation.
(k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director

ubZ fnYyh] 26 ] 2024


¼v½.—

31.03.2023, 31.03.2023, 25.10.2023, 10.11.2023


02.02.2024

0.00551%
(@ 0.00551%

(1) (2) (3) (4) (5)

1 र्ेरोविडाजोल गैर-ग्लास‍विशेष‍विशेषताएं‍पैकेज‍के ‍वलए‍ प्रवत‍वर्ली


100वर्ली‍पैक‍र्ें‍इं जेक्शि‍(0.5%डब्लू/िी)/‍ 0.25
500‍वर्लीग्रार्/‍100वर्ली

1. र्ैससा‍ओत्सुका‍फार्ाास्युटटकल‍इं वडया‍प्रा.‍वलवर्टेड यूरोहेड‍बोतल

2. र्ैससा‍डेविस‍के र्‍लेब‍प्रा०वलवर्टे ड‍‍ यूरोहेड‍प्रोपलीि‍बोतल


[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 89

3. र्ैससा‍रूसोर्ा‍लेबोरे टरीज‍प्रा०वलवर्टेड‍‍ यूरोहेड‍एफएफएस‍बोतल

4. र्ेससा‍सवचि‍पैरेंटेरल‍प्रा.‍वलवर्टेड "सेफ‍पोटा"

5. र्ैससा‍बायोवसिजी‍लाइफके यर‍प्राइिेट‍वलवर्टेड "बायोपोटा"

6. र्ैससा‍प्रोवर्या‍थेरेप्यूटटक्स‍प्राइिेट‍वलवर्टेड प्रोकै प-एर्टी

0.00551%

31.03.2023, 25.10.2023, 10.11.2023


02.02.2024

0.00551%

कोई‍अन्य‍विविर्ााता‍जो‍विशेष‍सुविधाओं‍िाले‍ पैकेजों‍र्ें‍ र्ेरोविडाजोल‍इं जेक्शि‍यूरो‍हेड‍के ‍साथ‍प्लावस्टक‍बोतल‍र्ें‍


गैर-ग्लास‍ कं टेिर‍ र्ें‍ पैकेज‍ के ‍ वलए‍ 100वर्ली‍ पैक‍ र्ें‍ इं जेक्शि‍ (0.5%डब्लू/िी)/‍ 500‍ वर्लीग्रार्/‍ 100वर्ली‍ विशेष‍
विशेषताएं‍ हैं, के ‍ वलए‍ अलग‍ अवधकतर्‍ र्ूल्य‍ का‍ दािा‍ करता‍ है‍ तो‍ िह‍ अलग‍ अवधकतर्‍ र्ूल्य‍ अिुर्ोदि‍ के ‍ वलए‍
एिपीपीए‍को‍आिेदि‍करे गा।

यदद‍संशोधि‍दकया‍जाता‍है‍तो, इसकी‍सूचिा‍ऐसे‍संशोधिों‍को‍दकए‍जािे‍ के ‍पंद्रह‍ददिों‍के ‍भीतर‍की‍अिवध‍र्ें‍प्रपत्र-।।‍


के ‍रूप‍र्ें‍इलेक्रॉविक‍अथिा‍िास्तविक‍दकसी‍भी‍तौर‍पर‍सरकार‍को‍अग्रेवषत‍की‍जाएगी‍और‍इस‍उप-पैराग्राफ‍के ‍तहत‍
सूचिा‍प्रस्तुत‍िहीं‍दकए‍जािे‍को‍अवधकतर्‍खुदरा‍र्ूल्य‍र्ें‍संशोधि‍िहीं‍दकया‍जािा‍र्ािा‍जाएगा‍और‍संबंवधत‍विर्ाा ता‍
अवधक‍शुल्क‍लेिे‍ की‍वतवथ‍से‍ उस‍पर‍ब्याज‍सवहत‍पूिा -संशोवधत‍अवधकतर्‍खुदरा‍र्ूल्य‍(एर्आरपी)‍से‍ अवधक‍की‍रावश‍
जर्ा‍करिे‍के ‍वलए‍उत्तरदायी‍होगा।

u
II I
90 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]


II III

II IV

[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]


युविका‍पंिार, सह यक‍विदेशक

ORDER
New Delhi, the 26th March, 2024
S.O. 1555(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11,14 and 16 of
the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession
of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing
Authority) S.O. No. 1576(E) dated 31.03.2023, 1584(E) dated 31.03.2023, 4663(E) dated 25.10.2023, 4889(E) dated
10.11.2023 and 426(E) dated 02.02.2024 in so far as it relate to formulation packs mentioned in the Table A below,
manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of
things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby
revises the price based on Wholesale price index (WPI) of 2023 as specified in column (5) of the Table A herein
below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled
formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength
and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE A
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Sl. Medicines Dosage form and Strength Unit Ceiling price (wef
No. 01.04.2024 with WPI @
0.00551%) (in Rs.)
(1) (2) (3) (4) (5)
1 Metronidazole Injection (0.5%w/v) /500mg/100ml Per ml
in 100ml pack for packages in non- 0.25
glass with special features

TABLE ‘B’
Sl. No. Name of Manufacturer Product /Brand Name
(1) (2) (3)
1 M/s Otsuka Pharmaceutical India Private Ltd. Eurohead bottle
2 M/s Denis Chem Lab Ltd. Eurohead Propylene Bottle
3 M/s Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle
4 M/s Sachin Parenteral Pvt. Ltd. “SAFE PORT”
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 91
5 M/s Biosynergy Lifecare Pvt. Ltd. “BIOPORT”
6 M/s Promea Therapeutics Pvt. Ltd. PROCAP-MT

Note:
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled
formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price
notified vide S.O. No. 1576(E) dated 31.03.2023, 4663(E) dated 25.10.2023, 4889(E) dated 10.11.2023 and
426(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P.
of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with
paragraph 16(2) of DPCO, 2013.
(d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(e) Any other manufacturer claiming separate ceiling price for Metronidazole Injection (0.5%w/v) /500mg/
100ml in 100ml pack for packages in non-glass container in plastic bottle with euro head having special
features shall apply to NPPA for separate ceiling price approval.
(f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a
copy to State Drug Controller and dealers.
(h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of
the DPCO, 2013.
(j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import
of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the
intended date of discontinuation.
(k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table
in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date
of notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director
92 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

ubZ fnYyh] 26 ] 2024


¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ]
2013 vkSj dk-vk- 5249¼v½ rkjh[k 11 uoEcj] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 11 ds
mi iSjk ¼3½ vkSj ¼4½ iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd
ea=ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds vkns'k dk- vk- 1575¼v½ fnukad 31.03.2023, dk-vk- 1583¼v½ fnukad
31.03.2023 vkSj dk-vk- 4890¼v½ fnukad 10.11.2023 vkns'k ds vf/kØe.k esa tgk¡ rd mldk lEcU/k uhps dh
lkj.kh ^d* ls lacaf/kr gSA uhps nh xbZ lkj.kh [k esa fofufnZ"V fuekZrk ds fo'ks"k mRikn ,oa iSsd vkdkj] mu ckrksa ds flok;
vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k
izkf/kdj.k] ,rn~}kjk] Fkksd ewY; lwpdkad ¼MCY;wihvkbZ½] 2023 ij vk/kkfjr la'kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d*
ds LraHk ¼5½ esa fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh xbZ Øe'k% rRLFkkuh izfof"V;ksa esa
fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½ esa dh xbZ rRLFkkuh izfof"V esa
fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds #i esa
fu;r djrh gSA

0.00551%
(@ 0.00551%

(1) (2) (3) (4) (5)

1 र्ेंिीटोल‍‍ गैर-ग्लास‍विशेष‍विशेषताएं‍पैकेज‍के ‍वलए‍ प्रवत‍वर्ली 0.40


100वर्ली‍पैक‍र्ें‍‍इं जेक्शि‍20%

1. र्ैससा‍ओत्सुका‍फार्ाास्युटटकल‍इं वडया‍प्रा.‍वलवर्टेड यूरोहेड‍बोतल

2. र्ैससा‍डेविस‍के र्‍लेब‍प्रा०वलवर्टे ड‍‍ यूरोहेड‍प्रोपलीि‍बोतल

3. र्ैससा‍रूसोर्ा‍लेबोरे टरीज‍प्रा०वलवर्टेड‍‍ यूरोहेड‍एफएफएस‍बोतल

4. र्ेससा‍सवचि‍पैरेंटेरल‍प्रा.‍वलवर्टेड "सेफ‍पोटा"

5. र्ैससा‍बायोवसिजी‍लाइफके यर‍प्राइिेट‍वलवर्टेड "बायोपोटा"

@0.00551%

31.03.2023, 31.03.2023
10.11.2023
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 93
0.00551%

कोई‍अन्य‍विविर्ााता‍जो‍विशेष‍सुविधाओं‍िाले‍ पैकेजों‍र्ें‍ र्ेंिीटोल‍यूरो‍हेड‍के ‍साथ‍प्लावस्टक‍बोतल‍र्ें‍ गैर -ग्लास‍कं टेिर‍


र्ें‍पैकेज‍के ‍वलए‍100‍वर्ली‍पैक‍र्ें‍इं जेक्शि‍20%‍की‍विशेष‍विशेषताएं‍हैं, के ‍वलए‍अलग‍अवधकतर्‍र्ूल्य‍का‍दािा‍करता‍
है‍तो‍िह‍अलग‍अवधकतर्‍र्ूल्य‍अिुर्ोदि‍के ‍वलए‍एिपीपीए‍को‍आिेदि‍करे गा।

यदद‍संशोधि‍दकया‍जाता‍है‍तो, इसकी‍सूचिा‍ऐसे‍संशोधिों‍को‍दकए‍जािे‍के ‍पंद्रह‍ददिों‍के ‍भीतर‍की‍अिवध‍र्ें‍प्रपत्र-।।‍के ‍


रूप‍र्ें‍ इलेक्रॉविक‍अथिा‍िास्तविक‍दकसी‍भी‍तौर‍पर‍सरकार‍को‍अग्रेवषत‍ की‍जाएगी‍और‍इस‍उप-पैराग्राफ‍के ‍तहत‍
सूचिा‍प्रस्तुत‍िहीं‍दकए‍जािे‍ को‍अवधकतर्‍खुदरा‍र्ूल्य‍र्ें‍ संशोधि‍िहीं‍दकया‍जािा‍र्ािा‍जाएगा‍और‍संबंवधत‍विर्ााता‍
अवधक‍शुल्क‍लेिे‍ की‍वतवथ‍से‍ उस‍पर‍ब्याज‍सवहत‍पूिा -संशोवधत‍अवधकतर्‍खुदरा‍र्ूल्य‍(एर्आरपी)‍से‍ अवधक‍की‍रावश‍
जर्ा‍करिे‍के ‍वलए‍उत्तरदायी‍होगा।

u II
I

(ञ)
II III

II IV

[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]


युविका‍पंिार, सहायक‍विदेशक

ORDER
New Delhi, the 26th March, 2024
S.O. 1556(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of
the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession
of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing
Authority) S.O. No. 1575(E) dated 31.03.2023, S. O. No. 1583(E) dated 31.03.2023 and S.O. No. 4890(E) dated
94 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

10.11.2023 in so far as it relate to formulation packs mentioned in the Table A below, manufactured by the
manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted
to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on
Wholesale price index(WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price
exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the
corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified
respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE A
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Sl. No. Medicines Dosage form and Strength Unit Ceiling price (wef 01.04.2024
with WPI @ 0.00551%) (in
Rs.)
(1) (2) (3) (4) (5)
1 Mannitol Injection 20% in 100 ml pack for packages in Per ml 0.40
non-glass with special features

TABLE ‘B’
Sl. No. Name of Manufacturer Product /Brand Name
(1) (2) (3)
1 M/s. Otsuka Pharmaceutical India Private Ltd. Eurohead bottle
2 M/s. Denis Chem Lab Ltd. Eurohead Propylene Bottle
3 M/s. Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle
4 M/s. Sachin Parenteral Pvt. Ltd. “SAFE PORT”
5 M/s. Biosynergy Lifecare Pvt. Ltd. “BIOPORT”

Note:
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) The manufacturers of scheduled formulations, selling abovesaid products/brandnameof scheduled
formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price
notified vide S.O. No. 1575(E) dated 31.03.2023, S.O. No. 1587(E) dated 31.03.2023 and S.O. No. 4890(E)
dated 10.11.2023 read with corrigendum (plus Goods and Services Tax as applicable, if any), may revise the
existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in
accordance with paragraph 16(2) of DPCO, 2013.
(d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(e) Any other manufacturer claiming separate ceiling price for Mannitol Injection 20% in 100 ml pack for
packages in non-glass container in plastic bottle with euro head having special features shall apply to NPPA
for separate ceiling price approval.
(f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a
copy to State Drug Controller and dealers.
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 95
(h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of
the DPCO, 2013.
(j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import
of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the
intended date of discontinuation.
(k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table
in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date
of notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director

ubZ fnYyh] 26 ] 2024


¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ]
2013 vkSj dk-vk- 5249¼v½ rkjh[k 22 uoEcj] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 11 ds
mi&iSjk ¼3½ vkSj ¼4½, iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd
ea=ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds 'kqf)&i= vkns'k dk-vk- 1569¼v½ fnukad 31.03.2023, dk-vk- 4891¼v½
fnukad 10.11.2023 vkSj dk-vk- 427¼v½ fnukad 02.02.2024 vkns'k ds vf/kØe.k esa tgk¡ rd mldk lEcU/k uhps dh
lkj.kh ^d*] uhps nh xbZ lkj.kh [k esa fofufnZ"V fuekZrk ds fo'ks"k mRikn ,oa iSsd vkdkj] mu ckrksa ds flok; vf/kØkUr
djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k]
,rn~}kjk] Fkksd ewY; lwpdkad ¼MCY;wihvkbZ½] 2023 ij vk/kkfjr la'kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d* ds LraHk
¼5½ esa fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh xbZ Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V
[kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½ esa dh xbZ rRLFkkuh izfof"V esa fofufnZ"V
vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds #i esa fu;r
djrh gSA

0.00551%
(@ 0.00551%

(1) (2) (3) (4) (5)


1 डेक्सरोज‍ गैर-ग्लास‍विशेष‍विशेषताएं‍पैकेज‍के ‍वलए‍ प्रवत‍वर्ली 0.24
(ग्लूकोज) 100वर्ली‍पैक‍र्ें‍‍इं जेक्शि‍(25%‍डब्ल्यू‍/िी)

1. र्ैससा‍ओत्सुका‍फार्ाास्युटटकल‍इं वडया‍प्रा.‍वलवर्टेड यूरोहेड‍बोतल

2. र्ैससा‍डेविस‍के र्‍लेब‍प्रा०वलवर्टे ड‍‍ यूरोहेड‍प्रोपलीि‍बोतल


96 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

3. र्ैससा‍रूसोर्ा‍लेबोरे टरीज‍प्रा०वलवर्टेड‍‍ यूरोहेड‍एफएफएस‍बोतल

4. र्ेससा‍सवचि‍पैरेंटेरल‍प्रा.‍वलवर्टेड "सेफ‍पोटा"

5. र्ैससा‍बायोवसिजी‍लाइफके यर‍प्राइिेट‍वलवर्टेड "बायोपोटा"

6. र्ैससा‍प्रोवर्या‍थेरेप्यूटटक्स‍प्राइिेट‍वलवर्टेड प्रोकै प-डी25

0.00551%

31.03.2023, 10.11.2023
02.02.2024

0.00551%

कोई‍अन्य‍विविर्ााता‍जो‍विशेष‍सुविधाओं‍िाले‍ पैकेजों‍र्ें‍ डेक्सरोज‍(ग्लूकोज)‍यूरो‍हेड‍के ‍साथ‍प्लावस्टक‍बोतल‍र्ें‍ गैर -


ग्लास‍ कं टेिर‍ र्ें‍ पैकेज‍ के ‍ वलए‍ 100‍ वर्ली‍ पैक‍ र्ें‍ इं जेक्शि‍ (25%‍ डब्ल्यू‍ /‍ िी)‍ की‍ विशेष‍ विशेषताएं‍ हैं‍ के ‍ वलए‍ अलग‍
अवधकतर्‍र्ूल्य‍का‍दािा‍करता‍है‍तो‍िह‍अलग‍अवधकतर्‍र्ूल्य‍अिुर्ोदि‍के ‍वलए‍एिपीपीए‍को‍आिेदि‍करे गा।

यदद‍संशोधि‍दकया‍जाता‍है‍तो, इसकी‍सूचिा‍ऐसे‍संशोधिों‍को‍दकए‍जािे‍के ‍पंद्रह‍ददिों‍के ‍भीतर‍की‍अिवध‍र्ें‍प्रपत्र-।।‍के ‍


रूप‍र्ें‍ इलेक्रॉविक‍अथिा‍िास्तविक‍दकसी‍भी‍तौर‍पर‍सरकार‍को‍अग्रेवषत‍ की‍जाएगी‍और‍इस‍उप-पैराग्राफ‍के ‍तहत‍
सूचिा‍प्रस्तुत‍िहीं‍दकए‍जािे‍ को‍अवधकतर्‍खुदरा‍र्ूल्य‍र्ें‍ संशोधि‍िहीं‍दकया‍जािा‍र्ािा‍जाएगा‍और‍संबंवधत‍विर्ााता‍
अवधक‍शुल्क‍लेिे‍ की‍वतवथ‍से‍ उस‍पर‍ब्याज‍सवहत‍पूिा -संशोवधत‍अवधकतर्‍खुदरा‍र्ूल्य‍(एर्आरपी)‍से‍ अवधक‍की‍रावश‍
जर्ा‍करिे‍के ‍वलए‍उत्तरदायी‍होगा।

(ञ)

u II
I
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 97

II III

II IV

(ड) bl vkns’k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh xbZ rRLFkkuh izfof"V esa fofufnZ"V ,slh fofufeZfr;ksa ds iSdksa dh
vf/kdre dher fu;r gksus ds ifj.kkeLo#i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns’k] ;fn dksbZ gks] tks bl
vkns’k ls iwoZ tkjh gq, gSa] Lor% gh vf/kØe.k gks tk;sx
a sA
[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]
युविका‍पंिार, सहायक‍विदेशक

ORDER
New Delhi, the 26th March, 2024
S.O. 1557(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of
the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession
of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing
Authority) S.O. 1569(E) dated 31.03.2023, S.O. 4891(E) dated 10.11.2023 and S.O. 427(E) dated 02.02.2024 in so far
as they relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in
Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such
supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price
index(WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of
Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding
entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in
the corresponding entries in columns (3) and (4) thereof:
Table A
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Sl. Medicines Dosage form and Strength Unit Ceiling price (wef
No 01.04.2024 with WPI @
0.00551%) (in Rs.)
(1) (2) (3) (4) (5)
1 Dextrose Injection (25% w/v) in 100 ml pack for packages Per ml 0.24
(Glucose) in non-glass with special features

TABLE ‘B’
Sl. Name of Manufacturer Product /Brand Name
No.
(1) (2) (3)
1 M/s Otsuka Pharmaceutical India Private Ltd. Eurohead bottle
2 M/s Denis Chem Lab Ltd. Eurohead Propylene Bottle
3 M/s Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle
4 M/s Sachin Parenteral Pvt. Ltd. “SAFE PORT”
5. M/s Biosynergy Lifecare Pvt. Ltd. “BIOPORT”
6. M/s Promea Therapeutics Pvt. Ltd. PROCAP-D25
98 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

Note:
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) The manufacturers of scheduled formulations, selling abovesaid products/brandname of scheduled
formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price
notified vide S.O.No. 1569(E) dated 31.03.2023, S.O. 4891(E) dated 10.11.2023 and S.O. 427(E) dated
02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their
formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2)
of DPCO, 2013.
(d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(e) Any other manufacturer claiming separate ceiling price for Dextrose (Glucose) Injection (25% w/v) in 100
ml pack for packages in non-glass container in plastic bottle with euro head having special features shall
apply to NPPA for separate ceiling price approval.
(f) For other special features claimed or any other pack size manufactured, the manufacturer shall approach
NPPA for specific price approval for its formulation.
(g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a
copy to State Drug Controller and dealers.
(i) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of
the DPCO, 2013.
(k) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or
import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to
the intended date of discontinuation.
(l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table
in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date
of notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 99

ubZ fnYyh] 26 ] 2024


¼v½.—भारत‍सरकार‍के ‍रसायि‍और‍उिारक‍र्ंत्रालय‍द्वारा‍जारी‍का.आ.‍1394(अ)‍तारीख‍30‍र्ई, 2013‍
और‍का.आ.‍5249(अ)‍तारीख‍11‍ििम्बर, 2022‍के ‍साथ‍पटित‍औषध‍(कीर्त‍वियंत्रण)‍आदेश, 2013‍के ‍पैरा‍5,11‍और‍15‍द्वारा‍
प्रदत्त‍शवियों‍का‍प्रयोग‍करते‍ हुए, राष्ट्रीय‍औषध‍र्ूल्य‍विधाारण‍प्रावधकरण‍(वजसको‍संविप्त‍रूप‍र्ें‍एिपीपीए‍कहा‍जाता‍है), िीचे‍की‍
सारणी‍के ‍स्तंभ‍(6)‍र्ें‍ विविर्दाष्ट‍‍खुदरा‍र्ूल्य‍को‍उि‍सारणी‍के ‍स्तंभ‍(3), (4)‍और‍(5)‍र्ें‍ तत्स्थािी‍प्रविवष्टयों‍र्ें‍ विविर्दाष्ट‍प्रबलता,
इकाई‍(यूविट)‍और‍विविर्ााता‍और‍विपणि‍कं पवियों‍के ‍िार्‍सवहत‍स्तंभ(2)‍र्ें‍ की‍तत्स्थािी‍प्रविवष्ट‍र्ें‍ से‍ प्रत्येक‍की, िस्तु‍ एिं‍ सेिा‍
कर, यदद‍कोई‍है, को‍छोड़कर‍अवधकतर्‍खुदरा‍र्ूल्य‍के ‍रूप‍र्ें‍वियत‍करती‍है

तावलका

क्रं.‍सं. विविर्र्ावत‍का‍ प्रबलता इकाई विविर्ााता‍और‍विपणि‍कं पिी खुदरा‍र्ूल्य‍


िार्/ब्ांड‍का‍िार् (रू.)
(1) (2) (3) (4) (5) (6)
वसटावग्लवप्टि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍
वपयोवग्लटाजोि‍ओर‍ वसटावग्लवप्टि‍फॉस्फे ट‍र्ोिोहाइड्रेट‍आईपी‍ फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍
र्ेटफॉर्र्ाि‍ वसटावग्लवप्टि‍100‍वर्लीग्रार्‍के ‍बराबर एबॉट‍हेल्थके यर‍प्राइिेट‍वलवर्टेड
1 हाइड्रोक्लोराइड‍ वपयोवग्लटाजोि‍हाइड्रोक्लोराइड‍आईपी‍ 1 गोली 14.00
(सस्टेंड‍टरलीज)‍गोली वपयोवग्लटाजोि‍15‍वर्लीग्रार्‍के ‍बराबर
र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍
वर्लीग्रार्‍(सस्टेंड‍टरलीज‍फॉर्ा)
वसटावग्लवप्टि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍
वपयोवग्लटाजोि‍ओर‍ वसटावग्लवप्टि‍फॉस्फे ट‍र्ोिोहाइड्रेट‍आईपी‍ फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍
र्ेटफॉर्र्ाि‍ वसटावग्लवप्टि‍100‍वर्लीग्रार्‍के ‍बराबर एबॉट‍हेल्थके यर‍प्राइिेट‍वलवर्टेड
2 हाइड्रोक्लोराइड‍ वपयोवग्लटाजोि‍हाइड्रोक्लोराइड‍आईपी‍ 1 गोली 15.32
(सस्टेंड‍टरलीज)‍गोली वपयोवग्लटाजोि‍15‍वर्लीग्रार्‍के ‍बराबर
र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍
वर्लीग्रार्‍(सस्टेंड‍टरलीज‍फॉर्ा)
वसटावग्लवप्टि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍
वपयोवग्लटाजोि‍ओर‍ वसटावग्लवप्टि‍फॉस्फे ट‍र्ोिोहाइड्रेट‍आईपी‍ फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍
र्ेटफॉर्र्ाि‍ वसटावग्लवप्टि‍100‍वर्लीग्रार्‍के ‍बराबर र्ैिकाइं ड‍फार्ाा‍वलवर्टेड
3 हाइड्रोक्लोराइड‍ वपयोवग्लटाजोि‍हाइड्रोक्लोराइड‍आईपी‍ 1 गोली 15.32
(सस्टेंड‍टरलीज)‍गोली वपयोवग्लटाजोि‍15‍वर्लीग्रार्‍के ‍बराबर
र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍
वर्लीग्रार्‍(सस्टेंड‍टरलीज‍फॉर्ा)
वसटावग्लवप्टि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍
वपयोवग्लटाजोि‍ओर‍ वसटावग्लवप्टि‍फॉस्फे ट‍र्ोिोहाइड्रेट‍आईपी‍ फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍
र्ेटफॉर्र्ाि‍ वसटावग्लवप्टि‍100‍वर्लीग्रार्‍के ‍बराबर र्ैिकाइं ड‍फार्ाा‍वलवर्टेड
4 हाइड्रोक्लोराइड‍ वपयोवग्लटाजोि‍हाइड्रोक्लोराइड‍आईपी‍ 1 गोली 14.00
(सस्टेंड‍टरलीज)‍गोली वपयोवग्लटाजोि‍15‍वर्लीग्रार्‍के ‍बराबर
र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍
वर्लीग्रार्‍(सस्टेंड‍टरलीज‍फॉर्ा)
र्ेटोप्रोलोल‍सवक्सिेट‍ प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेससा‍अजंता‍फार्ाा‍वलवर्टेड‍/‍
एक्सटेंडेड‍टरलीज, र्ेटोप्रोलोल‍सवक्सिेट‍आईपी‍47.50‍ र्ेससा‍सि‍फार्ाा‍लेबोरे टरीज‍
एम्लोवडपाइि‍और‍ वर्लीग्रार्‍ईक्यू।‍र्ेटोप्रोलोल‍टारेट‍50‍ वलवर्टेड
5 टेवल्र्सटाि‍गोवलयााँ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें) 1 गोली 14.60
एम्लोवडपाइि‍बेवसलेट‍आईपी‍ईक्यू।‍
एम्लोवडपाइि‍5‍वर्.ग्रा.
टेवल्र्सटाि‍आईपी‍40‍वर्लीग्रार्
100 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

क्रं.‍सं. विविर्र्ावत‍का‍ प्रबलता इकाई विविर्ााता‍और‍विपणि‍कं पिी खुदरा‍र्ूल्य‍


िार्/ब्ांड‍का‍िार् (रू.)
(1) (2) (3) (4) (5) (6)
वलिावग्लवप्टि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
र्ेटफॉर्र्ाि‍ वलिावग्लवप्टि‍आईपी‍5‍वर्लीग्रार्‍ वलवर्टेड/र्ैससा‍ल्यूवपि‍वलवर्टेड
6 हाइड्रोक्लोराइड‍ र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ 1 गोली 13.03
(एक्स्टेंडेड‍टरलीज)‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ
विटावर्ि‍डी3‍ प्रत्येक‍5‍वर्.ली.‍वसरप‍र्ें: र्ैससा‍रे िेिभेल‍हेल्थके यर‍
(कोलेकैल्सीफे रोल)‍ कॉलेकैवल्सफे रॉल‍आईपी‍60000‍आईयू प्राइिेट.‍वलवर्टेड‍/‍र्ैससा‍
7 1 वर्.ली. 12.53
ओरल‍सोल्यूसि एर्क्योर‍फार्ाास्यूटटकल्स‍
वलवर्टेड
विटावर्ि‍डी3‍ प्रत्येक‍5‍वर्.ली.‍र्ें‍शावर्ल‍हैं: र्ैससा‍रे िेिभेल‍हेल्थके यर‍प्राइिेट‍
8 (कोलेकैल्सीफे रोल)‍ कोलेकैवल्सफे रॉल‍आईपी‍(िैिो‍ड्रॉपलेट‍रूप‍र्ें)‍ 1 वर्.ली. वलवर्टेड‍/‍र्ैससा‍इं टास‍ 13.60
ओरल‍सोल्यूसि 60000‍आईयू फार्ाास्यूटटकल्स‍वलवर्टेड
वलिावग्लवप्टि‍‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोली‍र्ें: र्ेससा‍र्ोरपेि‍लैबोरे रीज‍
र्ेटफोर्र्ाि‍ वलिावग्लवप्टि‍2.5‍वर्.ग्रा. वलवर्टेड
9 1 गोली 8.97
हाइड्रोक्लोराइड‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍
गोली वर्लीग्रार्
दफिाइलफ्राइि‍ प्रत्येक‍5‍वर्.ली.‍र्ें: र्ेससा‍वतरुपवत‍र्ेवडके यर‍
हाइड्रोक्लोराइड, दफिाइलफ्राइि‍हाइड्रोक्लोराइड‍आईपी‍5‍ वलवर्टेड‍/‍र्ेससा‍र्ैकवलयोड्स‍
क्लोरफे विरार्ाइि‍ वर्लीग्रार् फार्ाास्यूटटकल्स‍वलवर्टेड
र्ैलेट, पैरावसटार्ोल, क्लोरफे विरार्ाइि‍र्ैलेट‍आईपी‍0.5‍
10 1 ml 0.95
सोवडयर्‍साइरेट‍और‍ वर्लीग्रार्
र्ेन्थॉल‍वसरप पेरावसटार्ोल‍आईपी‍125‍वर्लीग्रार्
सोवडयर्‍साइरेट‍आईपी‍60‍वर्लीग्रार्
र्ेन्थॉल‍आईपी‍1‍वर्लीग्रार्
पैरावसटार्ोल, प्रत्येक‍अलेवपत‍गोवलयााँ‍र्ें: र्ेससा‍आज्ञा‍बायोटेक‍प्रा.‍
दफिाइलफ्राइि‍ पेरावसटार्ोल‍आईपी‍500‍वर्लीग्रार् वलवर्टेड/र्ैससा‍र्ैकवलयोड्स‍
हाइड्रोक्लोराइड, दफिाइलफ्राइि‍हाइड्रोक्लोराइड‍आईपी‍5‍ फार्ाास्यूटटकल्स‍वलवर्टेड
11 कै फीि‍और‍ वर्लीग्रार् 1 गोली 3.70
वडफे िहाइड्रार्ाइि‍ कै फीि‍(विजाल)‍आईपी‍30‍वर्लीग्रार्
हाइड्रोक्लोराइड‍ वडफे िहाइड्रार्ाइि‍हाइड्रोक्लोराइड‍आईपी‍25‍
गोवलयााँ वर्लीग्रार्
वलिावग्लवप्टि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
र्ेटफॉर्र्ाि‍ वलिावग्लवप्टि‍5‍वर्.ग्रा. वलवर्टेड/र्ैससा‍र्ाइक्रो‍लैब्स‍
12 हाइड्रोक्लोराइड‍ र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍(एक्स्टेंडेड‍टरलीज‍ 1 गोली वलवर्टेड 11.60
(एक्स्टेंडेड‍टरलीज)‍ के ‍रूप‍र्ें)‍आईपी‍500‍वर्लीग्रार्
गोवलयााँ
सेफपोडोक्साइर्‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: र्ैससा‍ब्ूक्स‍लैबोरे टरीज‍वलवर्टेड‍
पोटेवशयर्‍क्लैिुलैिेट‍ सेफपोडोक्साइर्‍प्रोक्सेटटल‍आईपी‍ /‍र्ैससा‍जर्ाि‍रे र्ेडीज‍
गोली अन्हाईड्रोअस‍सेफपोडोक्साइर्‍200‍वर्.ग्रा.‍के ‍ फार्ाास्यूटटकल्स‍प्राइिेट‍वलवर्टेड
13 1 गोली 28.49
बराबर
पोटेवशयर्‍क्लैिुलैिेट‍वडलुटेड‍आईपी‍
क्लैिुलैिीक‍एवसड‍125‍वर्.ग्रा.‍के ‍बराबर
सेफपोडोक्साइर्‍ प्रत्येक‍5‍वर्.ली.‍रीकोंस्टीट्यूटेड‍सस्पेंशि‍र्ें: र्ैससा‍ब्ूक्स‍लैबोरे टरीज‍वलवर्टेड‍
14 1 वर्.ली. 4.94
प्रोक्सेटटल‍और‍ सेफपोडोक्साइर्‍प्रोक्सेटटल‍आईपी‍ /‍र्ैससा‍जर्ाि‍रे र्ेडीज‍
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 101

क्रं.‍सं. विविर्र्ावत‍का‍ प्रबलता इकाई विविर्ााता‍और‍विपणि‍कं पिी खुदरा‍र्ूल्य‍


िार्/ब्ांड‍का‍िार् (रू.)
(1) (2) (3) (4) (5) (6)
पोटेवशयर्‍क्लैिुलैिेट‍ अन्हाईड्रोअस‍सेफपोडोक्साइर्‍100‍वर्.ग्रा.‍के ‍ फार्ाास्यूटटकल्स‍प्राइिेट‍वलवर्टेड
ओरल‍सस्पेंशि बराबर
पोटेवशयर्‍क्लैिुलैिेट‍वडलुटेड‍आईपी‍
क्लैिुलैिीक‍एवसड‍62.50‍वर्.ग्रा.‍के ‍बराबर
वसवल्िवडवपि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: र्ैससा‍प्योर‍एंड‍क्योर‍हेल्थके यर‍
15 टेवल्र्सटाि‍गोवलयााँ वसल्िीवडपाइि‍आईपी‍10‍वर्लीग्रार् 1 गोली प्राइिेट‍वलवर्टेड‍वलवर्टेड/र्ैससा‍ 10.26
टेवल्र्सटाि‍आईपी‍40‍वर्लीग्रार् कै वडला‍फार्ाास्यूटटकल्स‍वलवर्टेड
र्ेफेिैवर्क‍एवसड‍और‍ प्रत्येक‍अलेवपत‍गोवलयााँ‍र्ें: र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
16 पेरावसटार्ोल‍ र्ेफेिैवर्क‍एवसड‍आईपी‍500‍वर्लीग्रार् 1 गोली वलवर्टेड/र्ैससा‍र्ाइक्रो‍लैब्स‍ 3.58
गोवलयााँ पेरावसटार्ोल‍आईपी‍325‍वर्लीग्रार् वलवर्टेड
पैंटोप्राजोल‍और‍ प्रत्येक‍एंटटक‍लेवपत‍गॉली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍
डोम्पेटरडोि‍गोली पैंटोप्राजोल‍सोवडयर्‍आईपी‍पैंटोप्राजोल‍40‍ फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍
17 1 गोली 7.04
वर्.ग्रा.‍के ‍बराबर जुिेंटस‍हेल्थके यर‍वलवर्टेड
डोम्पेटरडोि‍आईपी‍10‍वर्लीग्रार्
सेफपोडोक्साइर्‍और‍ प्रत्येक‍5‍वर्.ली.‍रीकोंस्टीट्यूटेड‍सस्पेंशि‍र्ें: र्ैससा‍ब्ूक्स‍लैबोरे टरीज‍वलवर्टेड‍
पोटेवशयर्‍क्लैिुलैिेट‍ सेफपोडोक्साइर्‍प्रोक्सेटटल‍आईपी‍ /‍र्ैससा‍जर्ाि‍रे र्ेडीज‍
ओरल‍सस्पेंशि अन्हाईड्रोअस‍सेफपोडोक्साइर्‍50‍वर्.ग्रा.‍के ‍ फार्ाास्यूटटकल्स‍प्राइिेट‍वलवर्टेड
18 1 वर्.ली. 3.17
बराबर
पोटेवशयर्‍क्लैिुलैिेट‍वडलुटेड‍आईपी‍
क्लैिुलैिीक‍एवसड‍31.25‍वर्.ग्रा.‍के ‍बराबर
एर्ोवक्सवसवलि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: र्ैससा‍र्वलक‍लाइफसाइं सेज‍प्रा.‍
पोटेवशयर्‍क्लैिुलैिेट‍ एर्ोवक्सवसवलि‍राइहाइड्रेट‍आईपी‍ वलवर्टेड‍/‍र्ैससा‍थेवर्स‍र्ेवडके यर‍
19 गोली एर्ोवक्सवसवलि‍250‍वर्.ग्रा.‍के ‍बराबर 1 गोली वलवर्टेड 17.46
पोटेवशयर्‍क्लैिुलैिेट‍वडलुटेड‍आईपी‍
क्लैिुलैिीक‍एवसड‍125‍वर्.ग्रा.‍के ‍बराबर
एर्ोवक्सवसवलि‍और‍ प्रत्येक‍5‍वर्.ली.‍रीकोंस्टीट्यूटेड‍सस्पेंशि‍र्ें: र्ैससा‍र्वलक‍लाइफसाइं सेज‍प्रा.‍
पोटेवशयर्‍क्लैिुलैिेट‍ एर्ोवक्सवसवलि‍राइहाइड्रेट‍आईपी‍ वलवर्टेड‍/‍र्ैससा‍थेवर्स‍र्ेवडके यर‍
20 ओरल‍सस्पेंशि एर्ोवक्सवसवलि‍600‍वर्.ग्रा.‍के ‍बराबर 1 वर्.ली. वलवर्टेड 3.18
पोटेवशयर्‍क्लैिुलैिेट‍वडलुटेड‍आईपी‍
क्लैिुलैिीक‍एवसड‍42.9‍वर्.ग्रा.‍के ‍बराबर
एसेक्लोफे िाक, प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: र्ैससा‍वथओि‍फार्ाास्यूटटकल्स‍
पेरावसटार्ोल‍और‍ एसेक्लोफे िाक‍आईपी‍100‍वर्लीग्रार् वलवर्टेड‍/‍र्ैससा‍जे.बी.‍के वर्कल्स‍
21 1 गोली 17.84
वथयोकोलवचकोसाइड‍ पेरावसटार्ोल‍आईपी‍325‍वर्लीग्रार् एंड‍फार्ाास्यूटटकल्स‍वलवर्टेड
गोली वथयोकोलवचकोसाइड‍आईपी‍4‍वर्लीग्रार्
वलिावग्लवप्टि‍‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोली‍र्ें: र्ेससा‍र्ोरपेि‍लैबोरे रीज‍
र्ेटफोर्र्ाि‍ वलिावग्लवप्टि‍2.5‍वर्.ग्रा. वलवर्टेड
22 1 गोली 7.92
हाइड्रोक्लोराइड‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍850‍
गोली वर्लीग्रार्
वलिावग्लवप्टि‍‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोली‍र्ें: र्ेससा‍र्ोरपेि‍लैबोरे रीज‍
र्ेटफोर्र्ाि‍ वलिावग्लवप्टि‍2.5‍वर्.ग्रा. वलवर्टेड
23 1 गोली 9.60
हाइड्रोक्लोराइड‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍
गोली वर्लीग्रार्
रोसुिास्टेटटि‍और‍ प्रत्येक‍हाडा‍वजलेटटि‍कै प्सूल‍र्ें: र्ैससा‍विंडलास‍बायोटेक‍वलवर्टेड‍
24 1 कै प्सूल 17.03
क्लोवपडोग्रेल‍कै प्सूल रोसुिास्टेटटि‍कै वल्शयर्‍आईपी‍रोसुिास्टेटटि‍ /‍र्ैससा‍एर्क्योर‍फार्ाास्यूटटकल्स‍
102 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

क्रं.‍सं. विविर्र्ावत‍का‍ प्रबलता इकाई विविर्ााता‍और‍विपणि‍कं पिी खुदरा‍र्ूल्य‍


िार्/ब्ांड‍का‍िार् (रू.)
(1) (2) (3) (4) (5) (6)
10‍वर्लीग्रार्‍(हल्के ‍िारं गी‍रं ग‍की‍दफल्र्‍ वलवर्टेड
लेवपत‍गोली‍के ‍रूप‍र्ें)‍के ‍बराबर‍
क्लोवपडोग्रेल‍वबसल्फे ट‍आईपी‍क्लोवपडोग्रेल‍
75‍वर्लीग्रार्‍(दो, हल्के ‍भूरे‍रं ग‍की‍दफल्र्‍
लेवपत‍गोवलयों‍के ‍रूप‍र्ें, प्रत्येक‍र्ें‍
क्लोवपडोग्रेल‍37.5‍वर्लीग्रार्‍होता‍है)‍के ‍
बराबर
रोसुिास्टेटटि‍और‍ प्रत्येक‍हाडा‍वजलेटटि‍कै प्सूल‍र्ें: र्ैससा‍विंडलास‍बायोटेक‍वलवर्टेड‍
क्लोवपडोग्रेल‍कै प्सूल रोसुिास्टेटटि‍कै वल्शयर्‍आईपी‍रोसुिास्टेटटि‍ /‍र्ैससा‍एर्क्योर‍फार्ाास्यूटटकल्स‍
20‍वर्लीग्रार्‍(हल्के ‍िारं गी‍रं ग‍की‍दफल्र्‍ वलवर्टेड
लेवपत‍गोली‍के ‍रूप‍र्ें)‍के ‍बराबर‍
25 क्लोवपडोग्रेल‍वबसल्फे ट‍आईपी‍क्लोवपडोग्रेल‍ 1 कै प्सूल 19.46
75‍वर्लीग्रार्‍(दो, हल्के ‍भूरे‍रं ग‍की‍दफल्र्‍
लेवपत‍गोवलयों‍के ‍रूप‍र्ें, प्रत्येक‍र्ें‍
क्लोवपडोग्रेल‍37.5‍वर्लीग्रार्‍होता‍है)‍के ‍
बराबर
एटोरिास्टेटटि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
फे िोफाइब्ेट‍गोली एटोरिास्टेटटि‍कै वल्शयर्‍आईपी‍ वलवर्टेड/र्ैससा‍एटरस‍
26 1 गोली 27.09
एटोरिास्टेटटि‍20‍वर्.ग्रा.‍के ‍बराबर लाइफसाइं सेज‍वलवर्टेड
फे िोफाइब्ेट‍आईपी‍160‍वर्लीग्रार्
एटोरिास्टेटटि, प्रत्येक‍हाडा‍वजलेटटि‍कै प्सूल‍र्ें: र्ैससा‍विंडलास‍बायोटेक‍वलवर्टेड‍
क्लोवपडोग्रेल‍और‍ एटोरिास्टेटटि‍कै वल्शयर्‍आईपी‍ /‍र्ैससा‍एटरस‍लाइफसाइं सेज‍
एवस्पटरि‍कै प्सूल एटोरिास्टेटटि‍40‍वर्लीग्रार्‍(हरे ‍रं ग‍की‍ वलवर्टेड
पैलेट्स‍के ‍रूप‍र्ें)‍के ‍बराबर,
क्लोवपडोग्रेल‍वबसल्फे ट‍आईपी‍क्लोवपडोग्रेल‍
27 75‍वर्लीग्रार्‍(दो‍लाल‍भूरे‍रं ग‍की‍दफल्र्‍ 1 कै प्सूल 13.84
लेवपत‍गोवलयों‍के ‍रूप‍र्ें, प्रत्येक‍र्ें‍37.5‍
वर्लीग्रार्‍क्लोवपडोग्रेल‍गोवलयां‍आईपी‍होती‍
हैं)‍के ‍बराबर,
एवस्पटरि‍आईपी‍75‍वर्लीग्रार्‍(एंटेटरक‍
लेवपत‍सफे द‍रं ग‍के ‍पैलेट्स‍के ‍रूप‍र्ें)
एटोरिास्टेटटि, और‍ प्रत्येक‍हाडा‍वजलेटटि‍कै प्सूल‍र्ें: र्ैससा‍विंडलास‍बायोटेक‍वलवर्टेड‍
क्लोवपडोग्रेल‍कै प्सूल एटोरिास्टेटटि‍कै वल्शयर्‍आईपी‍ /‍र्ैससा‍एटरस‍लाइफसाइं सेज‍
एटोरिास्टेटटि‍40‍वर्लीग्रार्‍(हरे ‍रं ग‍की‍ वलवर्टेड
गोलाकार‍पैलेट्स‍के ‍रूप‍र्ें)‍के ‍बराबर,
28 क्लोवपडोग्रेल‍वबसल्फे ट‍आईपी‍क्लोवपडोग्रेल‍ 1 कै प्सूल 26.88
75‍वर्लीग्रार्‍(दो‍लाल‍भूरे‍रं ग‍की‍दफल्र्‍
लेवपत‍गोवलयों‍के ‍रूप‍र्ें, प्रत्येक‍र्ें‍37.5‍
वर्लीग्रार्‍क्लोवपडोग्रेल‍गोवलयां‍आईपी‍होती‍
हैं)‍के ‍बराबर,
वग्लक्लाजाइड‍और‍ प्रत्येक‍अलेवपत‍गोवलयों‍र्ें: र्ैससा‍र्ेडीफोसा‍हेल्थके यर‍प्राइिेट‍
र्ेटफॉर्र्ाि‍ वग्लक्लाजाइड‍आईपी‍40‍वर्लीग्रार् वलवर्टेड‍/‍र्ैससा‍र्ैिकाइं ड‍फार्ाा‍
29 1 गोली 7.35
हाइड्रोक्लोराइड‍ र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड
गोवलयााँ वर्लीग्रार्
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 103

क्रं.‍सं. विविर्र्ावत‍का‍ प्रबलता इकाई विविर्ााता‍और‍विपणि‍कं पिी खुदरा‍र्ूल्य‍


िार्/ब्ांड‍का‍िार् (रू.)
(1) (2) (3) (4) (5) (6)
विल्डावग्लवप्टि‍ प्रत्येक‍अलेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
(एसआर)‍और‍ विल्डावग्लवप्टि‍आईपी‍100‍वर्लीग्रार्‍ वलवर्टेड/र्ैससा‍यूएसिी‍वलवर्टेड
30 र्ेटफॉर्र्ाि‍ (सस्टेंडेड‍टरलीज‍फॉर्ा‍के ‍रूप‍र्ें) 1 गोली 9.67
हाइड्रोक्लोराइड‍ र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍
(एसआर)‍गोवलयााँ वर्लीग्रार्‍(सस्टेंडेड‍टरलीज‍फॉर्ा‍के ‍रूप‍र्ें)
विल्डावग्लवप्टि‍ प्रत्येक‍अलेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
(एसआर)‍और‍ विल्डावग्लवप्टि‍आईपी‍100‍वर्लीग्रार्‍ वलवर्टेड/र्ैससा‍यूएसिी‍वलवर्टेड
31 र्ेटफॉर्र्ाि‍ (सस्टेंडेड‍टरलीज‍फॉर्ा‍के ‍रूप‍र्ें) 1 गोली 10.78
हाइड्रोक्लोराइड‍ र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍
(एसआर)‍गोवलयााँ वर्लीग्रार्‍(सस्टेंडेड‍टरलीज‍फॉर्ा‍के ‍रूप‍र्ें)
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
32 1 गोली वलवर्टेड/र्ैससा‍अल्के र्‍ 13.24
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍
लेबोरे टरीज‍वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
33 1 गोली वलवर्टेड/र्ैससा‍एटरस‍ 13.24
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍
लाइफसाइं सेज‍वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
34 1 गोली वलवर्टेड/र्ैससा‍एटरस‍ 14.92
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍
लाइफसाइं सेज‍वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
35 1 गोली 13.43
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड/र्ैससा‍यूएसिी‍वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
36 1 गोली 15.11
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड/र्ैससा‍यूएसिी‍वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
37 1 गोली वलवर्टेड‍/‍र्ैससा‍र्ैिकाइं ड‍फार्ाा‍ 15.11
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
वलवर्टेड
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍
104 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

क्रं.‍सं. विविर्र्ावत‍का‍ प्रबलता इकाई विविर्ााता‍और‍विपणि‍कं पिी खुदरा‍र्ूल्य‍


िार्/ब्ांड‍का‍िार् (रू.)
(1) (2) (3) (4) (5) (6)
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
38 1 गोली वलवर्टेड‍/‍र्ैससा‍र्ैिकाइं ड‍फार्ाा‍ 13.43
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍
वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
39 1 गोली वलवर्टेड/र्ैससा‍र्ाइक्रो‍लैब्स‍ 12.50
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍
वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
40 1 गोली वलवर्टेड/र्ैससा‍र्ाइक्रो‍लैब्स‍ 13.39
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍
वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
41 1 गोली वलवर्टेड‍/‍र्ैससा‍र्ेडले‍ 13.43
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍
फार्ाास्यूटटकल्स‍वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
42 1 गोली वलवर्टेड‍/‍र्ैससा‍र्ेडले‍ 15.11
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍
फार्ाास्यूटटकल्स‍वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
43 1 गोली 13.43
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड/र्ैससा‍ल्यूवपि‍वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
44 1 गोली 15.11
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड/र्ैससा‍ल्यूवपि‍वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 105

क्रं.‍सं. विविर्र्ावत‍का‍ प्रबलता इकाई विविर्ााता‍और‍विपणि‍कं पिी खुदरा‍र्ूल्य‍


िार्/ब्ांड‍का‍िार् (रू.)
(1) (2) (3) (4) (5) (6)
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍विंडलास‍बायोटेक‍वलवर्टेड‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
45 1 गोली /‍र्ैससा‍एर्क्योर‍फार्ाास्यूटटकल्स‍ 14.44
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍
वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍विंडलास‍बायोटेक‍वलवर्टेड‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
46 1 गोली /‍र्ैससा‍एर्क्योर‍फार्ाास्यूटटकल्स‍ 16.12
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍
वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
47 1 गोली वलवर्टेड/र्ैससा‍र्ाइक्रो‍लैब्स‍ 14.29
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍
वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍र्ैस्कॉट‍हेल्थ‍सीरीज‍प्रा.‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
48 1 गोली वलवर्टेड/र्ैससा‍र्ाइक्रो‍लैब्स‍ 15.18
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍
वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍एकम्स‍ड्रग्स‍एंड‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
49 1 गोली फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍डॉ.‍ 14.55
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍
रे ड्डीज‍लैबोरे टरीज‍वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍एकम्स‍ड्रग्स‍एंड‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
50 1 गोली फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍डॉ.‍ 16.23
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍
रे ड्डीज‍लैबोरे टरीज‍वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍एकम्स‍ड्रग्स‍एंड‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍
51 1 गोली 13.39
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ ब्लू‍क्रॉस‍लेबोरे टरीज‍प्राइिेट‍
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें) वलवर्टेड
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍
52 1 गोली 14.29
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍
106 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

क्रं.‍सं. विविर्र्ावत‍का‍ प्रबलता इकाई विविर्ााता‍और‍विपणि‍कं पिी खुदरा‍र्ूल्य‍


िार्/ब्ांड‍का‍िार् (रू.)
(1) (2) (3) (4) (5) (6)
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर ब्लू‍क्रॉस‍लेबोरे टरीज‍प्राइिेट‍
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍एकम्स‍ड्रग्स‍एंड‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
53 1 गोली फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ 16.00
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍
इं टास‍फार्ाास्यूटटकल्स‍वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्
डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍
र्ैससा‍एकम्स‍ड्रग्स‍एंड‍
हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के ‍बराबर
54 1 गोली फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ 14.55
(एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍
इं टास‍फार्ाास्यूटटकल्स‍वलवर्टेड
और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के ‍रूप‍र्ें)
गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें:
डापावग्लफ्लोवजि,
डैपावग्लफ्लोवजि‍प्रोपेिेवडओल‍र्ोिोहाइड्रेट‍
र्ेटफॉर्र्ाि‍
आईपी‍डैपावग्लफ्लोवजि‍5‍वर्.ग्रा.‍के ‍बराबर र्ैससा‍सि‍फार्ाा‍लेबोरे टरीज‍
55 हाइड्रोक्लोराइड‍और‍ 1 गोली 12.98
र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ वलवर्टेड
वग्लर्ेपाइराइड‍
वर्लीग्रार्
गोवलयााँ
वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्
प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें:
डापावग्लफ्लोवजि,
डैपावग्लफ्लोवजि‍प्रोपेिेवडओल‍र्ोिोहाइड्रेट‍
र्ेटफॉर्र्ाि‍
आईपी‍डैपावग्लफ्लोवजि‍5‍वर्.ग्रा.‍के ‍बराबर र्ैससा‍सि‍फार्ाा‍लेबोरे टरीज‍
56 हाइड्रोक्लोराइड‍और‍ 1 गोली 11.30
र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ वलवर्टेड
वग्लर्ेपाइराइड‍
वर्लीग्रार्
गोवलयााँ
वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें:
डापावग्लफ्लोवजि,
डैपावग्लफ्लोवजि‍प्रोपेिेवडओल‍र्ोिोहाइड्रेट‍
र्ेटफॉर्र्ाि‍
आईपी‍डैपावग्लफ्लोवजि‍5‍वर्.ग्रा.‍के ‍बराबर र्ैससा‍सि‍फार्ाा‍लेबोरे टरीज‍
57 हाइड्रोक्लोराइड‍और‍ 1 गोली 9.91
र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड
वग्लर्ेपाइराइड‍
वर्लीग्रार्
गोवलयााँ
वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार्
प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें:
डापावग्लफ्लोवजि,
डैपावग्लफ्लोवजि‍प्रोपेिेवडओल‍र्ोिोहाइड्रेट‍
र्ेटफॉर्र्ाि‍
आईपी‍डैपावग्लफ्लोवजि‍5‍वर्.ग्रा.‍के ‍बराबर र्ैससा‍सि‍फार्ाा‍लेबोरे टरीज‍
58 हाइड्रोक्लोराइड‍और‍ 1 गोली 11.59
र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड
वग्लर्ेपाइराइड‍
वर्लीग्रार्
गोवलयााँ
वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्
एजेलविवडवपि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ैससा‍एकम्स‍ड्रग्स‍एंड‍
र्ेटोप्रोलोल‍सवक्सिेट‍ एजेलविवडपाइि‍आईपी‍16‍वर्लीग्रार्
59 1 गोली फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ 15.92
(सस्टेन्ड‍टरलीज)‍ र्ेटोप्रोलोल‍सवक्सिेट‍आईपी‍र्ेटोप्रोलोल‍टारेट‍
टोरें ट‍फार्ाास्यूटटकल्स‍वलवर्टेड
गोवलयााँ 25‍वर्लीग्रार्‍(सस्टेन्ड‍टरलीज‍के ‍रूप‍र्ें)
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 107

क्रं.‍सं. विविर्र्ावत‍का‍ प्रबलता इकाई विविर्ााता‍और‍विपणि‍कं पिी खुदरा‍र्ूल्य‍


िार्/ब्ांड‍का‍िार् (रू.)
(1) (2) (3) (4) (5) (6)
एजेलविवडवपि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें:
र्ैससा‍एकम्स‍ड्रग्स‍एंड‍
र्ेटोप्रोलोल‍सवक्सिेट‍ एजेलविवडपाइि‍आईपी‍16‍वर्लीग्रार्
60 1 गोली फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ 17.23
(सस्टेन्ड‍टरलीज)‍ र्ेटोप्रोलोल‍सवक्सिेट‍आईपी‍र्ेटोप्रोलोल‍टारेट‍
टोरें ट‍फार्ाास्यूटटकल्स‍वलवर्टेड
गोवलयााँ 50‍वर्लीग्रार्‍(सस्टेन्ड‍टरलीज‍के ‍रूप‍र्ें)
प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें:
र्ेकोबालावर्ि‍आईपी‍500‍एर्सीजी
वजंक‍सल्फे ट‍र्ोिोहाइड्रेट‍आईपी‍61.8‍
र्ेकोबालावर्ि, वजंक, वर्लीग्रार्‍(एलेम्नेटल‍वजंक‍22.5‍वर्लीग्रार्‍के ‍
कै वल्शयर्‍पेंटोथेिेट, बराबर)
र्ेससा‍प्योर‍एंड‍क्योर‍हेल्थके यर‍
विटावर्ि‍बी6, कै वल्शयर्‍पेंटोथेिेट‍आईपी‍10‍वर्लीग्रार्
61 1 गोली प्रा.‍वलवर्टेड‍/‍र्ैससा‍ब्लू‍क्रॉस‍ 4.97
फोवलक‍एवसड, पाइटरडोवक्सि‍हाइड्रोक्लोराइड‍आईपी‍3‍
लेबोरे टरीज‍प्राइिेट‍वलवर्टेड
वियावसिार्ाइड‍और‍ वर्लीग्रार्
क्रोवर्यर्‍गोवलयााँ फोवलक‍एवसड‍आईपी‍1.5‍वर्लीग्रार्
वियावसिर्ाइड‍आईपी‍50‍वर्लीग्रार्
क्रोवर्यर्‍50‍एर्सीजी‍(क्रोवर्यर्‍वपकोवलिेट‍
आईपी‍के ‍रूप‍र्ें)
सेवफ्रएक्सोि‍और‍ प्रत्येक‍कॉवम्बपैक‍र्ें: र्ैससा‍ईस्ट‍अफ्रीकि‍(इं वडया)‍
सल्बैक्टर्‍इं जेक्शि भाग-‍I ओिरसीज‍/‍र्ैससा‍सॉफ्टडील‍
प्रत्येक‍िाईल‍र्ें: फार्ाास्यूटटकल्स‍प्राइिेट‍वलवर्टेड
सेवफ्रएक्सोि‍सोवडयर्‍आईपी‍(स्टेराइल)‍
अन्हाईड्रोअस‍सेवफ्रएक्सोि‍1000‍वर्लीग्रार्‍
के ‍बराबर,
62 1 िाईल 140.09
सल्बैक्टर्‍सोवडयर्‍आईपी‍(स्टेराइल)‍
सल्बैक्टर्‍500‍वर्.ग्रा.‍के ‍बराबर
भाग-‍II
(फोर‍रीकोंस्टीट्यूसि)
प्रत्येक‍एफएफएस‍एम्पाउल‍र्ें:‍
िाटर‍फोर‍इं जेक्शि‍आईपी‍10‍वर्.ली.
108 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

तावलका‍के ‍कॉलर्‍(3) और‍(5) र्ें‍ तत्स्थािी‍प्रविवष्टयों‍र्ें‍ विर्दाष्ट‍विविर्ााण‍और‍विपणि‍


कं पवियों‍ की‍ स्रेंथ‍ और‍ िार्‍ के ‍ साथ, उपरोि‍ तावलका‍ के ‍ कॉलर्‍ (2) र्ें‍ विर्दाष्ट‍ ऐसे‍ फॉर्ूालेशि‍ के ‍ खुदरा‍ र्ूल्य‍ के ‍
विधाारण‍के ‍पटरणार्स्िरूप, कॉलर्‍(2), (3) और‍(5) र्ें‍तत्स्थािी‍प्रविवष्टयों‍र्ें‍यथा‍विर्दाष्ट‍उस‍विविर्ााण‍और‍विपणि‍
कं पवियों‍ के ‍ वलए‍ विर्दाष्ट‍ स्रेंथ‍ के ‍ साथ‍ फॉर्ूालेशि‍ के ‍ खुदरा‍ र्ूल्य‍ को‍ विधााटरत‍ करिे‍ िाले‍ कोई‍ र्ूल्य‍ आदेश‍ यदद‍ इस‍
अवधसूचिा‍से‍पहले‍जारी‍दकए‍गए‍हो, तो‍उसे‍इसका‍स्थाि‍वलया‍र्ािा‍जाएगा।

[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]


युविका‍पंिार, सहायक‍विदेशक

ORDER
New Delhi, the 26th March, 2024
S.O. 1558(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)
Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued
by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing
Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below
as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the
corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing
company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
TABLE
Sl. Name of the Strength Unit Manufacturer & Retail
No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
Sitagliptin, Each film coated Bilayered M/s Akums Drugs &
Pioglitazone and Tablet Contain: Pharmaceuticals Ltd. /
Metformin M/s Abbott Healthcare
Sitagliptin Phosphate
Hydrochloride Pvt. Ltd.
Monohydrate IP eq. to
(Sustained Released)
1 Sitagliptin 100mg 1 Tablet 14.00
Tablet
Pioglitazone Hydrochloride IP
eq. to Pioglitazone 15 mg
Metformin Hydrochloride IP
500mg (Sustained Release Form)
Sitagliptin, Each film coated Bilayered M/s Akums Drugs &
Pioglitazone and Tablet Contain: Pharmaceuticals Ltd. /
Metformin M/s Abbott Healthcare
Sitagliptin Phosphate
Hydrochloride Pvt. Ltd.
Monohydrate IP eq. to
(Sustained Released)
Sitagliptin 100mg
2 Tablet 1 Tablet 15.32
Pioglitazone Hydrochloride IP
eq. to Pioglitazone 15 mg
Metformin Hydrochloride IP
1000mg (Sustained Release
Form)
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 109
Sl. Name of the Strength Unit Manufacturer & Retail
No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
Sitagliptin, Each film coated Bilayered M/s Akums Drugs &
Pioglitazone and Tablet Contain: Pharmaceuticals Ltd. /
Metformin M/s Mankind Pharma
Sitagliptin Phosphate
Hydrochloride Ltd.
Monohydrate IP eq. to
(Sustained Released)
Sitagliptin 100mg
3 Tablet 1 Tablet 15.32
Pioglitazone Hydrochloride IP
eq. to Pioglitazone 15 mg
Metformin Hydrochloride IP
1000mg (Sustained Release
Form)
Sitagliptin, Each film coated Bilayered M/s Akums Drugs &
Pioglitazone and Tablet Contain: Pharmaceuticals Ltd. /
Metformin M/s Mankind Pharma
Sitagliptin Phosphate
Hydrochloride Ltd.
Monohydrate IP eq. to
(Sustained Released)
4 Sitagliptin 100mg 1 Tablet 14.00
Tablet
Pioglitazone Hydrochloride IP
eq. to Pioglitazone 15 mg
Metformin Hydrochloride IP
500mg (Sustained Release Form)
Metoprolol Each film coated bilayered tablet M/s Ajanta Pharma
Succinate Extended contains: Limited / M/s Sun
Release, Amlodipine Pharma Laboratories
Metoprolol Succinate IP
and Telmisartan Limited
47.50mg eq. to Metoprolol
Tablet
5 Tartrate 50mg (As Extended 1 Tablet 14.60
release)
Amlodipine Besilate IP eq. to
Amlodipine 5mg
Telmisartan IP 40mg
Linagliptin & Each film coated bilayered tablet M/s Mascot Health
Metformin contains: Series Pvt. Ltd. / M/s
6 Hydrochloride 1 Tablet Lupin Limited 13.03
Linagliptin IP 5mgMetformin
(Extended Release)
Hydrochloride IP 500mg (As
Tablets
Extended release)
Vitamin D3 Each 5 ml syrup contains: M/s Ravenbhel
(Cholecalciferol) Healthcare Pvt. Ltd. /
7 Cholecalciferol IP 60000IU 1 ml 12.53
Oral Solution M/s Emcure
Pharmaceuticals Limited
Cholecalciferol Each 5ml contains: M/s Ravenbhel
(Vitamin D3) Oral Healthcare Pvt. Ltd. /
8 Cholecalciferol IP (In nano 1 ml 13.60
Solution 60000IU M/s Intas
Droplet form) 60000IU
Pharmaceuticals Ltd.
Linagliptin + Each film coated tablet contains: M/s Morepen
Metformin Laboratories Limited
Linagliptin 2.5mg
9 Hydrochloride 1 Tablet 8.97
Tablet Metformin Hydrochloride IP
500mg

10 Phenylephrine Each 5 ml contains: 1 ml M/s Tirupati Medicare 0.95


Hydrochloride, Limited / M/s Macleods
110 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

Sl. Name of the Strength Unit Manufacturer & Retail


No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
Chlorpheniramine Phenylephrine Hydrochloride IP Pharmaceuticals Limited
maleate, 5mg
Paracetamol,
Chlorpheniramine maleate IP
Sodium Citrate &
0.5mg
Menthol Syrup
Paracetamol IP 125mg
Sodium Citrate IP 60mg
Menthol IP 1mg
Paracetamol, Each uncoated tablet contains: M/s Aagya Biotech Pvt.
Phenylephrine Ltd. / M/s Macleods
Paracetamol IP 500mg
Hydrochloride, Pharmaceuticals Limited
Caffeine & Phenylephrine Hydrochloride IP
11 Diphenhydramine 5mg 1 Tablet 3.70
Hydrochloride
Tablet Caffeine (Anhydrous) IP 30mg
Diphenhydramine
Hydrochloride IP 25mg
Linagliptin & Each film coated bilayered tablet M/s Mascot Health
Metformin contains: Series Pvt. Ltd. / M/s
Hydrochloride Micro Labs Ltd.
12 Linagliptin 5mg 1 Tablet 11.60
(Extended Release)
Tablets Metformin Hydrochloride (as
Extended release) IP 500mg
Cefpodoxime & Each film coated tablet contains: M/s Brooks Laboratories
Potassium Ltd. / M/s German
Cefpodoxime Proxetil IP eq. to
Clavulanate Tablets Remedies
13 Anhydrous Cefpodoxime 200mg 1 Tablet 28.49
Pharmaceuticals Private
Potassium Clavulanate Diluted Limited
IP eq. to Clavulanic Acid 125mg
Cefpodoxime Each 5ml reconstituted M/s Brooks Laboratories
Proxetil & suspension contains: Ltd. / M/s German
Potassium Remedies
Cefpodoxime Proxetil IP eq. to
Clavulanate Oral Pharmaceuticals Private
14 Anhydrous Cefpodoxime 100mg 1 ml 4.94
suspension Limited
Potassium Clavulanate Diluted
IP eq. to Clavulanic Acid
62.50mg
Cilnidipine and Each film coated tablet contains: M/s Pure and Cure
Telmisartan Tablets Healthcare Pvt. Ltd. /
15 Cilnidipine IP 10mg 1 Tablet 10.26
M/s Cadila
Telmisartan IP 40mg Pharmaceuticals Ltd.
Mefenamic Acid & Each uncoated tablet contains: M/s Mascot Health
Paracetamol Tablets Series Pvt. Ltd. / M/s
16 Mefenamic Acid IP 500mg 1 Tablet 3.58
Micro Labs Limited
Paracetamol IP 325mg
Pantoprazole & Each enteric coated tablet M/s Akums Drugs &
Domperidone Tablet contains: Pharmaceuticals Ltd. /
M/s Zuventus
17 Pantoprazole Sodium IP eq. to 1 Tablet 7.04
Healthcare Limited
Pantoprazole 40mg
Domperidone IP 10mg
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 111
Sl. Name of the Strength Unit Manufacturer & Retail
No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
Cefpodoxime & Each 5ml of reconstituted M/s Brooks Laboratories
Potassium suspension contains: Ltd. / M/s German
Clavulanate Oral Remedies
Cefpodoxime Proxetil IP eq. to
suspension Pharmaceuticals Private
18 Anhydrous Cefpodoxime 50mg 1 ml 3.17
Limited
Potassium Clavulanate Diluted
IP eq. to Clavulanic Acid
31.25mg
Amoxycillin and Each film coated tablet contains: M/s Malik Lifesciences
Potassium Pvt. Ltd. / Themis
Amoxycillin Trihydrate IP eq. to
Clavulanate Tablets Medicare Ltd.
19 Amoxycillin 250mg 1 Tablet 17.46
IP
Potassium Clavulanate Diluted
IP eq. to Clavulanic Acid 125mg
Amoxycillin and Each 5ml of Reconstituted M/s Malik Lifesciences
Potassium suspension contains: Pvt. Ltd. / Themis
Clavulanate Oral Medicare Ltd.
Amoxycillin Trihydrate IP eq. to
20 suspenssion 1 ml 3.18
Amoxycillin 600mg
Potassium Clavulanate Diluted
IP eq. to Clavulanic Acid 42.9mg
Aceclofenac, Each film coated tablet contains: M/s Theon
Paracetamol & Pharmaceuticals Ltd. /
Aceclofenac IP 100mg
21 Thiocolchicoside 1 Tablet M/s J.B. Chemicals & 17.84
Tablets Paracetamol IP 325mg Pharmaceuticals Ltd.
Thiocolchicoside IP 4mg
Linagliptin + Each film coated tablet contains: M/s Morepen
Metformin Laboratories Limited
Linagliptin 2.5mg
22 Hydrochloride 1 Tablet 7.92
Tablet Metformin Hydrochloride IP
850mg
Linagliptin + Each film coated tablet contains: M/s Morepen
Metformin Laboratories Limited
Linagliptin 2.5mg
23 Hydrochloride 1 Tablet 9.60
Tablet Metformin Hydrochloride IP
1000mg
Rosuvastatin + Each hard gelatin capsule M/s Windlas Biotech
Clopidogrel contains: Ltd. / M/s Emcue
Capsules Pharmaceuticals Limited
Rosuvastatin Calcium IP eq. to
Rosuvastatin 10mg (as light
orange coloured film coated
1
24 tablet) 17.03
Capsule
Clopidogrel Bisulphate IP eq. to
Clopidogrel 75mg (As two, light
brown coloured film coated
tablets, each containing
clopidogrel Tablet 37.5mg
Rosuvastatin + Each hard gelatin capsule M/s Windlas Biotech
Clopidogrel contains: 1 Ltd. / M/s Emcue
25 19.46
Capsules Capsule Pharmaceuticals Limited
Rosuvastatin Calcium IP eq. to
Rosuvastatin 20mg (as light
112 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

Sl. Name of the Strength Unit Manufacturer & Retail


No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
orange coloured film coated
tablet)
Clopidogrel Bisulphate IP eq. to
Clopidogrel 75mg (As two, light
brown coloured film coated
tablets, each containing
clopidogrel Tablet 37.5mg
Atorvastatin and Each film coated tablet contains: M/s Mascot Health
Fenofibrate Tablets Series Pvt. Ltd. / M/s
Atorvastatin Calcium IP eq. to
26 1 Tablet Eris Lifesciences 27.09
Atorvastatin 20mg
Limited
Fenofibrate IP 160mg
Atorvastatin, Each hard gelatine capsule M/s Windlas Biotech
Clopidogrel & contains: Limited / M/s Eris
Aspirin Capsule Lifesciences Ltd.
Atorvastatin Calcium IP eq. to
Atorvastatin 40mg (As green
coloured pellets),
Clopidogrel Bisulphate IP eq. to 1
27 13.84
Clopidogrel 75mg (As two Capsule
reddish brown coloured film
coated tablet, each containg
37.5mg Clopidogrel Tablets IP),
Aspirin IP 75mg (As enteric
coated white-coloured pellets)
Atorvastatin & Each hard gelatine capsule M/s Windlas Biotech
Clopidogrel Capsule contains: Limited / M/s Eris
Lifesciences Ltd.
Atorvastatin Calcium IP eq. to
Atorvastatin 40mg (As green
coloured spherical pellets), 1
28 26.88
Capsule
Clopidogrel Bisulphate IP eq. to
Clopidogrel 75mg (As two
reddish brown coloured film
coated tablet, each containg
37.5mg Clopidogrel Tablets IP),
Gliclazide & Each uncoated tablets contains: M/s Mediforce
Metformin Healthcare Pvt ltd / M/s
Gliclazide IP 40mg
29 Hydrochloride 1 Tablet Mankind Pharma Ltd 7.35
Tablets Metformin Hydrochloride IP
500mg
Vildagliptin (SR) & Each uncoated bilayered tablet M/s Mascot Health
Metformin contains: Series Pvt. Ltd. / M/s
Hydrochloride (SR) USV Private Limited
Vildagliptin IP 100mg (As
Tablets
30 Sustained release form) 1 Tablet 9.67
Metformin Hydrochloride IP
500mg (As Sustained release
form)
Vildagliptin (SR) & Each uncoated bilayered tablet M/s Mascot Health
31 Metformin contains: 1 Tablet Series Pvt. Ltd. / M/s 10.78
Hydrochloride (SR) USV Private Limited
Vildagliptin IP 100mg (As
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 113
Sl. Name of the Strength Unit Manufacturer & Retail
No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
Tablets Sustained release form)
Metformin Hydrochloride IP
1000mg (As Sustained release
form)
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Mascot Health
Hydrochloride eq. to Dapagliflozin 10mg Series Pvt. Ltd. / M/s
32 1 Tablet 13.24
(Extended Release) Alkem Laboratories
and Glimepiride Metformin Hydrochloride IP Limited
Tablets 500mg (As Extended release)
Glimepiride IP 1 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Mascot Health
Hydrochloride eq. to Dapagliflozin 10mg Series Pvt. Ltd. / M/s
33 1 Tablet 13.24
(Extended Release) Eris Lifesciences
and Glimepiride Metformin Hydrochloride IP Limited
Tablets 500mg (As Extended release)
Glimepiride IP 1 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Mascot Health
Hydrochloride eq. to Dapagliflozin 10mg Series Pvt. Ltd. / M/s
34 1 Tablet 14.92
(Extended Release) Eris Lifesciences
and Glimepiride Metformin Hydrochloride IP Limited
Tablets 500mg (As Extended release)
Glimepiride IP 2 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Mascot Health
Hydrochloride eq. to Dapagliflozin 10mg
35 1 Tablet Series Pvt. Ltd. / M/s 13.43
(Extended Release)
Metformin Hydrochloride IP USV Private Limited
and Glimepiride
Tablets 500mg (As Extended release)
Glimepiride IP 1 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Mascot Health
Hydrochloride eq. to Dapagliflozin 10mg
36 1 Tablet Series Pvt. Ltd. / M/s 15.11
(Extended Release)
Metformin Hydrochloride IP USV Private Limited
and Glimepiride
Tablets 500mg (As Extended release)
Glimepiride IP 2 mg
Dapagliflozin, Each film coated bilayered tablet
Metformin contains: M/s Mascot Health
Hydrochloride
37 Dapagliflozin Propanediol USP 1 Tablet Series Pvt. Ltd. / M/s 15.11
(Extended Release)
eq. to Dapagliflozin 10mg Mankind Pharma Ltd.
and Glimepiride
Tablets Metformin Hydrochloride IP
114 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

Sl. Name of the Strength Unit Manufacturer & Retail


No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
500mg (As Extended release)
Glimepiride IP 2 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Mascot Health
Hydrochloride eq. to Dapagliflozin 10mg
38 1 Tablet Series Pvt. Ltd. / M/s 13.43
(Extended Release)
Metformin Hydrochloride IP Mankind Pharma Ltd.
and Glimepiride
Tablets 500mg (As Extended release)
Glimepiride IP 1 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Mascot Health
Hydrochloride eq. to Dapagliflozin 10mg
39 1 Tablet Series Pvt. Ltd. / M/s 12.50
(Extended Release)
Metformin Hydrochloride IP Micro Labs Limited
and Glimepiride
Tablets 500mg (As Extended release)
Glimepiride IP 1 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Mascot Health
Hydrochloride eq. to Dapagliflozin 10mg
40 1 Tablet Series Pvt. Ltd. / M/s 13.39
(Extended Release)
Metformin Hydrochloride IP Micro Labs Limited
and Glimepiride
Tablets 500mg (As Extended release)
Glimepiride IP 2 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Mascot Health
Hydrochloride eq. to Dapagliflozin 10mg Series Pvt. Ltd. / M/s
41 1 Tablet 13.43
(Extended Release) Medley Pharmaceuticals
and Glimepiride Metformin Hydrochloride IP Ltd.
Tablets 500mg (As Extended release)
Glimepiride IP 1 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Mascot Health
Hydrochloride eq. to Dapagliflozin 10mg Series Pvt. Ltd. / M/s
42 1 Tablet 15.11
(Extended Release) Medley Pharmaceuticals
and Glimepiride Metformin Hydrochloride IP Ltd.
Tablets 500mg (As Extended release)
Glimepiride IP 2 mg
Each film coated bilayered tablet
Dapagliflozin,
contains:
Metformin
M/s Mascot Health
Hydrochloride Dapagliflozin Propanediol USP
43 1 Tablet Series Pvt. Ltd. / M/s 13.43
(Extended Release) eq. to Dapagliflozin 10mg
Lupin Limited
and Glimepiride
Metformin Hydrochloride IP
Tablets
500mg (As Extended release)
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 115
Sl. Name of the Strength Unit Manufacturer & Retail
No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
Glimepiride IP 1 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Mascot Health
Hydrochloride eq. to Dapagliflozin 10mg
44 1 Tablet Series Pvt. Ltd. / M/s 15.11
(Extended Release)
Metformin Hydrochloride IP Lupin Limited
and Glimepiride
Tablets 500mg (As Extended release)
Glimepiride IP 2 mg
Each film coated tablet contains:
Dapagliflozin,
Metformin Dapagliflozin Propanediol USP
eq. to Dapagliflozin 10mg M/s Windlas Biotech
Hydrochloride
45 1 Tablet Limited / M/s Emcure 14.44
(Extended Release) Metformin Hydrochloride IP Pharmaceuticals Limited
and Glimepiride 1000mg (As Extended release)
Tablets
Glimepiride IP 1 mg
Each film coated tablet contains:
Dapagliflozin,
Metformin Dapagliflozin Propanediol USP
eq. to Dapagliflozin 10mg M/s Windlas Biotech
Hydrochloride
46 1 Tablet Limited / M/s Emcure 16.12
(Extended Release) Metformin Hydrochloride IP Pharmaceuticals Limited
and Glimepiride 1000mg (As Extended release)
Tablets
Glimepiride IP 2 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Mascot Health
Hydrochloride eq. to Dapagliflozin 10mg
47 1 Tablet Series Pvt. Ltd. / M/s 14.29
(Extended Release)
Metformin Hydrochloride IP Micro Labs Limited
and Glimepiride
Tablets 1000mg (As Extended release)
Glimepiride IP 1 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Mascot Health
Hydrochloride eq. to Dapagliflozin 10mg
48 1 Tablet Series Pvt. Ltd. / M/s 15.18
(Extended Release)
Metformin Hydrochloride IP Micro Labs Limited
and Glimepiride
Tablets 1000mg (As Extended release)
Glimepiride IP 2 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol eq. to M/s Akums Drugs &
Hydrochloride Dapagliflozin 10mg Pharmaceuticals Ltd. /
49 1 Tablet 14.55
(Extended Release) Dr. Reddy's Laboratories
and Glimepiride Metformin Hydrochloride IP Limited
Tablets 1000mg (As Extended release)
Glimepiride IP 1 mg
Dapagliflozin, Each film coated bilayered tablet M/s Akums Drugs &
50 Metformin 1 Tablet Pharmaceuticals Ltd. / 16.23
contains:
Hydrochloride Dr. Reddy's Laboratories
116 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

Sl. Name of the Strength Unit Manufacturer & Retail


No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
(Extended Release) Dapagliflozin Propanediol eq. to Limited
and Glimepiride Dapagliflozin 10mg
Tablets
Metformin Hydrochloride IP
1000mg (As Extended release)
Glimepiride IP 2 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Akums Drugs and
Hydrochloride eq. to Dapagliflozin 10mg Pharmaceuticals Ltd. /
51 1 Tablet 13.39
(Extended Release) M/s Blue Cross
and Glimepiride Metformin Hydrochloride IP Laboratories Pvt. Ltd.
Tablets 1000mg (As Extended release)
Glimepiride IP 1 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Akums Drugs and
Hydrochloride eq. to Dapagliflozin 10mg Pharmaceuticals Ltd. /
52 1 Tablet 14.29
(Extended Release) M/s Blue Cross
and Glimepiride Metformin Hydrochloride IP Laboratories Pvt. Ltd.
Tablets 1000mg (As Extended release)
Glimepiride IP 2 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Akums Drugs and
Hydrochloride eq. to Dapagliflozin 10mg Pharmaceuticals Ltd. /
53 1 Tablet 16.00
(Extended Release) M/s Intas
and Glimepiride Metformin Hydrochloride IP Pharmaceuticals Ltd.
Tablets 1000mg (As Extended release)
Glimepiride IP 2 mg
Each film coated bilayered tablet
Dapagliflozin, contains:
Metformin Dapagliflozin Propanediol USP M/s Akums Drugs and
Hydrochloride eq. to Dapagliflozin 10mg Pharmaceuticals Ltd. /
54 1 Tablet 14.55
(Extended Release) M/s Intas
and Glimepiride Metformin Hydrochloride IP Pharmaceuticals Ltd.
Tablets 1000mg (As Extended release)
Glimepiride IP 1 mg
Each film coated tablet contains:
Dapagliflozin Propanediol
Dapagliflozin, Monohydrate IP eq. to
Metformin Dapagliflozin 5mg M/s Sun Pharma
55 1 Tablet 12.98
Hydrochloride and Laboratories Limited
Glimepiride Tablets Metformin Hydrochloride IP
1000mg
Glimepiride IP 2 mg

Dapagliflozin, Each film coated tablet contains:


Metformin Dapagliflozin Propanediol M/s Sun Pharma
56 1 Tablet 11.30
Hydrochloride and Monohydrate IP eq. to Laboratories Limited
Glimepiride Tablets Dapagliflozin 5mg
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 117
Sl. Name of the Strength Unit Manufacturer & Retail
No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
Metformin Hydrochloride IP
1000mg
Glimepiride IP 1 mg
Each film coated tablet contains:
Dapagliflozin Propanediol
Dapagliflozin, Monohydrate IP eq. to
Metformin Dapagliflozin 5mg M/s Sun Pharma
57 1 Tablet 9.91
Hydrochloride and Laboratories Limited
Glimepiride Tablets Metformin Hydrochloride IP
500mg
Glimepiride IP 1 mg
Each film coated tablet contains:
Dapagliflozin Propanediol
Dapagliflozin, Monohydrate IP eq. to
Metformin Dapagliflozin 5mg M/s Sun Pharma
58 1 Tablet 11.59
Hydrochloride and Laboratories Limited
Glimepiride Tablets Metformin Hydrochloride IP
500mg
Glimepiride IP 2 mg
Each film coated bilayered tablet
contains:
Azelnidipine and M/s Akums Drugs &
Metoprolol Azelnidipine IP 16mg Pharmaceuticals Ltd. /
59 1 Tablet 15.92
Succinate (Sustained M/s Torrent
Metoprolol Succinate IP eq. to
Release) Tablet Pharmaceuticals Ltd.
Metoprolol Tartrate 25mg (as
Sustained release)
Each film coated bilayered tablet
contains:
Azelnidipine and M/s Akums Drugs &
Metoprolol Azelnidipine IP 16mg Pharmaceuticals Ltd. /
60 1 Tablet 17.23
Succinate (Sustained M/s Torrent
Metoprolol Succinate IP eq. to
Release) Tablet Pharmaceuticals Ltd.
Metoprolol Tartrate 50mg (as
Sustained release)
Each film coated tablet contains:
Mecobalamin IP 500mcg
Zinc Sulphate Monohydrate IP
Mecobalamin, Zinc, 61.8mg (eq. to elemental Zinc
Calcium 22.5mg) M/s Pure and Cure
Pantothenate, Calcium Pantothenate IP 10mg Healthcare Pvt. Ltd. /
61 Vitamin B6, Folic 1 Tablet M/s Blue Cross 4.97
Acid, Niacinamide Pyridoxine Hydrochloride IP Laboratories Private
& Chromium 3mg Limited
Tablets Folic Acid IP 1.5mg
Niacinamide IP 50mg
Chromium 50mcg (As
Chromium Picolinate IP)
Ceftriaxone and Each Combi pack Contains: M/s East African (India)
62 Sulbactam injection 1 Vial Overseas / M/s Softdeal 140.09
Part-I Each vial contains:
Pharmaceuticals Private
118 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

Sl. Name of the Strength Unit Manufacturer & Retail


No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
Ceftriaxone Sodium IP (Sterile) Limited
eq. to anhydrous Ceftriaxone
1000mg,
Sulbactam Sodium IP (Sterile)
eq. to Sulbactam 500mg
Part-II (For Reconstitution)
Each FFS Ampoule contains:
Sterile Water for Injection IP
10ml

Note:
(a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO,
2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of
Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State
Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned
above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated
under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the
Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent
Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned
manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price
notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be
liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO,
2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table
with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries
in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified
strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2),
(3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director

ubZ fnYyh] 26 ] 2024


¼ .—
का.आ.‍5249(अ)‍तारीख‍11‍ििम्बर,
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 119

(1) (2) (3) (4) (5) (6)


कम्पोजीसि:

रे र्ोवग्लफ़्लोवजि‍एटाबोिेट, रे र्ोवग्लफ़्लोवजि‍एटाबोिेट‍100‍
वर्.ग्रा. र्ैससा‍ग्लेिर्ाका ‍
1. विल्डावग्लवप्टि‍और‍ 1 गोली 8.76
र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍ विल्डावग्लवप्टि‍50‍वर्.ग्रा. फार्ाास्यूटटकल्स‍वलवर्टेड
गोवलयााँ
र्ेटफोर्र्ाि‍ हाइड्रोक्लोराइड‍ आईपी‍
500‍वर्लीग्रार्

कम्पोजीसि:

रे र्ोवग्लफ़्लोवजि‍एटाबोिेट‍100‍
एटाबोिेट, विल्डावग्लवप्टि‍ वर्.ग्रा. र्ैससा‍ग्लेिर्ाका ‍
2. और‍र्ेटफॉर्र्ाि‍ 1 गोली 9.06
विल्डावग्लवप्टि‍50‍वर्.ग्रा. फार्ाास्यूटटकल्स‍वलवर्टेड
हाइड्रोक्लोराइड‍गोवलयााँ
र्ेटफोर्र्ाि‍ हाइड्रोक्लोराइड‍ आईपी‍
1000‍वर्लीग्रार्

प्रत्येक‍िाईल‍र्ें:
र्ेससा‍बीडीआर‍
सेफ्टावजडाइर्‍और‍
सेफ्टावजडाइर्‍(सेफ्टावजडाइर्‍ फार्ाास्यूटटकल्स‍इं टरिेशिल‍
एविबैक्टर्‍पाउडर‍फोर‍
3. पेंटाहाइड्रेट‍के ‍रूप‍र्ें)‍आईपी‍2‍ग्रार् 1 िाईल प्राइिेट‍वलवर्टेड‍ 1696.43
कोंसंरेट‍फोर‍शोलूसि‍फोर‍
वलवर्टेड/र्ैससा‍िैटको‍फार्ाा‍
इं फ्यूजि एविबैक्टर्‍सोवडयर्‍एविबैक्टर्‍0.5‍
वलवर्टेड
ग्रार्‍के ‍बराबर

I
120 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

तावलका‍के ‍कॉलर्‍(3) और‍(5) र्ें‍ तत्स्थािी‍प्रविवष्टयों‍र्ें‍ विर्दाष्ट‍विविर्ााण‍और‍विपणि‍


कं पवियों‍ की‍ स्रेंथ‍ और‍ िार्‍ के ‍ साथ, उपरोि‍ तावलका‍ के ‍ कॉलर्‍ (2) र्ें‍ विर्दाष्ट‍ ऐसे‍ फॉर्ूालेशि‍ के ‍ खुदरा‍ र्ूल्य‍ के ‍
विधाारण‍के ‍पटरणार्स्िरूप, कॉलर्‍(2), (3) और‍(5) र्ें‍तत्स्थािी‍प्रविवष्टयों‍र्ें‍यथा‍विर्दाष्ट‍उस‍विविर्ााण‍और‍विपणि‍
कं पवियों‍ के ‍ वलए‍ विर्दाष्ट‍ स्रेंथ‍ के ‍ साथ‍ फॉर्ूालेशि‍ के ‍ खुदरा‍ र्ूल्य‍ को‍ विधााटरत‍ करिे‍ िाले‍ कोई‍ र्ूल्य‍ आदेश‍ यदद‍ इस‍
अवधसूचिा‍से‍पहले‍जारी‍दकए‍गए‍हो, तो‍उसे‍इसका‍स्थाि‍वलया‍र्ािा‍जाएगा।

[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]


युविका‍पंिार, सहायक‍विदेशक

ORDER
New Delhi, the 26th March, 2024
S.O. 1559E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)
Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued
by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing
Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below
as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the
corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing
company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
TABLE
Sl. Name of the Strength Unit Manufacturer & Retail Price
No. Scheduled Marketing Company (Rs.)
Formulation / Brand
Name
(1) (2) (3) (4) (5) (6)
1. Composition:
Remogliflozin Remogliflozin Etabonate
Etabonate, 100mg M/s Glenmark
Vildagliptin & 1 Tablet Pharmaceuticals 8.76
Metformin Vildagliptin 50mg Limited
Hydrochloride tablets Metformin Hydrochloride
IP 500mg tablets
2. Composition:
Remogliflozin
Remogliflozin Etabonate
Etabonate, M/s Glenmark
100mg
Vildagliptin & 1 Tablet Pharmaceuticals 9.06
Metformin Vildagliptin 50 mg Limited
Hydrochloride tablets Metformin Hydrochloride
IP 1000 mg tablets
3. Each vial contains:
M/s BDR
Ceftazidime and Ceftazidime (As
Pharmaceuticals
Avibactam powder Ceftazidime pentahydrate)
1Vial Internation Pvt. Ltd. / 1696.43
for concentrate for IP 2gram
M/s Natco Pharma
solution for infusion
Avibactam Sodium eq. to Limited
Avibactam 0.5gm

Note:
(a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(1)(u) of the DPCO,
2013 shall fix the retail price as specified in column (6) of the table hereinabove.
[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 121
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of
Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State
Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned
above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated
under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the
Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent
Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned
manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price
notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be
liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO,
2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table
with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries
in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified
strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2),
(3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director

Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054. MANOJ KUMAR
Digitally signed by
MANOJ KUMAR VERMA
VERMA Date: 2024.03.30
13:53:34 +05'30'

You might also like